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Abstract  
Neurodegenerative diseases are characterized by progressive degeneration of 
selective neurones in the nervous system and the formation of protein inclusions in 
surviving neurones. The mechanisms underlying neurodegeneration and 
neuroprotection in the nervous system remain elusive. Ubiquitin is one of the 
hallmarks of neuropathological inclusions in the majority of neurodegenerative 
diseases, including Alzheimer’s disease and Parkinson’s disease. Therefore, 
dysfunction of the ubiquitin proteasome system has been implicated in disease cause 
and/or progression. This thesis investigates a unique conditional genetic mouse model 
of neurodegeneration caused by conditional genetic 26S proteasomal depletion in 
mouse forebrain neurones. We have identified potential proteins targeted for 
ubiquitination in brain using bio-affinity chromatography of zinc finger protein 
ZNF216 coupled with mass spectrometry. This lead to the identification of several 
potential ubiquitinated proteins involved in gene expression and regulation. We have 
also investigated the global brain proteome in response to 26S proteasomal depletion 
in neurones using two-dimensional fluorescence difference in-gel electrophoresis 
coupled to mass spectrometry for protein identification. Several differentially 
expressed proteins were identified in the 26S proteasome-depleted cortex. Astrocytic 
intermediate filament proteins glial acid fibrillary protein and vimentin, as well as the 
antioxidant peroxiredxoin-6, were upregulated. Mitochondrial fumarate hydratase and 
stathmin-1, involved in the tricarboxylic acid cycle and cytoskeletal microtubule 
dynamics respectively, were downregulated. These proteins have been validated by 
biochemical and immunohistochemical approaches. Further analysis of oxidative 
stress revealed increased lipid and protein oxidation that may be involved in the 
neurodegeneration associated with 26S proteasomal depletion. However, we also 
show increased phospholipase A2 activity associated with peroxiredoxin-6 expression 
that may have additional roles in neurodegenerative and/or neuroprotective functions. 
Interestingly, the levels of reactive oxygen species were inversely correlated with the 
upregulation of peroxiredoxin-6. We suggest that peroxiredoxin-6 may play an 
important role in the brain in the protection against oxidative stress and our studies 
may improve our physiological and pathological understanding of neurodegenerative 
disease. 
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1.1 Introduction 
Neurodegenerative diseases are characterized by the progressive loss of neurones in 
specific regions of the nervous system and formation of protein inclusions in 
surviving neurones. These diseases are proteinopathies which affect protein 
homeostasis. Examples of proteinopathies and their associated abnormal proteins are 
given in Table 1.1, including major human neurodegenerative diseases such as 
Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and Alzheimer disease 
(AD). Mitochondrial impairment, oxidative stress and dysfunction of protein 
degradation are key hypotheses in disease cause and progression. However, the 
mechanisms involved in neurodegeneration and inclusion body formation in different 
regions of the brain remain unclear. 
The ubiquitin proteasome system (UPS) is the major pathway for degradation of 
unwanted soluble intracellular proteins (Ciechanover, 1994; Hochstrasser, 1996). 
Dysfunction of the UPS has been implicated in the pathogenesis of neurodegenerative 
diseases for over two decades (Lowe et al., 1993) and is supported by cellular and 
animal models (Bedford et al., 2008; Gavilan et al., 2009; Romero-Granados et al., 
2011). 
Animal models provide a tool to investigate the mechanisms involved in 
neurodegenerative diseases as well as evaluate new treatment strategies. A recently 
developed mouse model showing neurodegeneration and the formation of protein 
inclusions provided direct evidence for the importance of proteasomal dysfunction in 
neurodegenerative disease (Bedford et al., 2008). This was achieved by conditional 
genetic depletion of the 26S proteasome in mouse cortex (Psmc1
fl/fl
;CaMKIIα-Cre). 
This thesis is divided into 3 main areas of study that carried out on 
Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex and include;(1) investigations of the brain 
ubiquitome using bio-affinity chromatography (see chapter 3), (2) investigation of 
changes in the brain proteome in response to neuronal 26S proteasomal depletion 
using two dimensional fluorescence difference in-gel electrophoresis (2D-DIGE) (see 
chapter 4) and (3) investigations of oxidative stress and peroxiredoxin-6 (see chapter 
5). The overall aim is to identify mechanisms involved in neurodegeneration and 
inclusion formation that may be translated to human disease. 
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Table 1.1 Examples of proteinopathies 
Disease Name Abnormal protein References  
Parkinson’s disease α-synuclein  
ubiquitinated proteins  
 
 (Mayer, 2003; Stefanis, 
2012) 
Lewy body dementia α-synuclein 
ubiquitinated proteins  
 
(Mayer, 2003; Puschmann 
et al., 2012) 
Alzheimer’s disease  Amyloid-β 
Tau 
 
(Musiek and Holtzman, 
2012; Gilbert, 2013) 
Huntington’s disease Huntingtin 
 
(Hoffner and Djian, 2002) 
Familial amyotrophic 
lateral sclerosis 
Superoxide dismutase 
 
 
(Chattopadhyay and 
Valentine, 2009) 
Frontotemporal dementia Tau  
 
(Gasparini et al., 2007) 
 
Multiple systemic atrophy α-synuclein   
 
(Yoshida, 2007) 
Creutzfeldt-Jacob disease Prion  
 
(Head and Ironside, 2012) 
Progressive supranuclear 
palsy 
Tau protein 
 
 
(Kaat et al., 2011) 
Spinocerebellar ataxia Ataxin 
 
(Orr, 2012) 
Corticobasal degeneration Tau  
 
(Kouri et al., 2011) 
Familial encephalopathy 
with neuroserpin inclusion  
Neuroserpin 
 
 
(Davis et al., 2002) 
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1.2 The ubiquitin 26S proteasome system 
1.2.1 The 26S proteasome 
The 26S proteasome is a multi-protein complex present in the nucleus and cytosol of 
eukaryotic cells. It is an essential and abundant complex, constituting up to 1% of the 
intracellular protein content. The 26S proteasome performs proteolysis of unwanted 
proteins that are tagged with ubiquitin (ubiquitinated) as a signal for their degradation 
(see section 1.2.6). The 26S proteasome is made up of two sub-complexes; a barrel-
shaped 20S proteolytic core particle (CP) and a 19S regulatory particle (RP), which 
recognizes ubiquitinated proteins for degradation (Glickman et al., 1998; Lam et al., 
2002; da Fonseca and Morris, 2008). A 19S RP caps either end of the 20S CP to form 
the 26S proteasome that is essential for the ubiquitin proteasome system (UPS) (Wang 
et al., 1997; da Fonseca and Morris, 2008). 
1.2.2 The 20S core particle 
The structure and enzymatic activity of the 20S CP of the 26S proteasome have been 
described. The CP is a barrel-shaped elongated hollow cylinder with narrow 
constrictions at both ends of a central cavity (Smith et al., 2007). The CP consists of 
four stacked heptameric rings made up of α1/PSMA1 – α7/PSMA7 and β1/PSMB1-
β7/PSMB7 protein subunits, on the basis of their sequence similarity (Figure 1.1). The 
α/PSMA subunits form the outer rings of the 20S CP and the β/PSMB subunits form 
two inner rings (Coux et al., 1996). The N-terminal tails of the α/PSMA subunits gate 
entry into the 20S proteolytic CP, preventing unregulated access of substrates (Unno 
et al., 2002). Opening of the 20S CP is controlled by binding of the 19S RP 
(Glickman et al., 1998; Lam et al., 2002; Chen et al., 2008). The β/PSMB subunits are 
responsible for the proteolytic functions of the 20S proteasome; β1/PSMB1, 
β2/PSMB2 and β5/PSMB5 exhibit chymotrypsin-like, trypsin-like and peptidyl-
glutamyl peptide hydrolyzing activities respectively (Groll et al., 1997; Glickman and 
Ciechanover, 2002). The remaining β/PSMB subunits may form the scaffold structure 
of the proteasome barrel (Baldovino et al., 2006).  
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1.2.3 The 19S regulatory particle  
The 19S RP is made up of at least eighteen different subunit proteins divided into 
base and lid arrangements (Glickman et al., 1998; Chen et al., 2008). Figure 1.2 
shows the arrangement of the 19S RP. In the base, there are six non-redundant 
ATPases subunits that join to the 20S CP as well as three non-ATPase subunits 
(Glickman et al., 1998; Chen et al., 2008; Hendil et al., 2009; Kaneko et al., 2009). 
The lid is composed of eight non-ATPase subunits. Rpn10/S5a/PSMD4 is assumed to 
sit at the interface of the base and lid, interacting with Rpn2/S1/PSMD1 (base) and 
Rpn11/S13/ PSMD14 (lid) subunits (Hendil et al., 2009; Kaneko et al., 2009). The RP 
has several roles as part of the 26S proteasome, including substrate recognition, de-
ubiquitination, unfolding and translocation into the 20S CP. The subunits of the RP 
have specific roles. In the base, Rpt2/S4/PSMC1 controls substrate entry into the 20S 
CP by opening the pore gated by the 20S α/PSMA subunits (Köhler et al., 2001; 
Gillette et al., 2008). The Rpt5/S6a/PSMC3 subunit can recognize and bind 
polyubiquitinated proteins (Lam et al., 2002; Gillette et al., 2008). Rpn1/S2/PSMD2 
and Rpn2/S1/ PSMD1 direct substrate recruitment and translocation into the 
proteolytic chamber of CP (Rosenzweig et al., 2008). In the lid complex, 
Rpn11/S13/PSMD14 has deubiquitination (DUB) activity that facilitates degradation 
of ubiquitinated proteins (Koulich et al., 2008). Rpn13/ADRM1 is a ubiquitin receptor 
(Husnjak et al., 2008). 
1.2.4 Proteasome assembly 
The 20S proteasome behaves as a platform onto which the 19S RP can bind, forming 
the active 26S proteasome (Hendil et al., 2009). The biogenesis of the 20S CP is 
initiated by the formation of a pre-20S subcomplex; the α1/PSMA1 -α7/PSMA7 ring is 
formed by the action of proteasome-specific chaperones (Hirano et al., 2005; Hirano 
et al., 2006). This is followed by stepwise incorporation of the β/PSMB subunits, 
forming a half-proteasome (one α1/PSMA1 -α7/PSMA7 ring bound to one β1 /PSMB1 
- β7/PSMB7 ring). Two half-proteasomes combine to form a mature 20S CP (Hirano 
et al., 2006; Fricke et al., 2007; Le Tallec  B, 2007; Hirano et al., 2008). 
The base and lid of the 19S RP are assembled independently. For the base, assembly 
is initiated by association of Rpt3/S6b/PSMC4, Rpt6/S8/PSMC5 and 
Rpt1/S7/PSMC2, Rpt2/S4/PSMC1, Rpn1/S2/PSMD2 subcomplexes, followed by 
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incorporation of Rpt4/S10b/PSMC6, Rpt5/S6a/PSMC3 and Rpn2/S1/PSMD1 
(Kaneko et al., 2009; Murata et al., 2009).  
There are also two lid subcomplexes; Rpn6/S9/PSMD11, Rpn8/S12/PSMD7, 
Rpn9/S11/PSMD13, Rpn11/S13/PSMD14 and Rpn3/S3/PSMD3, 
Rpn7/S10a/PSMD6, Rpn12/S14/PSMD8, Rpn7/S10a/PSMD6 which combine 
together and ultimately with the base through the Rpn10/S5a/PSMD4 subunit (Murata 
et al., 2009). 
The assembly of the 26S proteasome is achieved through specific interaction between 
20S CP and 19S RP subunits: Rpt6/S8/PSMC5 is known to interact with α2/PSMA2, 
Rpt2/S4/PSMC1 binds to α7/PSMA7, Rpt5/S6a PSMC3 can bind to α4/PSMA4 and 
Rpn2/S1/PSMD1 joins to the α/PSMA ring of the 20S CP (Satoh et al., 2001; Gillette 
et al., 2008; Rosenzweig et al., 2008). 
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Figure 1.1  
 
 
 
 
Figure 1.1 Schematic representation of the 20S core particle. The α/PSMA subunits 
form the outer rings of 20S CP; and β/PSMB subunits form two inner rings. Abbreviations: 
PSMA, PSMB: proteasomal subunits of mammalian subunits A or B. 
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Figure 1.2 
 
 
 
 
 
Figure 1.2 Schematic representation of the 19S regulatory particle. Deletion of the 
base subunit ATPase PSMC1 causes failure in the formation of 26S proteasome, which is the 
basis for creation of Psmc1
fl/fl;CaMKIIα-Cre mouse model of neurodegeneration. 
Abbreviations: PSMC, PSMD: proteasomal subunits of mammalian subunits C or D;   S: 
proteasome subunits for Saccharomyces cerevisiae; Rpn: non ATPase regulatory particles; 
Rpt: ATPase regulatory particles. 
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1.2.5 Ubiquitin 
Ubiquitin is a 76 amino acid protein with a molecular weight of 8.5 kDa. Ubiquitin is 
expressed in all eukaryotic cells by four genes; RpS27A and Uba52 both produce a 
single copy of ubiquitin fused with ribosomal protein (S27a and L40 respectively), 
while Ubb and Ubc are polyubiquitin encoding genes. The products of these genes are 
ubiquitin precursors, which are deubiquitinated to release ubiquitin monomers 
(Wiborg et al., 1985; Baker and Board, 1987a, b; Redman and Rechsteiner, 1989).  
Post-translational modification by ubiquitin involves different topologies; a single 
ubiquitin molecule (mono-ubiquitinated), several mono-ubiquitins (multiple mono-
ubiquitination) or polyubiquitination via the diverse lysine residues in ubiquitin. 
Ubiquitin has seven lysine residues; lys6, lys11, lys27, lys29, lys33, lys48, and lys63 
as well as N-terminal tail that are involved in ubiquitination allowing the formation of 
diverse polyubiquitin chains (Weissman, 2001; Passmore and Barford, 2004). 
Ubiquitin modifications are decoded by ubiquitin receptors or ubiquitin binding 
domains (UBD) that interact non-covalently with the ubiquitin signals. Taken 
together, the combination of ubiquitin modifications and UBDs leads to a wide range 
of signals that have been shown to be involved in a variety of intracellular biological 
processes, such as DNA repair, endocytosis, autophagy, inflammation and 
proteasomal degradation (Husnjak and Dikic, 2012).   
1.2.6 Ubiquitination 
The post-translational modification of a protein substrate, with ubiquitin is called 
ubiquitination. It is thought that proteins targeted for 26S proteasomal degradation are 
tagged with at least four ubiquitins in a polyubiquitin chain linked through lysine 48 
(Chau et al., 1989). However, recently it was shown that all the ubiquitin linkage-
types with the exception of lysine 63 may facilitate proteasomal degradation (Xu et 
al., 2009). 
Ubiquitination is a multistep process (Figure 1.3). An ubiquitin-activating enzyme 
(E1) activates and binds to ubiquitin through the formation of a thiol-ester bond with 
the C-terminal glycine (Gly76) residue of ubiquitin molecule in an ATP-dependent 
step. The activated ubiquitin is transferred to a cysteine group of a second enzyme; an 
ubiquitin-conjugating enzyme (E2). The ubiquitin molecule is then transferred to the 
substrate by the action of an ubiquitin ligase enzyme (E3). This sequence of events 
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leads to the formation of an isopeptide bond between a lysine residue of the substrate 
protein and the C-terminal glycine of ubiquitin. This may be followed by the 
sequential addition of ubiquitin to a lysine residue in the substrate bound ubiquitin, 
forming a lysine-specific polyubiquitin chains (Ciechanover, 1994; Pickart, 2001; 
Glickman and Ciechanover, 2002; Johnston and Madura, 2004). Subunits of the 26S 
proteasome recognize lysine 48-tagged unwanted proteins as a signal for degradation. 
These are bound, deubiquitinated, unfolded and translocated into the 20S CP for 
degradation into short peptides; ubiquitin molecules are recycled for further signalling  
(Liu and Jacobson, 2012). 
1.2.6.1 The ubiquitin activation enzyme (E1): It is the product of a single gene that 
facilitates the activation of ubiquitin by an ATP-dependent process. It has a reactive 
cysteine residue that can bind to the ubiquitin molecule through a thiol-ester bond. 
The E1 enzyme carries activated ubiquitin to the E2 ubiquitin conjugating enzyme 
(Pickart, 2001; Johnston and Madura, 2004). 
1.2.6.2 The ubiquitin conjugating enzyme (E2): It is a family of proteins designated 
Ubc for S.cerevisiae or UBCH for human. The E2 has a reactive cysteine residue that 
can form a thiol-ester bond with the ubiquitin molecule transferred from E1 in another 
ATP dependent step (Jentsch et al., 1990). The E2 can also interact with the E3 
ubiquitin ligase (see section 1.2.6.3) to enhance ubiquitin-substrate binding (Johnston 
and Madura, 2004). Several E2 isozymes have been identified that may have specific 
functions. For example, Ubc1 can mediate lysine 48-linked polyubiquitin chains of 
unwanted substrates for 26S proteasome degradation (Rodrigo-Brenni and Morgan, 
2007), while Ubc13 mediates lysine 63-linked polyubiquitin chains involved in cell 
signalling  (Hofmann and Pickart, 1999; Deng et al., 2000). 
1.2.6.3 The ubiquitin ligase enzyme (E3): There are two families; one containing 
proteins with a HECT (homologous to E6-AP C-terminus) domain and the other with 
a RING (Really Interesting New Gene) finger domain. Both domains, in association 
with other proteins found in the E3 complex, can bind to the E2 and facilitate 
substrate recognition and ubiquitination.  
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Figure 1.3 
 
 
 
Figure 1.3 Protein ubiquitination and degradation by the ubiquitin 26S proteasome 
system 
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1.2.7 Unanchored polyubiquitin chains 
Unanchored polyubiquitin chains (‘free’) are not attached to a substrate protein. In 
early studies, these chains were chemically synthesized; the chain length was between 
two to eight ubiquitin molecules (Piotrowski et al., 1997). However, the detection of 
Ubp14 in yeast supported the presence of unanchored ubiquitin chains. Ubp14 
disassembles unanchored polyubiquitin chains in vitro (Amerik et al., 1997). In 
human cells, knockdown of isopeptidase T (Iso-T), a specific deubiquitinase for 
unanchored polyubiquitin chains, causes increased levels of free polyubiquitin chains 
that may compete with polyubiquitinated protein substrates for proteasome binding 
(Dayal et al., 2009). Few studies have investigated the physiological function of 
unanchored polyubiquitin chains, but a recent study suggested lysine 63-linked free 
chains may be involved in activating kinases in vitro (Xia et al., 2009) and in innate 
immunity (Zeng et al., 2010).  
1.2.8 Ubiquitin specific peptidases (deubiquitinating enzymes) 
Deubiquitinating enzymes (DUBs) are a large family of proteases that are specific for 
ubiquitin. They are also known as ubiquitin hydrolyses. They are categorized into two 
main families; ubiquitin carboxy-terminal hydrolases (UCH) and ubiquitin-specific 
proteases (USP) (Reyes-Turcu et al., 2009). DUBs release ubiquitin from its fusion 
proteins or polyubiquitin chains during proteasomal degradation. This provides an 
essential pool of mono-ubiquitin for signalling. Moreover, DUBs can reverse the 
ubiquitination of target substrate proteins and generate mono-ubiquitin from 
unanchored polyubiquitin chains (Dayal et al., 2009). DUBs are important enzymes in 
intracellular ubiquitin homeostasis. 
1.2.9 Ubiquitin binding proteins 
Ubiquitin binding proteins (UBP) are a family of proteins that bind non-covalently to 
ubiquitin and ubiquitinated proteins via their ubiquitin binding domains (UBD), 
which depends on the ubiquitin chain length and linkage-type. UBDs bind to ubiquitin 
mainly through isoleucine-44, aspartate-58 and C-terminal (Gly-Gly) residues 
(Husnjak and Dikic, 2012). UBPs have different structures and functions. For 
example, the zinc finger UBD is present in DUB enzymes such as isopeptidase T (Iso-
T or USP5), which has ability to bind and deubiquitinate unanchored polyubiquitin 
chains (Reyes-Turcu et al., 2009). The UBD of ubiquitin conjugating enzymes (E2) 
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has an essential role in the processes of protein substrate ubiquitination as described 
in section 1.2.6.2. The radiation sensitivity abnormal 23 protein (Rad23) contains two 
UBDs and may shuttle ubiquitinated proteins for proteasomal degradation (Kang et 
al., 2006). UBPs have also been identified in endocytosis and NF-қB signalling  
(Dikic et al., 2009). Importantly, some of these proteins are now used in bio-affinity 
chromatography techniques to pull-down ubiquitinated proteins from crude tissue 
homogenates for the purpose of their subsequent identification. Examples of these 
proteins are proteasomal subunit Rpn10/S5a/PSMD4 (Layfield et al., 2001) and zinc 
finger proteins-ZNF216 (Strachan et al., 2012). The identification of ubiquitinated 
protein substrates would significantly contribute to our understanding of the UPS and 
its functions in vivo.  
 
1.3 Protein homeostasis and neurodegenerative diseases 
Protein homeostasis involves protein synthesis as well as degradation and is essential 
for survival (Balch et al., 2008; Douglas and Dillin, 2010). The pathological 
hallmarks of neurodegenerative diseases are selective progressive neuronal loss and 
the formation of protein inclusions in surviving neurones. Changes in protein 
homeostasis have been implicated in a number of neurodegenerative diseases 
characterized by the accumulation of proteins in inclusions, e.g. Lewy bodies (LB). 
1.3.1 Lewy body diseases 
LB are the hallmark of a spectrum of neurodegenerative diseases known as the 
synucleinopathies because the major component of LB is the pre-synaptic protein α-
synuclein (Spillantini et al., 1998). Parkinson’s disease (PD) and dementia with Lewy 
bodies (DLB) are examples of LB diseases, but these abnormal protein inclusions are 
a common feature of Alzheimer’s disease (AD). The symptoms of the disease depend 
on the anatomical region of the brain affected by the formation of LB and 
neurodegeneration, e.g. brain stem and forebrain in PD and DLB patients respectively 
(Nussbaum and Polymeropoulos, 1997; Thomas, 2006). Therefore, although they are 
defined neurodegenerative diseases, they share common neuropathological features 
and may involve similar molecular mechanisms of disease cause and/or progression. 
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1.3.2 The Lewy body 
Histological studies reveal the formation of eosinophilic cytoplasmic inclusions in 
surviving neurones in neurodegenerative diseases; LB (Dunnett and Björklund, 1999; 
Mattila et al., 2000). There are two morphological types of LB. The classical LB has a 
dense core surrounded by a halo and is found in brain stem regions associated with 
PD. The cortical LB is less defined and without a halo; found in cortical regions 
associated with Parkinson’s disease with dementia (PDD) and DLB (Sakamoto et al., 
2002). There is also the Pale body (PB), which is considered a LB precursor 
(Hayashida et al., 1993). 
Compartmentalization of aggregated proteins may prevent potentially toxic proteins 
affecting normal neuronal function. It is also possible that the protein inclusions cause 
cellular damage. However, the role of protein inclusions in promoting 
neurodegeneration or neuroprotection is the subject of debate. Several studies have 
suggested LB formation is integral to the progression of neurodegeneration, showing 
reduced protein aggregation is neuroprotective (Trojanowski et al., 1998 ; Zhang et 
al., 2005 ; Pan et al., 2008; Gavilan et al., 2009). Interestingly, LB are absent in some 
cases of familial PD and are present in the aging asymptomatic population (Harrower 
et al., 2005). The mechanisms involved in protein inclusion formation remain elusive, 
including the role of ubiquitin. 
1.3.3 Parkinson’s disease  
PD was first described by the English physician, James Parkinson, as a shaking palsy 
(Parkinson, 2002). The disease is the most common movement disorder resulting 
primarily from an impairment of the basal ganglia that regulate voluntary movement 
(Jankovic, 2008). This is caused by loss of dopaminergic neurones in the substantia 
nigra pars compacta that project to the basal ganglia (putamen and caudate nuclei) 
leading to a decrease in dopamine signalling and alterations in the activity of the 
neuronal circuits within the basal ganglia (Bartels and Leenders, 2009). The motor 
dysfunction often co-presents with other non-motor symptoms, including autonomic 
dysfunction and a behavioural phenotype. In the later stages of disease dementia is 
also common, which may be associated with prevalent LB in the neocortex as in PDD 
(Stein, 1990; Braak et al., 2003; Jankovic, 2008). 
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The symptoms of PD can be treated by various drugs, which aim to increase 
dopaminergic activity in the brain, such as the dopamine precursor levodopa (L-
DOPA /carbidopa) and dopamine agonists. In the early stages of L-DOPA/carbidopa 
treatment, symptoms are reduced and patients well-treated. However, with long-term 
therapy tolerance develops leading to motor fluctuation with dyskinesia (Sujith and 
Lane, 2009 ). Dopamine agonists include lisuride, pergolide, pramipexole ropinirole 
and rotigotine are used to treat the motor symptoms of PD (Müller, 2012). These also 
are associated with side effects and some have been withdrawn from use. Monoamine 
oxidase inhibitors, such as rasagiline and selegiline, which act to decrease dopamine 
metabolism are also used as mono-therapy in early PD and provide mild symptomatic 
benefits (Lang and Lees, 2002; Schapira, 2005). Catechol-o-methyltransferase 
inhibitors tolcapone and entacapone have been used in adjunctive therapy with L-
DOPA/carbidopa to inhibit dopamine degradation and decrease tolerance effects due 
to continuous dopamine therapy. However, their use has been restricted to specific 
cases (Bonifacio et al., 2007). There are several non-pharmacological treatments for 
PD, including stem cell therapy, but this is still far from clinical testing and has only 
shown limited effectiveness in animal models of PD (Glavaski-Joksimovic and Bohn, 
2013). Neurosurgical intervention by deep brain stimulation (DBS) has shown 
increased interest due to the adverse effects of drug treatment.  DBS of the 
subthalamic nucleus (STN) and the globus pallidus internus (GPi) has been 
documented to improve the L-DOPA response in PD. There are specific criteria for 
this type of treatment, including the presence of disability and absence of cognitive 
dysfunction which limits its therapeutic use (deSouza et al., 2013). This summarizes 
several of the treatment options for PD, which only provide symptomatic relief, and 
highlights the need to develop treatments to prevent and slow progression of this 
disease. 
1.3.4 Dementia with Lewy bodies 
Dementia is a condition of progressive loss of cognitive ability. The main symptoms 
of dementia are loss of memory, confusion, difficulty with speech and understanding, 
changes in personality and behavior often with visual hallucinations and parkinsonism 
(Galasko, 2001). There are many different types of dementia. AD is the most common 
dementia and neurodegenerative disease. DLB is the second most common cause of 
cognitive impairment in the elderly after AD (Zaccai et al., 2005). DLB may occur in 
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a ‘pure’ form, but it is increasingly recognized that this occurs in conjunction with PD 
in the condition of PDD (Horimoto et al., 2003).  
The pharmacological treatment of DLB is mainly aimed at reducing disease 
symptoms. Dysfunction of cholinergic activity in the forebrain is thought to be the 
predominant patho-physiological mechanism in the development of DLB and PDD 
and the nucleus of Meynert is frequently affected by LB (Whitehouse et al., 1983). 
However, widespread distribution of LB has been described, including the cerebral 
cortex, midbrain, brainstem nuclei, basal forebrain nuclei and limbic cortical region 
(Braak et al., 2003; Neef and Walling, 2006). Since the disease presents with low 
levels of acetylcholine in the brain, treatment includes the use of acetylcholinesterase 
inhibitors (Gomez-Tortosa et al., 1998). Rivastigmine, donezepil and galanthamine 
have been used for treatment of dementia (O'Brien and Burns, 2011; Osona-Nunez et 
al., 2011). Although these drugs may improve cognitive function in PDD, they can 
worsen the symptoms of parkinsonism (Almaraz et al., 2009). Importantly, similar to 
other neurodegenerative diseases, current treatments do not delay dementia 
progression (Masoodi, 2013). 
1.3.5 Dysfunction of the UPS and neurodegenerative disease 
Interestingly, ubiquitinated and UPS proteins are a consistent feature of the inclusion 
bodies present in surviving neurones of the major neurodegenerative diseases, 
including PD, AD and DLB (Mayer et al., 1989). This observation suggests 
impairment of the UPS is involved in disease cause and/or progression. Several 
studies have been reported to support this hypothesis. The proteolytic activity of the 
20S proteasome was shown to be impaired in patients with sporadic PD (McNaught et 
al., 2003). The use of pharmacological inhibitors of the 20S proteasome has been 
controversial. However, an important study using conditional genetic depletion of 26S 
proteasomes in mouse brain neurones showed 26S proteasomal dysfunction caused 
neurodegeneration and the formation of inclusions resembling human pale bodies 
(Bedford et al., 2008). Neurodegenerative diseases are age-related and accumulation 
of ubiquitinated proteins was detected in aged drosophila, associated with a decline in 
the assembly of 19S RP and 20S CP (Tonoki et al., 2009). These studies suggest that 
removal of unwanted proteins is important to maintain cellular proteostasis and 
survival.  
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The presence of ubiquitinated α-synuclein in LB inclusions implicates dysfunction of 
their degradation. The UPS is the major pathway for the degradation of α-synuclein 
under normal conditions (Bennett et al., 1999) suggesting dysfunction of this system 
may lead to the accumulation of α-synuclein in inclusions. Mutations in α-synuclein 
have been described in PD and DLB (Zarranz et al., 2004). Further support for the 
involvement of the UPS in neurodegenerative disease progression includes mutations 
in the genes encoding DUB ubiquitin carboxyl-terminal esterase L1 (UCHL1) and E3 
ubiquitin ligase Parkin associated with familial cases of PD (Leroy et al., 1998). 
Reduced levels of UCHL1 have been described in patients with DLB (Barrachina et 
al., 2006). Taken together, these studies suggested that the role of the UPS in disease 
cause and/or progression needs to be further investigated and will form part of this 
aims of this thesis. 
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1.4 Oxidative stress and neurodegeneration 
Oxidative stress is one of the key hypotheses implicated in the pathogenesis of several 
neurodegenerative diseases. A relationship between proteasomal dysfunction and 
oxidative stress has been described that may be relevant to human disease. 
The superoxide anion (O2 −), hydrogen peroxide (H2O2) and hydroxyl radical (HO•) 
are collectively known as reactive oxygen species (ROS). They are mainly generated 
from the mitochondria during the process of oxidative phosphorylation (OXPHOS). 
Superoxide radicals formed during this process are converted to hydrogen peroxide. 
Hydrogen peroxide can be further converted to water and oxygen by peroxidases or 
partially reduced to form further harmful molecules such as the hydroxyl radical 
(Murphy, 2009). Another source of ROS in the cell is the enzyme nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, which generates the superoxide 
radical as part of the electron transfer from NADPH to oxygen. Studies have 
suggested that this enzyme is the major source of ROS in the brain and that NADPH 
oxidase enzyme activity is increased in neurodegenerative disease (Shimohama et al., 
2000). Another form of reactive species is reactive nitrogen species (RNS) such as 
nitric oxide (NO) and peroxynitrite (ONOO−). Nitric oxide may be generated during 
normal cellular metabolic processes; in neurones it is generated from L-arginine by 
the enzyme neuronal nitric oxide synthase for normal signalling in learning and 
memory (Jacoby et al., 2001; Sadeghian et al., 2011). Therefore, reactive species are 
continuously produced during normal cellular activities and must be tightly controlled 
to protect the cell form oxidative stress. 
Reactive species are tightly controlled by specific antioxidant enzymes, e.g. catalase, 
superoxide dismutase, glutathione peroxidase and other peroxidase, as well as 
antioxidant compounds such as reduced glutathione (GSH), vitamin C and E. Failure 
of the cellular antioxidant protection or increased levels of reactive species will lead 
to oxidative and/or nitrative stress, which oxidizes critical cellular constituents (Pryor 
and Stanley, 1975; Shacter, 2000). 
Oxidative stress has been implicated in the brains of patients with PD and DLB 
associated with changes in protein homeostasis such as α-synuclein aggregation 
(Castellani et al., 1996; Giasson et al., 2000; Yan et al., 2012). Mitochondrial 
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dysfunction is a key hypothesis in neurodegenerative disease pathogenesis and a 
source of ROS (Onyango, 2008; Shadrina and Slominskii, 2008; Moran et al., 2012). 
Exogenous exposure of cells to herbicides compound such as Paraquat that can 
produce reactive species has been reported to cause neurodegeneration (Miller, 2007; 
Sun et al., 2010). Failure of antioxidant enzymes can also cause neurodegeneration. 
Superoxide dismutase detoxifies superoxide radicals to hydrogen peroxide, which is a 
less reactive species. Mutations in superoxide dismutase cause a fatal 
neurodegenerative disorder called familial amyotrophic lateral sclerosis (FALS) 
(Deng et al., 1993). A mouse model of AD has been created by deletion of superoxide 
dismutase; this mouse showed increased oxidative stress with accumulation and 
oligomerization of β-amyloid protein and cognitive impairment (Murakami et al., 
2011).  
Peroxiredoxins are a group of enzymes with peroxidase activity that facilitate the 
reduction of hydrogen peroxide, lipid peroxides and peroxynitrite (Wood et al., 2003). 
A transgenic mouse overexpressing peroxiredoxin-2 was shown to tolerate neuronal 
injury caused by ischemia (Gan et al., 2012), a condition usually followed by 
increased production of ROS as result of increased utilization of oxygen for 
compensation. 
1.4.1 Lipid peroxidation 
Membrane phospholipids are the most vulnerable cellular component to oxidation. 
Lipid peroxidation is a well-known mechanism of cellular damage. Polyunsaturated 
fatty acids can be oxidized by ROS/RNS. Figure 1.4 shows the lipid peroxidation 
cascade. The reactive species extracts a hydrogen atom from their structural 
backbone, leaving behind a carbon radical. This has the ability to combine with 
oxygen to make a peroxy radical. The peroxy radical, in turn, can start a cascade of 
hydrogen abstraction from neighboring backbones, splitting the carbon backbone to 
form unstable lipid hydroperoxides that are ultimately converted to stable end 
products such as malondialdehyde (MDA) and / or 4-Hydroxynonenal (HNE) (Byun 
et al., 1999; Rodenas et al., 2000). MDA levels have been used extensively as an 
indicator of oxidative stress in the biological milieu. Lipid peroxidation may lead to 
inhibition of membrane function, destroying its barrier properties (Stadelmann-
Ingrand et al., 2004).   
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Figure 1.4 
 
 
 
  
 
 
 
 
Figure 1.4  Lipid peroxidation cascade. Lipid peroxidation is initiated by hydrogen (H) 
abstraction, propagation and decomposition to carbonyl products such as aldehydes, e.g. 
malondialdehyde (MDA) and 4-Hydroxynonenal (HNE). Diagram taken from (Conrad et al., 
2013). 
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1.4.2 Protein oxidation 
Proteins are also a target of ROS/RNS and their oxidation leads to covalent 
modification of proteins to form reactive aldehydes or ketones. Several amino acid 
acyl side chains can be oxidized into carbonyls, e.g. lysine, arginine, proline and 
threonine, whereas others such as Tyrosine undergo to nitration by peroxynitrite 
(Shacter, 2000). Oxidative damage to proteins causes loss of function and 
hydrophobicity. This could potentially lead to increased aggregation, which has been 
shown in AD brain tissue together with the accumulation of ubiquitinated proteins 
(Dasuri et al., 2010). Protein nitration may also facilitate protein aggregation 
associated with neurodegenerative disease; nitrated α-synuclein has been reported to 
aggregate (Giasson et al., 2000). The proteasome is vulnerable to oxidative 
modification and proteasomal proteins are targets of ROS/RNS, which causes 
inhibition of proteasomal activity (Glockzin et al., 1999; Osna et al., 2004). In 
particular, the Rpt5/S6a/PSMC3 ATPase subunit of 26S proteasome has been shown 
to undergo oxidation modification (Ishii et al., 2005). Further components of the UPS 
may be oxidatively modified; this has been shown for UCHL1, which was associated 
with increased aggregation of proteins in AD and PD (Choi et al., 2004). Proteasomal 
dysfunction and oxidative stress are implicated in the pathogenesis of several 
neurodegenerative diseases, but their relationship with each other requires further 
investigation. 
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1.5 Reactivation of astrocytes in neurodegenerative diseases 
Astrocytes are ubiquitously expressed star-shaped glial cells present in most regions 
of the central nervous system. They have extensive finely branched processes that 
make physical contact with the neuron’s dendrites and synapses (Halassa et al., 2007). 
Astrocytes also contact cerebral blood vessels and control cerebral blood flow (Parri 
and Crunelli, 2003) through the release of nitric oxide, arachidonic acid and 
prostaglandins (Haydon and Carmignoto, 2006; Iadecola and Nedergaard, 2007). The 
astrocytes therefore connect neuronal cells, providing structural integrity and control 
brain blood supply. Increased reactivity and number of astrocytes has been 
documented in several neurodegeneration diseases (Pekny and Nilsson, 2005; 
Sofroniew and Vinters, 2010; Yata K, 2011). The 26S proteasome-depleted mouse 
model showed evidence of extensive astrocytic gliosis in the affected brain regions 
(Figure 1.5) (Bedford et al., 2008). Therefore, we will briefly review the role of 
astrocytes in physiology and pathology. 
1.5.1 The role of astrocytes 
In normal physiology, astrocytes can release the amino acid neurotransmitter 
glutamate to provoke signals in adjacent neurones and also express the glutamate 
transporter to remove glutamate from the synaptic space (Parpura and Haydon, 2000; 
Santello and Volterra, 2009). Therefore, astrocytes promote a role in synaptic 
transmission by regulating the extracellular levels of glutamate, providing protection 
from glutamate’s excitotoxicity. Astrocytes have also been reported to take up 
increased extracellular potassium ions following neuronal activity via a potassium 
channel to maintain resting membrane potential (Walz, 2000). Metabolically, 
astrocytes can store glycogen and supply energy substrates to the neurones. They can 
perform glycolysis and release lactate into the extracellular space, which can be taken 
up by neurones (Choi et al., 2012). Astrocytes can provide neurones with protective 
antioxidants such as GSH (Sagara et al., 1996). In general, astrocytes are recognized 
to play an important role in the normal function of the central nervous tissue.  
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1.5.2 Reactive astrogliosis 
Astrocytes respond to neurodegeneration by a process referred to as reactive 
astrogliosis. This involves changes in their morphology, function and number. These 
changes have been considered as one of pathological features of neurodegenerative 
brain pathology. In general, astrocytes reactivation is characterized by extensive 
proliferation and the formation of glial scar (Sofroniew, 2009). The intracellular 
changes include increased expression of glial fibrillary acidic protein (GFAP) with 
hypertrophy of the astrocytic cell body and processes. In severe reactivation these 
processes overlap forming a barrier around the dying neurones. This barrier may be 
neuroprotective against inflammatory cell migration, but may also prevent the local 
re-growth of nerve fibres (Bush et al., 1999).  
There are many intra- and inter-cellular signalling molecules involved in reactive 
astrogliosis. These include polypeptide growth factors such as tumor necrosis factor-
alpha (TNF-α), interferon-γ (INFγ), cytokines such as interleukin 6 (IL-6), 
neurotransmitters such as glutamate, purines and reactive species such as nitric oxide 
as well as proteins associated with neurodegeneration such as β-amyloid (Hamby et 
al., 2008; Sofroniew, 2009). The antioxidant transcription factor, nuclear factor 
erythroid 2-related factor 2 (Nrf2), that controls the expression of antioxidant proteins 
has been reported to be activated in astrocytes and provided protection against 
neurotoxin, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced toxicity 
in mice modeling PD (Chen et al., 2009). 
 
1.6 26S proteasomal depletion mouse model; Psmc1
fl/fl
;CaMKIIα-Cre 
To increase understanding of the contribution of the UPS to neurodegenerative 
disease, a conditional genetic mouse model causing specifically 26S proteasomal 
depletion in neurones was created. Using Cre recombinase/loxP conditional gene 
targeting, inactivation of an essential subunit of the 19 RP, ATPase Psmc1 (see 
section 1.2.4), lead to depletion of 26S proteasomes in forebrain neurones (Bedford et 
al., 2008). The floxed Psmc1 gene was inactivated by calcium calmodulin-dependent 
protein kinase IIα promoter-driven Cre recombinase. This strategy did not affect the 
formation and activity of the ubiquitin-independent 20S proteasome.  
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Neuropathological studies of the mouse cortical brain tissue showed that 26S 
proteasomal depletion caused the formation of intraneuronal Lewy-like inclusions and 
neurodegeneration. Figure 1.5 shown extensive cortical neurodegeneration in 26S 
proteasome-depleted mouse cortex. The intraneuronal lewy-like protein inclusions 
were similar to human PB, containing ubiquitin, α-synuclein mitochondria (Figure 
1.6). The 26S proteasomal depletion mouse model also showed evidence of extensive 
gliosis in regions of neurodegeneration as indicated by changed morphology of 
astrocytes and increased number (Figure 1.5). Behavioural studies demonstrated a 
deficit in learning and memory in the Morris water maze test. The mice also showed 
growth retardation and premature death before 12 weeks of age. The 
neuropathological as well as behavioural changes in Psmc1
fl/fl;CaMKIIα-Cre mice 
make it a useful model to study mechanisms of neurodegeneration. This model is 
unique, leading to accumulation of ubiquitinated proteins and α-synuclein resembling 
pale bodies of human synucleinopathies and neurodegeneration. Other models of PD 
include α-synuclein transgenic and parkin knockout mice; genes associated with the 
familial disease.  Although these mice show evidence of behavioural and biochemical 
changes related to PD, but not to PDD or DLB, importantly, they do not display 
extensive neurodegeneration as seen in human disease (Periquet et al., 2005). In 
addition, aggregates of α-synuclein in these models do not resemble paranuclear LB 
like the Psmc1
fl/fl;CaMKIIα-Cre mice. 
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Figure 1.5 
 
 
 
 
Bedford, l et al., 2008, J Neurosci 28, 8189-98 
Figure 1.5 Extensive cortical neurodegeneration in Psmc1
fl/fl
;CaMKIIα-Cre mouse 
cortex. Histological examination of coronal brain sections from control and 
Psmc1
fl/fl
;CaMKIIα-Cre (mutant) mice. A, hematoxylin and eosin (H&E)-stained whole brain 
sections, and B, at higher magnification. The arrows indicate pyknotic nuclei in the 
Psmc1
fl/fl
;CaMKIIα-Cre cortex. Immunohistochemistry with cleaved caspase 9 (C) and glial 
acidic fibrillary protein (GFAP) (D).                                 
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Figure 1.6 
 
 
 
 
 
Bedford, l et al., 2008, J Neurosci 28, 8189-98 
Figure 1.6 Lewy-like intraneuronal inclusion pathology in Psmc1
fl/fl
;CaMKIIα-Cre 
mouse cortical neurones at 6 weeks of age. A-C, show mouse (left-hand side) and human 
(right-hand side) inclusions stained with H&E, ubiquitin and α-synuclein respectively. E-G, 
show ultrastructure of mouse Lewy-like inclusions. E, shows the paranuclear inclusion (n, 
nucleus; i, inclusion), G and F show mitochondria (arrows), and H, shows autophagosome-
like dense bodies.  
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Aim 
Together, the investigations in this thesis aim to identify mechanisms involved in 
neurodegeneration and inclusion formation that may be translated to human disease. 
There are limited studies investigating the ubiquitome in mouse brain in vivo. One of 
the aims of this thesis was to identify novel ubiquitinated proteins in mouse brain 
neurones that further studies would investigate their function. These proteins may be 
new proteasomal substrates or involved in the formation of LB and associated with 
neurodegeneration. The Psmcl
fl/fl
;CaMKIIα-Cre mouse displays extensive 
accumulation of ubiquitinated protein in the mouse forebrain making it an ideal model 
for this aim. The use of bioaffinity chromatography with immobilized ubiquitin 
binding domain (UBD) attached to solid beads (matrices) was chosen to capture 
polyubiquitinated proteins from tissue homogenate (Strachan et al., 2012). This study 
used ZNF216 protein which contains an N-terminal ZnF A20 UBD to capture 
ubiquitinated proteins (Hishiya et al., 2006). 
In addition to the ubiquitome study, which is specific for one protein category, we 
aimed to investigate the global proteome in Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex. To 
our knowledge this is novel; there are limited proteomic studies associated with 
accumulation of ubiquitinated proteins in vivo. We chose to use 2-dimensional 
fluorescence difference in-gel electrophoresis (2-D DIGE) introduced by Unlu et al. 
(1997) (Unlü, 1997). This is a sensitive proteomics technique that can visualize 
thousands of proteins spots following two-dimensional protein analysis gel 
electrophoresis (2-D PAGE) and has been used in basic research as well as clinical 
studies (Jesse et al., 2012; Wang, 2010). Differential protein expression identified in 
the Psmc1
fl/fl
;CaMKIIα-Cre compared to control cortices may lead to the 
identification of novel proteins involved in neurodegeneration that can be translated to 
human disease, i.e. biomarkers, protective and /or detrimental signalling. We aimed to 
understand the mechanisms of neurodegeneration associated with 26 proteasome 
dysfunction in mammalian brain tissue. The proteins identified will be further 
investigated using biochemical approaches and immunohistochemistry. 
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CHAPTER 2 
 
Materials and Methods 
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2.1 Experimental animals 
2.1.1 Generation of Psmc1
fl/fl;CaMKIIα-Cre Mice 
Mice were generated by conditional Cre/loxP gene targeting. A key subunit of the 26S 
proteasome, ATPase Psmc1, was inactivated by crossing floxed Psmc1 mice 
(Psmc1
fl/fl
) with mice expressing Cre recombinase from the calcium calmodulin-
dependent protein kinase IIα promoter (CaMKIIα-Cre) (Bedford et al., 2008). This 
leads to the inactivation of Psmc1 in forebrain neurones (Psmc1
fl/fl
;CaMKIIα-Cre) at 
approximately postnatal week two. Psmc1
fl/fl
;CaMKIIα-Wt and Psmc1fl/wt;CaMKIIα-
Wt littermates were used as controls. Mice were housed under constant conditions of 
12 /12 h light-dark cycle and 21 ± 2 °C room temperature. Food and water were 
accessible ad libitum. All experiments were carried out in accordance with the Home 
Office Animals (Scientific Procedures) Act 1986, under the Home Office project 
license number 40/3394 and personal license 70/14272.  
 
2.1.2 Extraction of genomic DNA from mouse tissues 
2.1.2.1 Reagents 
1) Tissue lysis buffer: 100 mM Tris-HCL pH 8.5, 5 mM Na-EDTA, 0.2 % SDS 
and 200 mM NaCl. 
2) Proteinase K (10 mg /ml). 
3) Isopropanol. 
4) 70 % ethanol. 
2.1.2.2 Protocol  
Mouse tail or ear notches were used for extraction of genomic DNA (gDNA). 
Samples were placed in a 1.5 ml eppendorf tube and incubated overnight (12-24 hrs) 
at 55 °C in tissue lysis buffer (700 µl for tail or 500 µl for ear notches) containing a 
final concentration of 0.5 mg /ml proteinase K. The samples were vortexed and then 
centrifuged at 9300 x g for 10 minutes at room temperature. The supernatant was 
transferred into a new eppendorf tube with an equal volume of isopropanol to 
precipitate the gDNA. The tubes were shaken vigorously followed by centrifugation 
at 16100 x g for 10 minutes at room temperature. The supernatant was discarded and 
500 µl of 70 % ethanol added to the gDNA pellet and again centrifuged at 16100 x g 
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for 10 minutes at room temperature. The 70 % ethanol was discarded and gDNA 
pellet air dried at room temperature. 50-150 µl of nuclease-free water was added to 
the pellet. 
2.1.3 Polymerase Chain Reaction (PCR) 
2.1.3.1 Reagents 
1) Primers: 4 µM Cre (sense and antisense), 4 µM Psmc1-LB3 (sense), 4 µM 
Psmc1-D1360 (sense) and 4 µM Psmc1-X316 (antisense) (sequences are given 
in appendix I-A). 
2) 10X PCR buffer containing 20 mM MgCl2 (Fermentase). 
3) DNA polymerase 5 U/µl (Fermentase). 
4) 1 mM deoxynucleotide triphosphates (dNTPs). 
2.1.3.2 Protocol  
The final reaction volume for each PCR was 10 µl containing final concentrations: 0.5 
µl of gDNA template. The PCR was performed in a thermo-cycle PCR (Master cycle- 
eppendorf
®
) under the condition of 94°C for 3 minutes, and then for 30 cycle of 94°C 
for 1 minute, 60°C for 30 seconds and 72°C for 30 seconds. 
2.1.4 Agarose gel electrophoresis 
2.1.4.1 Reagents 
1) Tris-acetate EDTA buffer (TAE): 40 mM Tris-acetate, 1 mM EDTA pH 8 
with HCL. 
2) 4 % agarose gel solution (4.5 g agarose in 150 ml TAE). 
3) Ethidium bromide solution (1 % w/v in water). 
4) 50-1350 bp DNA Ladder  
2.1.4.2 Protocol 
The 4 % agarose gel solution was melted using a microwave. 7 µl of ethidium 
bromide was added to the melted agarose once cooled to approximately 55
o
C. The gel 
was poured into a gel tray pre-fitted with combs. Once the gel was set, TAE buffer 
was poured into the gel apparatus to cover the gel. The PCR samples and DNA ladder 
were loaded. A constant voltage of 150 V was applied for electrophoresis. PCR bands 
were detected by using a UV trans-illuminator (Figure 2.1).  
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Figure 2.1 
 
 
 
 
 
Figure 2.1  Representative image of Psmc1 and Cre genotyping. PCR products for 
Psmc1 (image A) and Cre (image B) following electrophoresis. Bands were detected using a 
UV trans-illuminator. Psmc1
fl 
 395 bp; Psmc1
wt 
 349 bp; Cre-recombinasae as shown. 
Examples of mouse genotypes: 
Mouse number 1 is Psmc1
fl/wt
;CaMKIIα-Wt (control) 
Mouse number 2 is Psmc1
fl/fl
;CaMKIIα-Wt (control) 
Mouse number 3 is Psmc1
fl/fl
;CaMKIIα-Cre (mutant) 
Mouse number 14 is Psmc1
fl/wt
;CaMKIIα-Cre (control) 
  
Psmc1fl   
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Sample numbers
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400-
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2.2 Preparation of affinity chromatography matrices and capture of 
ubiquitinated proteins 
2.2.1 Preparation of E. coli glycerol stock  
2.2.1.1 Reagents 
1) XL10-Gold® Escherichia coli: transformed with pGEX-4T-1 plasmid with 
GST-ZNF216 wild-type or GST-C30/33A ZNF216 mutant, containing β-
Lactam antibiotic selection cassette (kindly provided by Dr Layfield).  
2) 80 % (v/v) glycerol. 
3) Luria Broth (LB, 25 g /L). 
4) 2 ml Cryo tubes. 
2.2.1.2 Protocol 
1.5 ml of an overnight culture of E. coli transformed with either GST-ZNF216 wild-
type or GST-C30/33A ZNF216 mutant was spun down at 3300 x g 4˚C for 10 minutes 
and the supernatant discarded. Cell pellets were re-suspended in 425 µl of LB plus 75 
µl of 80 % (v/v) glycerol, transferred to a Cryo Tube and snapped frozen in liquid 
nitrogen. Bacterial glycerol stocks were stored at -80˚C. 
2.2.2 Plasmid purification for sequencing 
2.2.2.1 Reagents 
1) 1.5 ml overnight cultures of GST-ZNF216 wild-type and GST-C30/33A 
ZNF216 mutant E. coli. 
2) QIAprep Spin Mini-prep Kit for plasmid purification (Qiagen®). 
2.2.2.2 Protocol  
Plasmids were purified from overnight bacterial cultures of 1.5 ml. The protocol was 
performed as described in the QIAprep Spin Mini-prep Kit. The plasmids were 
quantified using a Thermo Scientific NanoDrop® ND-1000 spectrophotometer. 15 µl 
of 95 ng /µl plasmid was submitted for sequencing.  
The DNA sequencing results from both plasmids (GST-ZNF216 wild-type and GST-
C30/33A ZNF216 mutant) were blasted against each other for comparison using 
http://blast.ncbi.nlm.nih.gov/Blast. The DNA sequences were translated into 
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corresponding amino acid sequences using http://web.expasy.org/translate/. The 
comparative sequencing is presented in Appendix I-B and C. 
 
2.2.3 Preparation of 20 ml overnight E. coli culture  
2.2.3.1 Reagents  
1) Antibiotic stock solution (80 mg /ml ampicillin plus 20 mg /ml oxacillin). 
2) LB (25 g /L). 
3) Bacto-agar (15 g /L). 
2.2.3.2 Protocol 
LB-agar plates for E. coli expressing GST-ZNF216 wild-type and GST-C30/33A 
ZNF216 mutant were prepared using the reagents described. This mixture was 
autoclaved for sterilization, cooled and the antibiotic added to a final concentration of 
80 µg /ml ampicillin and 20 µg /ml oxacillin. From the bacterial glycerol stocks 
(Section 2.2.1) cells were streaking onto LB-agar plates and incubated at 30˚C 
overnight. A single colony from each plate was inoculated into 20 ml LB media 
containing antibiotics at a final concentration of 80 µg /ml ampicillin and 20 µg /ml 
oxacillin. The cultures were incubated overnight at 37˚C with shaking. 
 
2.2.4 Bacterial expression of recombinant proteins  
2.2.4.1 Reagents 
1) 500 ml of LB (25 g /L). 
2) 200 mM isopropyl-β-D-thiogalactopyrinosid (200 mM IPTG stock). 
3) Tris-buffered saline (TBS) with 1% Triton-100 pH 7.5 (TBST-100): 10 mM 
Tris, 150 mM sodium chloride and 0.1 % (v/v) Triton-x 100. 
4) Spectrophotometer for OD600 (BioPhotometer- eppendorf 
® 
) 
2.2.4.2 Protocol 
20 ml overnight cultures (Section 2.2.3) were diluted into 500 ml of LB containing 
antibiotics and grown for 3 hours with shaking at 37 °C and 190 rpm until OD600 = 
0.6-0.8 (growth phase). GST-recombinant protein expression was induced by adding 
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0.5 ml of stock IPTG an incubated for a further 3 hours with shaking. The culture was 
spun down at 4000 x g 4˚C for 30 minutes. Supernatants were discarded and the 
resultant pellets re-suspended in 5-10 ml TBST-100 and stored at -20˚C until required 
for protein purification. 
 
2.2.5 Purification of GST-ZNF216 recombinant proteins  
2.2.5.1 Reagents 
1) Chromatography columns - 10 ml and 50 ml capacity (BIORAD). 
2) Glutathione Sepharose 4B (GSH) beads (GE Healthcare). 
3) Tris-buffered saline (TBS) with 1 % Triton-100 pH 7.5 (TBST-100): 10 mM 
Tris, 150 mM sodium chloride and 0.1 % (v/v) Triton-x 100. 
2.2.5.2 Protocol 
The bacterial pellets prepared in Section 2.2.4 were thawed and sonicated on ice at ~ 6 
microns for 15 seconds 7 times. The bacterial was then spun down for 30 minutes at 
43000 x g 4˚C (Avanti JA 25.5 rotor type). The supernatant-1 was collected and kept 
on ice. An aliquot from the supernatant was kept for SDS-PAGE to visualize 
expression of recombinant proteins (see section 3.2.2). The pellets were discarded. 
A separate chromatography column was set up for each type of recombinant protein 
(GST-ZNF216 wild-type and GST-C30/33A ZNF216 mutant). A 10 ml or 50 ml 
column was used depending on the volume of recombinant protein. One volume 
(usually 1 ml) of ethanol pre-soaked glutathione (GSH) beads was added to each 
column and the ethanol storage buffer allowed running through. The GSH beads were 
washed with 5-10 volumes of TBST-100. Supernatant-1 was then added to the 
column and kept for 3 hours gently rotating in the cold room, allowing GSH bead-
GST-recombinant protein binding. After incubation, the supernatant-1 was allowed to 
run through and GSH beads washed three times with 5-10 volumes of TBST-100. A 
sample of the beads was kept for SDS-PAGE to check the binding to recombinant 
protein. The beads were washed twice with Thrombin Cleavage Buffer (TCB) to 
equilibrate before adding thrombin for GST-recombinant protein cleavage. 
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2.2.6 Thrombin cleavage of GST-recombinant proteins 
2.2.6.1 Reagents 
1) 0.5 U /µl thrombin (Sigma). 
2) Thrombin Cleavage Buffer (TCB); 20 mM Tris, 150 mM sodium chloride and 
2.5 mM calcium chloride dehydrate, pH 8.4 adjusted with HCL. 
2.2.6.2 Protocol 
One volume of thrombin-TCB solution (5 U Thrombin /1 ml TCB) was added to one 
volume containing GSH beads bound to recombinant protein. The columns were then 
rotated overnight in the cold room. The column flow through was collected and kept 
on ice. A further one volume of TCB was added to each column and incubated in the 
cold room for 1 hour to collect any residual recombinant proteins. This flow though 
was collected and pooled with the first overnight flow though (supernatant-2). An 
aliquot from the pooled supernatant-2 as well as of beads was kept for SDS-PAGE to 
characterize the cleavage of fusion protein by thrombin. The resultant supernatant-2 
should be cleaved ZNF216 recombinant proteins and was stored at -20˚C.  
 
2.2.7 Coupling ZNF 216 purified proteins to Sepharose beads - preparation of 
ZNF216 affinity matrices 
2.2.7.1 Reagents 
1) Cyanogen bromide activated – Sepharose-4B (CNBr) (GE Healthcare). 
2) Coupling buffer: 100 mM sodium hydrogen carbonate, 500 mM sodium 
chloride, pH 8.3. 
3) 1 mM hydrochloric acid. 
4) 1 M ethanolamine pH 8. 
5) Washing buffer 1: 100 mM sodium acetate, 500 mM sodium chloride, pH 4. 
6) Washing buffer 2: 100 mM Tris-HCl, 500 mM sodium chloride, pH 8. 
7) Column storage buffer: 50 % TBS, 50 % glycerol, 1 mM DTT, sodium azide, 
pH 7.4. 
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2.2.7.2 Protocol 
CNBr Sepharose beads were hydrated by incubation with 1mM hydrochloric acid (1 g 
/3.5 ml) for 15 minutes on a rocking platform. The Sepharose beads-HCl suspension 
was placed in the column and the hydrochloric acid allowed running through. The 
beads were washed twice with 5-10 volumes of coupling buffer. Supernatant-2 (see 
section 2.2.6) was thawed and protein concentration determined. A sample was kept 
for SDS-PAGE analysis. Supernatant-2 was added to the column of activated CNBr 
Sepharose (1 ml solid beads volume to 1- 4 mg ZNF216 protein) and incubated for 3 
hours rotating in a cold room to allow CNBr beads-ZNF216 protein binding. After 
incubation, the buffer was allowed to run through and a sample was kept for SDS-
PAGE analysis to check the unbound protein. Sepharose beads were washed twice 
with 5-10 ml ethanolamine; a further similar volume of ethanolamine was added and 
the columns incubated overnight rotating in the cold room to block nonspecific 
binding site in the sepharose beads. The ethanolamine was allowed to run through the 
column and the beads were washed with 5-10 bead volumes of coupling buffer 
followed by washing 4 times alternating between washing buffers 1 and 2. These 
ZNF216 affinity matrices were then washed and stored with 5 volumes of storage 
buffer. Matrices used immediately were kept in TBS only. ZNF216 affinity matrices 
were kept at 4°C. 
 
2.2.8 Capture of ubiquitinated proteins from brain tissue homogenate 
2.2.8.1 Reagents 
1) Washing buffer (TBS-NP40): 10 mM Tris, 150 mM sodium chlorifd, Nonidet 
P- 40, 1 mM DTT, pH 7.4. 
2) Protease inhibitor cocktail (Sigma-Aldrich). 
3) N-ethylmaleimide (NEM). 
4) Phenylmethane sulfonyl fluoride (PMSF). 
5) Homogenizing buffer: TBS-NP40, protease inhibitor cocktail (1:100), 5 mM 
NEM, 1 mM phenylmethane sulfonyl fluoride (PMSF), and pH 7.4. 
6) 1 M DTT. 
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2.2.8.2 Protocol 
Mouse brain cortices were homogenized using a Dounce glass homogenizer in cold 
homogenizing buffer. Each brain cortex was homogenized in 2-2.5 ml homogenizing 
buffer. Homogenates were clarified by centrifugation at 30800 x g for 20 minutes. 
The supernatants were incubated with 10 mM DTT for 15 minutes to remove the 
NEM in homogenizing buffer. Protein concentration was determined by Bradford. 
Equal amounts of protein in a similar volume of supernatant were incubated with the 
pre-washed ZNF216 affinity matrices (see 2.2.7) in a column for 3 hours rotating in 
the cold room. The column flow through was then collected and a sample from this 
kept for Western blot analysis of the unbound fraction. The affinity matrices were 
washed 3 times for 10 minutes, and stored in TBS-NP40 (1 ml beads to 1 ml buffer; 
50 % slurry). Samples from the bound matrices were collected to investigate the 
binding of ubiquitinated proteins by western blot analysis. 
 
2.2.9 Capture of Lysine- 48 synthetic polyubiquitin chain  
2.2.9.1 Reagents 
1) Washing buffer (TBS-NP40): 10 mM Tris, 150 mM sodium chloride, Nonidet 
P-40, 1 mM DTT, pH 7.4. 
2) Synthetic Lys48 polyubiquitn chain. 
2.2.9.2 Protocol 
An amount of 2 µg of Synthetic Lys48 polyubiquitn chain were dissolved in 800 µl 
TBS-NP40 buffer and incubated with the pre-washed 200 µl of 50 % slurry of 
ZNF216 affinity matrices (see 2.2.7) in an eppendorf tube for 3 hours rotating in the 
cold room. This was followed by centrifugation and the supernatant was then 
collected and a sample from this kept for Western blot analysis of the unbound 
fraction. The affinity matrices were washed 3 times for 10 minutes, and samples from 
the bound matrices were collected to investigate the binding of synthetic Lys48 
polyubiquitn by Western blot analysis. 
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2.2.10 Deubiquitination using ubiquitin-specific protease (USP2) enzyme 
2.2.10.1 Reagents 
1) USP2 catalytic domain (0.5 µg /µl; UW9850 Enzo Life Sciences). 
2) ZNF216 affinity matrices bound to ubiquitinated proteins (see section 2.2.8). 
3) Deubiquitinase buffer (DUB buffer): 50 mM Tris-HCl, 1 mM DTT, pH 7.4. 
4) TBS-NP40 (see section 2.2.8.1).  
5) 2 ml eppendorfs. 
2.2.10.2 Protocol 
ZNF216 affinity matrices were washed 3 times for 10 minutes each time with TBS-
NP40 in rotating columns. 50 % slurry of affinity matrices were transferred into 2 ml 
eppendorf tubes. USP2 was added (10 µg /0.4 ml 50 % slurry) and the affinity 
matrices were incubated at 37 °C rotating overnight. Matrices were centrifuged at 400 
x g using a top bench centrifuge for 5 minutes at room temperature. The supernatants* 
were collected carefully and the beads were washed with DUB buffer. A 20 µl sample 
of the supernatant and 50 µl fraction of matrices was also collected for Western 
blotting analysis. The rest of the supernatant* following incubation with DUB actions 
was submitted for mass spectrometry. In an alternative approach, the supernatant* 
was filtered through a 5 kDa cut-off filter, involving centrifugation at 450 x g for 30 
minutes (HARRIER 18 / 80 MSE centrifuge). This resulted in a reduction in the 
supernatant volume from original of 1-2 ml to approximately 60-50 µl. These samples 
were subjected to 2 dimensional gels (DG) or 1DG SDS-PAGE.  The resultant protein 
spots or bands were excised from the silver stained gel trypsinated (see section 2.3.7 
and 2.4.4) and submitted for mass spectrometry; Matrix – associated laser desorption 
ionization– time of flight (MALDI-TOF-MS) was used. The generated peptide mass 
fingerprints by MALDI-TOF-MS were analyzed by uploading the data into Mascot 
search engine (http://www.matrixscience.com); using the following parameters; “mus 
musculus” species, carbamidomethyl as a fixed modification, methionine oxidation as 
variable modification and Swiss-Prot as a database to compare candidate peptides. 
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2.3 Protein analysis 
2.3.1 Bradford assay for protein quantitation 
2.3.1.1 Reagents 
1) Bradford reagent:100 mg of Coomassie Brilliant Blue G2, 50 ml ethanol, 100 
ml perchloric acid and 50 ml deionized water. 
2) Bovine serum albumin (BSA) standard solution: 1 mg /ml water  
2.3.1.2 Protocol  
A known volume of protein sample was pipetted into a 96 well plate and made up to a 
volume of 50 µl. A standard curve (0-50 µg standard protein) was generated using the 
BSA solution. All samples and standards were analyzed in duplicate. 150 µl of 
Bradford reagent (1:11 ml deionized water) was added into each sample and the 
standard. The resultant blue color was measured using a spectrophotometer at 595 nm 
(SPECTRA MAX 190) and the protein concentration determined from the standard 
curve. 
 
2.3.2 One dimensional (1DG) sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) - large gradient gel (5-20 %) 
2.3.2.1 Reagents 
1) 30 % (w/v) acrylamide solution.  
2) 10 % sodium dodecyl sulphate (SDS).  
3) Buffer A: 1.1 M Tris, 0.1 % SDS and 30 % glycerol, pH 8.8. 
4) Buffer B: 1.1 M Tris, 0.1 % SDS pH 8.8. 
5) Electrode Buffer: 25 mM Tris, 190 mM Glycine and 0.1% SDS. 
6) Stacking gel buffer: 150 mM Tris, 0.1% SDS, pH 6.8. 
7) Gel application buffer (2x GAB): 150 mM Tris, 8 M Urea, 2.5 % SDS, 20 % 
Glycerol (v/v), 10% (v/v) 2-mercaptoethanol, 3% DTT (w/v) and 
bromophenol blue, pH 6.8.  
8) Ammonium per-sulphate (AMPS): 10 % (w/v) AMPS solution. 
9) N, N, N, N- Tetramethylene diamine (TEMED). 
10) Stacking gel solution: 5 ml of stacking gel buffer, 1 ml acrylamide, 5 µl 
TEMED and 100 µl of AMPS. 
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11) Protein ladder: ColorPlus Prestained broad range (10-230 kDa). 
12) Gel electrophoresis system. 
2.3.2.2 Protocol 
The gel solutions (5 % and 20 %) were prepared in a total volume of 10 ml each. The 
5 % gel solution was prepared using 1.67 ml of acrylamide, 3.3 ml of buffer A and 
5ml deionized water. The 20 % gel solution was prepared with 6.6 ml of acrylamide 
and 3.3 ml buffer B. 10 µl of TEMED and 100 µl of AMPS were added to the gel 
solutions just before use to facilitate gel polymerization. The gradient gel was poured 
with gentle agitation starting with the 20 % of gel solution and mixing in the 5 % 
solution.  Using a Pasteur pipette, a water-saturated butanol solution was layer a top 
gel whilst the gel polymerized. After polymerization, the butanol layer was decanted. 
A stacking gel was poured on top of the gradient gel and a sample comb inserted. 
Once the stacking gel had polymerized, the comb was removed before loading the 
protein samples for separation. Protein samples for SDS-PAGE were treated with 2 x 
GAB and boiled for 5 minutes before loading. The samples were subjected to 
electrophoresis using electrode buffer at constant current 40mA supplied by an 
electrophoresis power pack. Once the proteins were separated the gel was ready for 
staining or Western blot analysis.  
 
2.3.3 1DG SDS-PAGE - mini gradient (10-18%) and 12% gel 
2.3.3.1 Protocol 
Table 2.1 below shows the volume and solution concentrations used for mini gels. 
The 10-18 % gradient mini gel was prepared by using the gradient apparatus. The 
methods follow that described in section 2.3.2.2, using 5µl TEMED and 25 µl of 
AMPS. The stacking gel solution was prepared using 700 µl of water, 165 µl of 30 % 
acrylamide, 125 µl of 1.1 M Tris pH 8.8, 10 µl of 10 % SDS, 10 µl AMPS and 5 µl 
TEMED. The separation carried out at 200 mA using a Mini-protean (Bio-Rad) 
system. 
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Table 2.1 volumes and concentration of compounds used to prepare SDS-PAGE, 
mini gel 
Solution  10 %  12 %  18 %  
30 % acrylamide 1.5 ml 1.8 ml 2.7 ml 
1.1 M Tris  pH 8.8  1.5 ml 1.5 ml - 
1.1 M Tris, 30 % glycerol pH 8.8  - - 1.5 ml 
10 % (w/v) SDS 45 µl 45 µl 45 µl 
Water  1.455 ml 1.155 ml 0.255 ml 
 
2.3.4 Two dimensional (2DG) gel electrophoresis 
2.3.4.1 Reagents 
1) Tissue homogenization buffer; 30 mM Tris, 8 M Urea, 4 % Chaps in 
Nanopure water, pH 8.8. 
2) Isoelectric focusing sample buffer: Destreak rehydration solution (GE 
Healthcare).  
3) Carrier Ampholytes in aqueous solution: IPG buffer, pH 3-10NL (GE 
Healthcare). 
4) Immobilised non-linear pH 3-10 strip gel (Immobiline TM Dry Strip gel, pH 
gradient 3-10 NL, 7 cm length). 
5) Equilibration base buffer I: 6 M urea, 2 % SDS, 20 % glycerol, 50 mM Tris-
HCl pH 8.8, 2 % DTT, in Nanopure water. 
6) Equilibration base buffer II: 6 M urea, 2 % SDS, 20 % glycerol, 50 mM Tris-
HCl pH 8.8, 2.5 % iodoacetamide, in Nanopure water. 
7) All components of SDS-PAGE (see section 2.3.2.1).  
8)  0.5 % agarose with 0.1 (w/v) bromophenol blue  
9) Mineral oil (Bio-Rad). 
10)  ColorPlus Prestained protein ladder (broad range 10-230 kDa). 
11)  PROTEAN IEF system (BIO-RAD) 
  
 42 
 
2.3.4.2 Protocol 
1) Sample preparation:  
Mouse cortices were homogenized in cold homogenization buffer using ceramic 
beads (MPbio Lysing matrix D) and beads-beater twice at a setting of 6 m /sec for 20 
seconds. The resulting homogenates were centrifuged at 4°C and 16100 x g for 10 
minutes. The supernatants were transferred to fresh eppendorf tubes and protein 
concentrations determined by Bradford assay (see section 2.3.1). 
2) First dimension isoelectric focusing (IEF) 
Protein samples were made up to 65 µl with homogenizing buffer. 65 µl of destreak 
rehydration solution was mixed with 2 % ampholytes 3-10NL and added to the 
protein sample. Samples were vortexed and loaded into individual channels of a mini 
IEF tray (BIO-RAD PROTEAN IEF system). An IPG strip (NL 3-10) was laid into 
each channel gel side down with the acidic end toward the anode. The IPG strips were 
allowed to passively hydrate for 1 hour. The IPG strips were then covered with 1 ml 
of mineral oil and IEF was performed using the BGF (Bioassay Guided Fractionation) 
focusing program as indicted below: 
 Step 1: 250V-LINEAR-20 min 
 Step 2: 4000V-LINEAR-2hours 
 Step 3: 4000V-RAPID-10000 V hours 
 Step 4: 500V-RAPID-25 hour 
3) Equilibration of IPG strips 
The focused IPG strips were equilibrated with equilibrium buffer I then II. The 
focused IPG strips were placed in 1 ml of equilibrium buffer I (DTT) and gently 
shaken for 15 minutes at room temperature. This was followed by a similar incubation 
with equilibrium buffer II (Iodoacetamide).  
4)  Second dimension electrophoresis 
The 12 % or 10-18 % SDS-PAGE gel was prepared as described in the section 2.3.3 
up to the point of the resolving gel. The focused and equilibrated IPG strip was then 
placed on the top of the resolving gel. 5 µl of protein ladder was applied to paper 
wicks and placed at the acidic end of the IPG focused strip. The strips were covered 
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with 5 % melted agarose. Electrophoresis was run using Mini-protean (Bio-Rad) 
supplied with 200 mA and 135 V. Following separation, the gel was either stained 
with Coomassie Blue stain or silver nitrite or the gel was processed to Western 
blotting.  
 
2.3.5 Coomassie Blue staining 
2.3.5.1 Reagents 
1) Coomassie Blue stain: 50 % Methanol, 20 % Acetic Acid, 0.12 % (w/v) 
Coomassie Brilliant Blue in water. 
2) Coomassie Blue de-stain: 10 % Methanol and 10 % Acetic Acid in water. 
2.3.5.2 Protocol 
Immerse gel for 1-2 hours in Coomassie stain on a rocking platform. De-stain with 
several changes of solution until the non-specific background becomes clear. 
 
2.3.6 Colloidal Coomassie staining 
2.3.6.1 Reagents 
1) CooBlue Max stain  
2) 7 % (v/v) glacial acetic acid. 
2.3.6.2 Protocol 
This stain was compatible with mass spectrometry. The gel was placed in a tray and 
washed with 7 % glacial acetic acid for 15-20 minutes with gentle shaking. The gel 
was then immersed in 20 ml of CooBlue Max stain for 1-2 hours with gentle shaking. 
The stained gel was washed with an excess of ultra-pure water to remove any 
background. 
  
 44 
 
2.3.7 Silver staining  
2.3.7.1 Reagents 
1) Plus One Silver Staining kit, protein (GE Healthcare). 
2) Fixing solution (30 % (v/v) ethanol, 10 % (v/v) glacial acetic acid). 
3) Sensitizing solution (30 % ethanol, 5 % (w/v) sodium thiosulphate, 6 % (w/v) 
sodium acetate). 
4) Staining solution (2.5 % (w/v) silver nitrate). 
5) Developing solution (2.5 % (w/v) sodium carbonate, 24 µl from 5 % (w/v) 
sodium thiosulphate and 150 µl from 35 % (v/v) formaldehyde). 
6) Stopping solution (12 % acetic acid). 
2.3.7.2 Protocol 
All steps were performed as indicated in the manufacturer’s protocol using gentle 
shaking for incubation and nanopure water.  
First the gels were incubated in fixing solution for 60 minutes twice. This was 
followed by incubation for 2 hours in sensitizing solution. The sensitizing solution 
was removed and gels washed with excess water for 5 x 8 minutes. Silver reaction 
was performed by incubating the gels with the silver staining solution for 60 minutes. 
The gel was washed with water four times for one minute each time. Developing 
solution was added and left for 2-5 minutes or until the protein spots reached the 
desired intensity. The gels were then immediately transferred into stopping solution 
for 45 minutes. Gels were washed with water for 2 x 30 minutes.  
 
2.3.8 Western blotting analysis 
2.3.8.1 Reagents 
1) Western transfer buffer: 25 mM Tris-HCl, 190 mM glycine, 20 % methanol 
(v/v) in deionized water. 
2) Electrophoretic transfer apparatus (Bio-Rad).  
3) Nitrocellulose membrane (Hybond-C) 
4) TBST: Tris buffered saline, 0.1 % (v/v) Tween.  
5) PBST: Phosphate buffered saline, 0.1 % (v/v) Tween. 
6) 4 % (w/v) non-fat dry milk solution (Marvel®) in TBST or PBST. 
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7) Primary antibodies and secondary antibody conjugated to Horseradish 
Peroxidase (HRP). 
8) Chemiluminescent substrate (ECL). 
9) X-ray film; Lumi- Film Chemiluminescent detection film. 
10) Developing solution (Calumet Photograph LTD 757314). 
11) Fixative solution (Calumet Photograph LTD 2000RT). 
2.3.8.2 Protocol 
Following separation of proteins by SDS-PAGE (described in section 2.3.2) the gel 
was placed onto nitrocellulose membrane that had been soaked in transfer buffer. This 
was placed between two sheets of Whatman 3 mm filter paper and transferred into 
cassettes for protein transfer, which was performed at 10 V and 40 mA overnight. 
After transfer, the membranes were blocked with 4 % (w/v) Marvel in TBS-T or PBS-
T for 1 hour with gentle shaking. The membrane was then incubated with primary 
antibody in 4 % (w/v) Marvel either for 1 hour at room temperature or overnight at 
4°C. The membrane was then washed with TBS-T or PBS-T three times for 10 
minutes each. Primary antibodies and their concentrations are detailed in Appendix I. 
The secondary antibody was used at 1:3000 in 4 % (w/v) Marvel for 1 hour, followed 
by washing with TBS-T or PBS-T three times for 10 minutes each. Immunoreactivity 
was detected using ECL according to the manufacturer’s protocol and the 
chemiluminescence signal was detected using X-ray film. For densitometry analyses 
of band signal intensity the X-ray films were scanned and ScnImage software used. 
Immunoreactivity for all blots was normalized to β-actin as a protein loading control. 
2.3.9 Striping of antibody from the nitrocellulose membrane 
2.3.9.1Reagents 
Stripping buffer: 0.5 M Tris-HCl, pH 6.8, 10 % SDS (w/v), 0.8 % 2-mercapto- 
ethanol (v/v).  
2.3.9.2 Protocol  
The membrane was washed with TBST or PBST and then incubated in stripping 
buffer at 55°C for 30-45 minutes on a rocking platform. The membrane was washed 
several times with TBS-T or PBS-T. 
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 2.4 Two-dimensional fluorescence difference in-gel electrophoresis 
(2D-DIGE) 
2.4.1 Reagents 
For reagents see section 2.3.4 (2D PAGE) and as follows: 
1) CyDyeTM DIGE for protein labeling (0.2 mM N-hydroxy succinimide ester of 
the fluorescent cyanine dyes Cy2, Cy3 and Cy5). 
2) Tissue homogenizing buffer: 30 mM Tris, 8 M Urea, 4 % Chaps in Nanopure 
water, pH 8.8. 
3) 10 mM lysine. 
 
2.4.2 Protocol 
2.4.2.1 Sample preparation 
Cortices from control and Psmc1
fl/fl
;CaMKIIα-Cre mouse brains aged 6 weeks were 
involved in this study (n = 4). Cortices were homogenized in pre-cooled 
homogenizing buffer as described in section 2.4.1. Protein concentration was 
determined using Bradford assay.  
2.4.2.2 Experimental design and CyDye labeling 
The cyanine dyes (Cy2, Cy3 and Cy5) used for 2D-DIGE contain N-
hydroxysuccinimide ester derivatives which bind to the ε-amino group of lysine 
residue in proteins. Because of the distinct excitation and emission fluorescent 
spectra of each CyDye, the labeled samples and internal standard are mixed and run 
together on one gel. This minimizes gel-to-gel variability, allowing easy protein 
spot-matching and accurate quantitative analysis of spot pixel volume. This method 
also decreases the number of gels used compared to conventional 2D-PAGE. 
To avoid any labeling bias arising from the fluorescent dyes, a dye-swap with Cy3 
and Cy5 was incorporated in the experiment. Cy2 was used to label the internal 
standard. Table 2.2 summarizes the CyDye labeling and experimental design.  
For CyDye labeling, 15 µg of each protein sample was incubated individually with 
120 pmol of Cy3, Cy5 or Cy2 for 30 minutes on ice in the dark. Following this 
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incubation, the reaction was stopped by adding 1µl of 10 mM lysine and incubating 
for a further 10 minutes in the dark. After this labeling, one control (15 µg) and one 
Psmc1
fl/fl
;CaMKIIα-Cre (15 µg) sample and 15 µg of pooled internal standard were 
combined together in an eppendorf tube. These samples were subjected to first 
dimensional IEF.  
*All steps involved in 2D-DIGE were performed in the dark. 
Table 2.2 Experimental design for 2D-DIGE analysis 
Gel  
No. 
Cy2 (internal standard) Cy3 Cy5 
1 All sample mixture control sample 1 Psmc1fl/fl; CaMKIIα-Cre 
sample 5 
2 All sample mixture control sample 2 Psmc1fl/fl; CaMKIIα-Cre 
sample 6 
3 All sample mixture Psmc1fl/fl; CaMKIIα-Cre 
sample 7 
control sample 3 
4 All sample mixture Psmc1fl/fl; CaMKIIα-Cre 
sample 8 
control sample 4 
 
2.4.2.3 First dimension isoelectric focusing (IEF) 
The volume of each pre-labeled combined sample (45 µg) was made up to 65 µl 
with homogenizing buffer. IEF was performed as described in section 2.3.4.  
2.4.2.4 Equilibration of IPG strips 
The focused IPG strips were equilibrated with equilibration buffers I and II as 
described in section 2.3.4.  
2.4.2.5 Second dimension electrophoresis 
A 10-18 % gradient SDS-PAGE was used and electrophoresis was carried out as 
described in section 2.3.4 
2.4.2.6 Gel imaging  
Following second dimension electrophoresis, the gels were removed from the glass 
plates, rinsed with deionized water and scanned using a Fujifilm scanner (FLA-5100 
imager scanner) at 50 µm resolution. Each gel was scanned at the three different 
wavelengths for the fluorescent CyDyes. Cy2 images were scanned at 473 nm, Cy3 
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at 532 nm and Cy5 at 635 nm. Therefore, three fluorescence images were produced 
for each gel. All images were saved for analysis. Two gels were randomly selected 
and stained with silver nitrite. 
2.4.2.7 Analysis of 2D-DIGE images to identify differential abundant spots 
Progenesis SameSpot software (Nonlinear Dynamics - version 4.0) was used for 
analysis of the CyDye 2D-DIGE images. In brief, the 3 images from each gel were 
grouped; one of the images was selected as a reference; all the images were then 
carefully aligned and the pixel density of each spot was normalized to the internal 
control. The results of image analysis were given as fold-change between control 
and Psmc1
fl/fl
;CaMKIIα-Cre samples using ANOVA (p < 0.05) and 1.2 fold 
changes. 
 
2.4.3 Preparative 2DG and spot picking  
Preparative 2DG gels stained with colloidal Coomassie were used for protein spot 
identification by mass spectroscopy. This used a pooled cortical sample from control 
and Psmc1
fl/fl
;CaMKIIα-Cre mice. 2DG separation was performed as described in 
section 2.3.4. Gels were stained and the differentially expressed protein spots 
identified using Progenesis Samespot visually matched and selected for picking. 
Spots were picked using cut micropipette tips and the gel plug transferred into 
eppendorf tubes for protein extractions. 
2.4.4 Protein extraction for MALDI-TOF-MS  
2.4.4.1 Reagents 
1) 10 mM DTT 
2) 50 mM iodoacetamide 
3) Acetonitrile (HPLC grade) 
4) 25 mM ammonium bicarbonate 
5) 12.5 ng /µl trypsin (sequencing grade) 
2.4.4.2 Protocol 
Protein in the gel plugs from section 2.4.3 was reduced with 10 mM DTT and 
alkylated with 50 mM iodoacetamide. The plugs were then dehydrated in 50 µl of 
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acetonitrile and 25 mM ammonium bicarbonate solution (2:1) for 15 minutes. This 
solution was discarded and the gel plug rehydrated using 50 µl of 25 mM 
ammonium bicarbonate solution for 10 minutes. This dehydration / rehydration 
cycle was repeated once and gel plugs were dried up for 15 minutes. For protein 
extraction, gel plugs were incubated with 4 µl of 12.5 ng / µl of trypsin in 25 mM 
ammonium bicarbonate solution for 30 minutes. The trypsin solution was discarded 
and gel plugs were covered with 10 µl of 25 mM ammonium bicarbonate solution 
and incubated at 37°C for 4 hours. The tubes were placed on vigorous shaker for 20 
minutes, and the supernatants were transferred to new eppendorf tubes and retained. 
This was followed by addition of 10 µl of acetonitrile: water mixture (20:80) and 
allowed to rehydrate plugs for 15 minutes. The supernatants containing the peptide 
digest were removed and combined with the previously retained fraction and 
submitted for protein identification by MALDI-TOF-MS (see section 2.2.10.2). 
 
2.4.5 Protein validation following MALDI-TOF-MS 
Proteins selected for validation following identification by MALDI-TOF-MS were 
based on antibody availability. Western blot analysis was performed as described in 
section 2.3.8 using 12 % one dimensional mini SDS-PAGE. 2DG Western blots 
were also performed. A minimum of three control and Psmc1
fl/fl; CaMKIIα-Cre 
mice were used for validation. Samples were homogenized in the same buffer as for 
2D-DIGE. Immunoreactivity for all blots was normalized to protein loaded using β-
actin.  
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2.5 Histological studies of brain sections - protein localization 
Coronal histological sections of cerebral cortices of brain mice were prepped in 
Pathology department- Clinical School; The University of Nottingham. The tissues 
sections were provided as paraffin embedded sections. 
 
2.5.1 Double immunofluorescent 
 2.5.1.1 Material and reagents 
1) Coronal histological sections of cerebral cortices. 
2) Xylene 
3) Ethanol, 100 %, 95 % and 70 % dilutions 
4) Coplin jar ( for slide washing) 
5) Antigen retrieval buffer solution: 10 mM sodium citrate buffer containing 
0.05 % Tween, pH 6 
6) MOM TM kit; for detection of mouse primary antibody on mouse tissue 
(VECTOR Lab, Inc.)  
7) 10 % goat serum (VECTASTAIN Elite rabbit IgG, ABC kit) 
8) Secondary fluorescent antibodies: Rhodamine Red gout anti mouse IgG; 
Alexa Flour gout anti rabbit IgG  (Invitrogen). 
9) Hoechst 33342 stock 
10) PBS  
 
2.5.1.2 Protocol 
Brain cortices sections were deparaffinized by immersion the slides in xylene for 10 
minutes, and  gradually rehydrated by ethanol, using three consecutive 10 minutes 
incubation of sections with 100 %, 95 % and finally in 70 %. The slides were then 
placed in a beaker under gentle running tap water for 10 minutes. They were 
transferred into another beaker containing a heated retrieval buffer solution at 100 
°C, and heated for further 20 minutes. The beaker was placed on shaker platform for 
20 minutes with gentle shaking, and slides were washed gently in running water for 
10 minutes.  
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For blocking of nonspecific binding sites on tissue cortex, sections were covered 
with 70 µl of blocking reagents and incubated for 1 hour in humid chamber; we used 
MOM Ig blocking solution for mouse antibody (1 drop of stock solution in 1.25 ml 
PBS) and 10 % goat serum were used for rabbit antibodies. The sections were then 
washed in three changes with PBS for 5-10 minutes each.  
For labeling procedure, MOM diluent was used for mouse primary antibody and its 
corresponding secondary (80 µl of concentrated protein in 1 ml PBS). For rabbit 
primary, PBS was used as diluents. Antibodies solutions of 65 µl were covered brain 
section within a frame. The sections were covered and incubated in humid chamber 
for overnight at 4°C. They were washed in the PBS for 3x10 minutes each. 
Corresponding secondary antibody were applied and sections were incubated for 1 
hour in the dark humid chamber.  A control sections were included which prepared 
in the similar way except no primary antibodies were used. 
The brain sections were then washed with PBS for 3x10minutes, and the second 
labeling for marker protein was performed using cell specific marker for astrocytes 
or neurones. The section were washed in PBS and counterstained to visualize nuclei 
by Hoechst in a concentration of 1:5000 in PBS. The sections were incubated in the 
dark for 15 minutes followed by 3 washing and cover slip with fluorescence 
mounting medium. Slides were kept at 4°C and in the dark until investigated by 
fluorescent microscope. 
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2.6 Measures of oxidative stress markers 
 2.6.1 Determination of Malondialdehyde (MDA) 
2.6.1.1 Reagents and solutions 
1) N-methyl-2-phenylindol (MPD). 
2) HCL 12 M. 
3) MDA-standard. 1, 1, 3, 3-tetramethoxypropane (TMOP). 
4) Butylated hydroxytoluene (BHT). 
5) Acetonitrile 
6) Methanol 
7) 10 mM Tris-HCL buffer pH 7.0 
8) PBS pH 7.4 
2.6.1.2 Preparation of stock solutions 
1) Reacting reagent (R1) was prepared by dissolving 0.28 g of MPD in 100 ml 
of acetonitrile. From this stock 18 ml was mixed with 6 ml methanol, to end 
up with working concentration of 10.3 mM and 24 ml of reacting reagent 
(R2). This was prepared just before the experiment. 
2) 10 mM of TMOP for MDA standard stock was prepared by adding 82.5 µl of 
TMOP to 50 ml Tris-HCL buffer. 
3) BHT stock of 0.5 M was prepared by dissolving 0.56 g of BHT in 5 ml of 
acetonitrile. 
All these stocks were preserved in fridges at 4°C. 
2.6.1.3 Preparation of MDA Standard Curve. 
10 mM of TMOP stock was diluted to 20 µM (1:500-v/v) in water just prior to use. 
This was then used to prepare a serial dilution for standard curve. The table below 
indicated the volumes of TMOP and water used to give 120 µl as a final volume.  
Table 2.3 Volumes of TMOP for MDA standard curve  
Standard  S1 S2 S3 S4 S5 S6 S7 S8 
Volume of 20 µM  TMOP, (µl) 0 3.75 7.5 15 30 60 90 120 
Volume of water (µl) 120 116.25 112.5 105 90 60 30 0 
Final conc. (µM) 0 0.125 0.25 0.5 1.0 2.0 3.0 4.0 
 53 
 
2.6.1.4 Sample Preparation for MDA Measurement. 
Brain cortices from control and Psmc1
fl/fl
;CaMKIIα-Cre mice were placed in 500 µl 
pre-cooled phosphate buffer, pH 7.4. A volume of 5µl of 0.5M BHT was added to 
each tube to prevent sample auto oxidation. Ceramic beads (MP bio Lysing matrix 
D) and beads-beater at setting of 5 m/sec for 15 seconds were used for 
homogenization and this was repeated once. The homogenates were then centrifuged 
at 4°C and 16100 x g for 10 minutes using top bench centrifuge, and the clear 
supernatant fractions were transferred to a new eppendorf tubes. The protein 
concentrations were determined using Bradford assay.  
Samples were adjusted to the same concentration of protein (9.5 µg / µl). To 
measure total MDA, hydrolysis step was performed by adding1.5-2.5 µl of HCL to 
sample and blank to bring their pH upto 1-2 (using litmus paper), then they were 
heated at 60 °C for 80 minutes. 
2.6.1.5 Assay procedure for MDA measurement 
A sample volume of 60 µl was transferred to a labeled eppendorf; the test was 
carried out by using duplicate sample as well as blank for each individual brain 
cortex. A volume of 190 µl from R1 reagent was added to each sample, alternatively 
for sample blank 1:3 mixture of methanol: acetonitrile was used, all tubes were 
vortexed. Blank was included for each sample to correct any absorbance A586 data 
due to sample inherent color. A volume of 45 µl HCL was added; tubes were 
vortexed vigorously and incubated at 45 °C for 1hour. Then after they were 
centrifuged at 16100 x g for 10 minutes, clear supernatants were separated carefully 
from the rest of the precipitate and transferred into a new eppendorf. A reactant 
volume of 150 µl from sample or blank was transferred to 96- micro-well plate and 
the absorbance was measured at 586 nm using spectrophotometer (SPECTRA MAX 
190). 
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Figure 2.2  
 
 
 
 
 
Figure 2.2  Representative standard curve of MDA. 
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2.6.2 Estimation of protein carbonyl group  
2.6.2.1 Reagents and solutions 
1- 50 mM Tris-HCl   
2- 10 mM 2,4- dinitrophenylhydrazine (DNPH) in 2.5 M HCl 
3- 6 M Guanidine HCl in water. 
4- 10 % and 20 % Trichloroacetic acid-TCA (w/v) in water 
5- Ethanol : Ethyl acetate solution 1:1 (v/v)  
6- 2.5 M HCl 
 
2.6.2.2 Protocol 
Mice brain cortices were placed in tubes containing 500 µl pre-cooled phosphate 
buffer, pH 7.4. The samples were prepared as described in section 2.6.1.4; and 
protein concentration was determined using Bradford assay.  
Samples of 200 µl with similar protein concentration (2.5 µg / µl) were used in 
duplicate with a blank for each one. 800 µl of DNPH was added to the sample, 
whereas sample blank was mixed with 800 µl of 2.5 M HCl. These were incubated 
in the dark at room temperature for 1 hour, while they were vortexed every 15 
minutes. A volume of 1 ml of 20 % TCA was added; tubes were vortexed and 
incubated on ice for 5 minutes. They were centrifuged at 16100 x g for 10 minutes at 
4°C and the supernatants were discarded. The resultant pellets were re-suspended in 
1 ml of 10 % TCA with vigorous vortex, incubated on ice for 5 minutes and 
centrifuged as mentioned above. The supernatants were discarded and pellets were 
re-suspended in ethanol: ethyl acetate mixture, small spatula and vortex were used to 
facilitate pellets solubilization. These were centrifuged at 16100 x g for 10 minutes 
at 4 °C and pellets were re-suspended in 500 µl 6 M guanidine-HCl with vortex. 
Debris not soluble was removed by centrifugation at 16100 x g for 10 minutes, and 
the reactant volume of 220 µl of supernatants was transferred into 96- micro-well 
plate. The absorbance was measured at 370 nm using SPECTRA MAX 190 plat 
reader.  
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The average sample absorbance was subtracted from average sample blank to give 
corrected absorbance (CA). The concentration of carbonyl group was calculated by 
using the following equation: 
Protein carbonyl (nM / ml) = [(CA) / (* 0.011)] (500 µl / 200 µl) 
* is an actual extinction coefficient for DNPH. This value has been adjusted for the 
path length of the solution in the well. 
500 µl is the volume used for last pellet re-suspension. 
200 µl is the original volume of sample used for the assay. 
 
2.6.3 Determination of nitrated proteins 
This were measured using Western blot analysis using mouse anti- nitrotyrosine 
antibody and performed as described in section 2.3.8 
2.6.3.1 Reagents and solutions 
1- Radioimmunoprecipitation assay buffer (RIPA); 50 mM Tris-HCl pH7.4, 
150 mM sodium chloride, 0.5 % Sodium deoxycholate, 1 % NP-40 and 0.1% 
SDS. 
2- Gel application buffer (2x GAB): 150 mM Tris, 2.5 % SDS, 20 % Glycerol 
(v/v), 10 % 2-mercaptoehtanol (v/v), DTT (3 % w/v) and bromophenol Blue, 
pH 6.8 adjusted with HCL.  
3- 12 % SDS-PAGE 
4- Anti- nitrotyrosine antibody 
5- Ingredient for preparation of  peroxynitrite solution; 0.6 M sodium nitrate, 
0.6 M hydrochloric acid / 1.2 M hydrogen peroxide solution, 0.9 M sodium 
hydroxide, manganese oxide (solid) , 0.45 M sodium hydroxide. 
2.6.3.2 Preparation of peroxynitrite solution 
This was synthesized by sodium nitrate and acidic hydrogen peroxide using method 
described by Koppenol et al., 1996. Equal volumes (usually 5 ml) of ice cold 0.6 M 
sodium nitrate and 0.6 M hydrochloric acid / 1.2 M hydrogen peroxide solution were 
mixed and vortexed.  10 ml of 0.9 M sodium hydroxide was added immediately to 
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preserve the peroxynitrite. 1 gram of manganese oxide was added to this solution 
and stirred in fume cupboard until the rising bubbles disappears. The solution was 
filtered and incubated for 3 hours at -80°C. The resulted liquid fraction of the upper 
layer was collected and diluted in 0.45 M sodium hydroxide.  Typically 80-100 mM 
peroxynitrite was obtained from this solution. The solution can be additionally 
diluted in 0.45 M sodium hydroxide to prepare the required concentrations. 
2.6.3.3 Preparation of positive control of nitrated proteins 
This was produced by incubating sample from mouse brain cortex with peroxynitrite 
solution prepared previously (see section 2.6.3.2), to obtain a positive control for 
anti-tyrosine Western blotting. 10 µl of protein sample in RIPA buffer was mixed 
with diluted peroxynitrite solution (0.1-1 mM), this was treated with GAB and 
heated for 5 minutes in boiling water bath. 
2.6.4 Measurement of reactive oxygen species (ROS) in cortical tissue  
2.6.4.1 Reagents and solutions 
Cellular reactive oxygen species detection assay kit (DCFDA)-MitoSciences, 
ab113851 was used. This contain reactant reagent of 20 mM 2, 7- 
dichlororfluorescein diacetate, ROS inducer for positive control (55 mM tert-butyl 
hydrogen peroxide, TBHP) and buffer. A concentration of 40 µM DCFDA was used 
to give a final concentration of 20 µM in sample mixture. 
2.6.4.2 Protocol 
Samples from mice cortices were prepared as described in section 2.6.1.4, using the 
provided buffer for homogenization and protein concentration was determined using 
Bradford assay. A sample volume of 100 µl (4 µg / µl) was transferred into a black 
96-micro-well plates and mixed with 100 µl of 40 µM DCFDA.  A sample negative 
control which contains no DCFDA as well as a positive control which is a sample 
pretreated with 1 µl 55 mM TBHP and DCFDA were included. This strategy was 
applied for normal and test tissues. The positive control was to ensure if the 
enzymatic system and redox potential of both samples (wild and muatant) were 
efficient. The well plate was incubated at 37°C for 30 minutes and fluorescence 
detected at 485 nm of excitation and 520 emission spectra using Pherastar FS -BMG 
lab tech. 
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2.7 Assay of total phospholipase activity (PLA2) 
2.7.1 Reagents and solutions 
EnzChek
®
 Phospholipase A2 Assay Kit, Catalog Number: E10217 (Invitrogen). This 
kit contains the following reagents: 
1) PLA2 substrate (Red / Green BODIPY
® 
PC-A2) 
2) Dioleoylphosphatidylcholine (DOPC).  
3) Dioleoylphosphatidylglycerol (DOPG). 
4) Phospholipase A2, enzyme from honey bee venom.  
5) Dimethylsulfoxide (DMSO).  
6) 5 x PLA2 reaction buffer. 
The solutions preparation and assay method were performed as recommended by the 
manufacturer. 
2.7.1.1 Preparation of solutions 
1) 1 mM PLA2 substrate: one vial of this substrate was allowed to warm to 
room temperature and dissolved in 40 µl of DMSO. This was aliquoted and 
stored at - 20°C until needed.  
2) 1x reaction buffer: 1 ml of 10 x reaction buffer was diluted to 1x in deionized 
water, and stored at 4°C. 
3) 10 mM of DOPC solution was prepared by dissolving the content of one 
DOPC vial in 100 µl of ethanol and stored at -20°C.  
4) 10 mM of DOPG solution was prepared by dissolving the content of one 
DOPG vial in 100 µl of ethanol and this was stored at -20°C.  
5) 500 Units / ml PLA2 enzyme: this stock solution of the enzyme was prepared 
by dissolving one vial of PLA2 enzyme into 80 µl of 1x reaction buffer.  
2.7.1.2 Preparation of sample  
Brain micel cortices were placed in 500 µl pre-cooled 1x reaction buffer provided. 
They were homogenized as described in section 2.6.1.4, the supernatant protein 
concentrations were determined using Bradford assay.  
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2.7.2 Protocol 
Serial dilutions from PLA2 enzyme (500 U / ml) were prepared for standard curve. 
They were ranging from 0-10 U / ml using 1x reaction buffer as a diluent. These all 
were prepared in a volume of 50 µl in each assigned well of black 96-micro-well 
plate. 
A volume of 10 µl from 10 mM DOPC, 10 mM DOPG and 1 mM of PLA2 substrate 
were mixed together, vortexed, and kept protected from light. This 30 µl of lipid 
mixture was injected slowly into 5 ml beaker containing 2.5 ml 1x reaction buffer, 
while vortex is formed for 1 minute. This gave a substrate-liposome mix which was 
kept protected from light. 
Supernatants from brain cortex homogenate in a volume of 50 µl and 2 µg / µl 
proteins concentartion were added to each assigned microplate well in duplicated 
similar volume of each sample was included for sample blank. To both standard and 
test sample, a volume 50 µl of substrate-liposome mix was added, and similar 
volume of 1x buffer was added to sample blank. The plate was protected from light 
and incubated at room temperature for 10 minutes. A Fluorescent measures were 
recorded at 485 nm excitation and 520 nm emission using Pherastar FS -BMG lab 
tech. Following this first measure, several times point was recorded. 
The standard curve was built up from serial dilution of PLA2 enzyme stock. Each 
reading for test sample was subtracted from the sample blank, this was to correct for 
background fluorescence. For each time point, an independent standard curve for 
PLA2 activity was constructed and used for calculation of sample PLA2 activities. 
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Figure 2.3 
 
 
 
 
 
 
 
                         Figure 2.3  Representative standard curves for PLA2 activity 
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CHAPTER 3 
 
Investigation into ubiquitinated proteins in the 
Psmc1fl/fl;CaMKIIα-Cre mouse cortex 
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3.1 Introduction 
Accumulation of ubiquitinated proteins associated with ubiquitin-positive protein 
inclusions is a consistent neuropathological feature of the major human 
neurodegenerative diseases (Lowe et al., 1993). Ubiquitin-positive protein inclusions 
and accumulation of ubiquitinated proteins are evident in the Psmc1
fl/fl
;CaMKIIα-
Cre mouse cortex following 26S proteasomal depletion making this a useful model 
to investigate ubiquitinated proteins in neurones in vivo (Bedford et al., 2008). 
Interestingly, Lewy bodies in PD and DLB contain lysine 48-specific ubiquitinated 
α-synuclein, suggesting impairment of the ubiquitin 26S proteasome system 
(Gorbatyuk et al., 2008). 
Since protein ubiquitination is a dynamic process involving ubiquitination and 
deubiquitination, it is difficult to study ubiquitinated proteins without enrichment 
such as by proteasome inhibition. Therefore, a study of the Psmc1
fl/fl;CaMKIIα-Cre 
mouse cortex following 26S proteasomal depletion in neurones will be a valuable in 
vivo contribution to the current literature. Numerous large-scale proteomic studies 
investigating ubiquitinated proteins have been reported in vitro (Kirkpatrick et al., 
2005; Jeon et al., 2007; Zhou et al., 2007; Bazile et al., 2008; Meierhofer et al., 
2008). In these studies, cells were transfected with tagged ubiquitin, e.g. histidine-
tagged ubiquitin, and ubiquitinated proteins were captured using ion metal affinity 
chromatography. These approaches have proved to be a useful research tool, but the 
ability to investigate ubiquitinated proteins in their physiological context in vivo 
such as in the mouse brain without overexpression or tagging would expand this 
data. 
To our knowledge there are limited studies investigating the ubiquitome in vivo in 
the mouse brain. This study used affinity chromatography with immobilized 
ZNF216 protein. The rat ZNF216 protein sequence is 213 amino acid residues. It 
contains an N-terminal ZnF A20 ubiquitin binding domain (UBD) between amino 
acids 11-35 and a C-terminal ZnF AN1 domain between amino acids 154-191 
(Huang et al., 2004a). Point mutation of the cysteine residues at positions 30 and 33 
by alanine substitution (C30A/C33A) abrogates the ubiquitin binding of the A20 
domain of ZNF216 protein (Hishiya et al., 2006). We have used ZNF216 affinity 
matrices to capture ubiquitinated proteins from the Psmc1
fl/fl;CaMKIIα-Cre cortex. 
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3.2. Results 
3.2.1. Accumulation of polyubiquitinated proteins in Psmc1
fl/fl;CaMKIIα-Cre 
mouse cortex 
Control and Psmc1
fl/fl;CaMKIIα-Cre mouse cortices were homogenized in urea 
homogenizing buffer and separated by 12 % SDS-PAGE. This was followed by 
overnight protein transfer to nitrocellulose membrane and Western blot analysis 
carried out using an in-house anti-ubiquitin rabbit polyclonal antibody. Cortical 
samples were investigated at 2, 3, 4 and 6 weeks of age. High molecular weight 
polyubiquitinated proteins increased with age (Figure 3.1A-D). Quantitation of the 
ubiquitin smear above 50 kDa showed a significant difference at 3, 4 and 6 weeks 
between Psmc1
fl/fl;CaMKIIα-Cre and control cortices (p < 0.05). The most 
significant difference was at 6 weeks of age. Therefore we decided to use 6 week-
old mice for the investigations in this chapter. We also noted the presence of 
polyubiquitin chains in the Psmc1
fl/fl
;CaMKIIα-Cre cortex which migrate similarly 
to the synthetic Lys48-specific polyubiquitin chains, suggesting the accumulation of 
free unanchored polyubiquitin in the Psmc1
fl/fl;CaMKIIα-Cre cortex compared to the 
control (Figure 3.1D). 
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 Figure 3.1                                                 
A-2 weeks age 
 
  
 
B-3 weeks age 
 
  
  
 
 
Control Psmc1 fl/fl;CaMKIIα-Cre
U
b
iq
u
it
in
a
te
d
 p
ro
te
in
s 
Mono-ubiquitin
ACTN
kDa
50-
25-
15-
Mono-Ubiquitin 
ACTN
Control
kDa
50-
25-
15-
Psmc1 fl/fl;CaMKIIα-Cre
U
b
iq
u
it
in
a
te
d
 p
ro
te
in
s 
0
2
4
6
8
10
Ubiquitin / 2 weeks
Control Psmc1
fl /fl
;CaMKII-Cre
B
a
n
d
 i
n
te
n
s
it
y
 r
a
ti
o
 t
o
 A
C
T
N
0
2
4
6
8
10 Ubiquitin / 3 weeks
*
Control Psmc1 fl /fl;CaMKII-Cre
B
a
n
d
 i
n
te
n
s
it
y
 r
a
ti
o
 t
o
 A
C
T
N
 65 
 
 
Figure 3.1 continued. 
C- 4 weeks age 
  
D-6 weeks age 
  
 
Figure 3.1 Anti-ubiquitin Western blot analysis of control and Psmc1
fl/fl;CaMKIIα-
Cre cortex samples from mice at 2 (A), 3 (B), 4(C) and 6 (D) weeks of age. The left panel 
shows a representative Western blot image (50 µg protein). The blot was stripped and re-
probed with β-actin (ACTN) for normalization of protein loading. The right panel shows 
quantitation of the corresponding Western blot using densitometry (> 50 kDa; boxed region 
shown in A) normalized to β-actin. Data were analyzed versus control mice using unpaired 
student t-test and presented as mean ± SEM (n = 3) *p < 0.05.  
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3.2.2 Purification of ZNF216 recombinant proteins   
This was carried out to prepare recombinant ZNF216 proteins for affinity matrices 
for the capture of ubiquitinated proteins. Wild-type and mutant GST-ZNF216 fusion 
proteins were expressed in E.coli cultures from plasmids encoding the corresponding 
GST-tagged ZNF216 proteins. Following growth (OD600 = 0.6 - 0.8), bacterial cells 
were lysed by sonication in TBS-Triton and clarified by centrifugation. The clarified 
supernatant was then incubated with glutathione (GSH)-Sepharose beads to purify 
the GST-fusion proteins. Figure 3.2A shows capture of the ZNF216-GST fusion 
proteins on GSH beads at approximately 52 kDa. The GSH beads-GST fusion 
proteins were then incubated with thrombin to cleave the ZNF216 proteins from 
their GST-tag. The GST-tag contains a sequence of six amino acids (Leu-Val-Pro-
Arg-Gly-Ser) that are recognized by thrombin. Following cleavage ZNF216 proteins 
were collected in the flow from chromatography columns. The GST-tag remains 
bound to GSH beads. Cleaved ZNF216 wild-type and mutant proteins migrated at 
approximately at 34 and 32 kDa respectively on SDS-PAGE as shown in Figure 
3.2B. We expect that both ZNF216 wild-type and mutant proteins have the same 
molecular weight, but the mutation causes them to migrate differently on SDS-
PAGE. Figure 3.3 shows a schematic diagram representing the steps described in 
this section. The purified ZNF216 proteins were then immobilized onto another 
chromatographic solid phase (Cyanogen bromide activated sepharose beads) for 
affinity purification of ubiquitinated proteins (see section 3.2.3).  
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Figure 3.2 
 
 
 
 
 
Figure 3.2 Coomassie Blue-stained SDS-PAGE gel showing immobilized GST 
ZNF216 fusion proteins and their thrombin cleavage. (A) Binding of GST ZNF216 
fusion proteins to GSH beads as indicated by the arrows. The fusion proteins are 
approximately 52 kDa. (B) ZNF216 proteins following thrombin cleavage. ZNF216 wild-
type (Wt) and mutant (C30/33A) migrated at approximately 34 kDa 32 kDa respectively. 
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Figure 3.3 
  
 
 
 
Figure 3.3 Schematic representation for the production of recombinant ZNF216 
proteins. The expression of GST-ZNF216 recombinant proteins was induced in bacterial 
E.coli cultures with IPTG (isopropylthio-β-galactoside). This was followed by cell lysis and 
incubation of the clarified bacterial lysate with glutathione (GSH)-Sepharose beads in 
chromatographic columns. Following binding between GSH beads and GST-ZNF216 fusion 
proteins, thrombin was added to the column and incubated overnight at 4°C for cleavage of 
the ZNF216 fusion proteins. The flow through from the column containing the ZNF216 
proteins was collected and kept for preparing ZNF216 affinity matrices. Samples from the 
GSH beads-GST ZNF216 fusion proteins and from the flow through were taken for SDS-
PAGE analysis and are shown in Figure 3.2.  
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3.2.3 Preparation of ZNF216 affinity matrices for the capture of ubiquitinated 
proteins  
Cyanogen bromide activated sepharose beads (CNBr beads) were used to 
immobilize purified ZNF216 recombinant proteins to provide a chromatography 
stationary phase (affinity matrices) for the capture of ubiquitinated proteins. CNBr 
beads have an imido-carbonate group that can bind to primary amines of proteins. 
Therefore, ZNF216 protein binds to CNBr beads through an amide bond.  
Figure 3.4 shows the binding of purified recombinant ZNF216 proteins from section 
3.2.2 with CNBr beads. We investigated two CNBr beads: ZNF216 protein ratios 
(1:1 and 1:4) to determine the optimal concentration of ZNF216 protein for 
preparing affinity matrices. The results show that both ratios investigated resulted in 
immobilizing ZNF216 proteins and we decided to use 1:4 for the preparation of 
affinity matrices.  
Following binding of ZNF216 proteins to CNBr beads, the affinity matrices were 
washed and incubated with ethanolamine to block any remaining active sites. The 
ZNF216 affinity matrices were prepared in TBS to yield 50 % slurry (this slurry 
contains 50 % solid beads and 50 % buffer) and stored at 4°C. 
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Figure 3.4 
 
 
 
 
 
Figure 3.4 Binding of ZNF216 proteins to CNBr activated Sepharose beads. A 
Coomassie Blue-stained gel showing before (Before) and after (After) binding using two 
ratios: 1:1 and 1:4 beads: protein (µg protein: µl of beads volume). ZNF216 proteins are 
indicated by the *. Note that the lower molecular weight bands may be degradation 
products.  
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3.2.4 Binding of ubiquitinated proteins to ZNF216 affinity matrices 
Cortical mouse tissue from control and Psmc1
fl/fl;CaMKIIα-Cre mice was 
homogenized in TBS-NP40 buffer using a glass dounce homogenizer. This results in 
detergent-soluble proteins for investigation. The buffer contained the cysteine 
protease inhibitor N-ethylmaleimide to inhibit deubiquitination as well as a protease 
inhibitor cocktail to inhibit trypsin-like activity in the mouse cortical homogenates.  
Figure 3.5 shows a schematic representation for the capture of ubiquitinated proteins 
using ZNF216 affinity matrices. Previous studies have shown in mammalian cells in 
vitro that the ZNF216-Wt protein has the ability to bind ubiquitinated proteins, but 
that the ZNF216-mutant does not (Hishiya et al., 2006). Furthermore, the ZnF A20 
ubiquitin binding domain of ZNF216 was used for affinity purification of 
endogenous polyubiquitin chains from skeletal muscle homogenates (Strachan et al., 
2012). 
Solubilized protein from brain tissue homogenates of the control and 
Psmc1
fl/fl;CaMKIIα-Cre mice were incubated with ZNF216-Wt or ZNF216-mutant 
affinity matrices. Capture of ubiquitinated proteins was investigated by Western blot 
analysis using an in-house anti-ubiquitin polyclonal rabbit antibody. The unbound 
fraction was also investigated by collecting the flow-through from the 
chromatographic column following incubation.  
The results in Figure 3.6 show that ZNF216-Wt can capture ubiquitinated proteins 
(Figure 3.6; lanes 1 and 5), while the ZNF216-mutant does not (Figure 3.6; lanes 3 
and 7). We sometimes note a very low ubiquitin signal in the ZNF216-mutant 
affinity matrix, but this is not significant compared to the ZNF216-Wt (Figure 3.6; 
lanes 5 and 7). We also note that the affinity matrices had no affinity for mono-
ubiquitin. ZNF216-Wt affinity matrices capture mostly high molecular weight 
ubiquitinated proteins (Figure 3.6). We were interested in the identity of these 
ubiquitinated proteins and these were significantly increased in the 
Psmc1
fl/fl;CaMKIIα-Cre cortex (Figure 3.6; lanes 1 and 5). The ZNF216-mutant 
affinity matrix is a suitable control for any false positive proteins bound to the 
ZNF216 protein via a domain other than the ubiquitin binding domain. 
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Figure 3.5 
 
 
 
 
 
 
Figure 3.5 Schematic representation of the capture of ubiquitinated proteins using 
ZNF216 affinity matrices. Purified ZNF216-Wt (A) and ZNF216-mutant (B) were coupled 
to CNBr beads to produce affinity matrices. Affinity matrices were incubated with clarified 
homogenates from mouse brain cortex. The ZNF216-Wt affinity matrix should capture 
ubiquitinated proteins, whilst the ZNF216-mutant affinity matrix should not. The ZNF216-
mutant is used as a control for proteins that bind to ZNF216 through domains other than the 
A20 ubiquitin binding domain, e.g. 1 and 2. 
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Figure 3.6  
 
 
 
 
 
Figure 3.6 Capture of ubiquitinated proteins from mouse brain. Anti-ubiquitin 
Western blot following incubation of ZNF216-Wt and ZNF216-mutant affinity matrices 
with cortical homogenates from control and Psmc1
fl/fl
;CaMKIIα-Cre mice at 6 weeks-old. 
Ubiquitinated proteins appear as a high molecular weight smear. ZNF216-Wt matrices 
capture ubiquitinated proteins (lanes 1 and 5) whilst the ZNF216-mutant do not (lanes 3 and 
7). The Western blot shows the captured ubiquitinated proteins (bound) as well as a sample 
of the flow-through following binding (flow). 
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3.2.5 Evaluation of the binding capacity of ZNF216-Wt affinity matrices  
We sought to evaluate the binding capacity of ZNF216-Wt affinity matrices. This 
was to determine the protein concentration required for optimal capture of 
ubiquitinated proteins. The aim was to capture sufficient ubiquitinated proteins for 
subsequent identification by mass spectrometry. 
The binding capacity was evaluated using a constant amount of matrices (50 µl of 50 
% slurry) with increasing amounts of protein homogenate from Psmc1
fl/fl;CaMKIIα-
Cre mouse cortex (50-200 µg). Figure 3.7 shows that high molecular weight 
ubiquitinated proteins consistently bound to ZNF216-Wt matrices and this increased 
with the increasing amounts of cortical protein homogenate. 
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Figure 3.7 
 
 
 
 
 
 
Figure 3.7 Evaluation of the binding capacity of ZNF216-Wt affinity matrices. An 
anti-ubiquitin Western blot following incubation of 50 µl of affinity matrices with 50 (1:1), 
100 (1:2) and 200 (1:4) µg of protein from Psmc1
fl/fl;CaMKIIα-Cre brain cortex at 6 weeks 
of age.  
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 3.2.6 Deubiquitination of captured ubiquitinated proteins using ubiquitin 
specific protease 2  
Using a commercially available deubiquitinase (DUB) enzyme with ubiquitin 
specific protease activity (USP2), the ubiquitinated proteins captured by ZNF216 
affinity matrices were deubiquitinated, releasing the proteins from the matrices for 
further identification. USP2 has been shown in vitro to trim ubiquitinated proteins 
and unanchored polyubiquitin chains bound to affinity matrices (Shahnawaz et al., 
2007). Figure 3.8 shows a schematic representation of the deubiquitination of 
captured polyubiquitinated proteins on ZNF216-Wt affinity matrices using USP2. 
Target proteins captured via the A20 ubiquitin binding domain are released into the 
soluble phase that can be used for target protein identification by mass spectrometry. 
The deubiquitination activity of USP2 was investigated by ubiquitin Western 
blotting using ZNF216-Wt affinity matrices bound to cortical homogenate as well as 
synthetic Lysine-48 unanchored polyubiquitin chains. Figure 3.9 shows that USP2 
deubiquitinated the captured polyubiquitinated proteins on ZNF216-Wt affinity 
matrices. The high molecular weight ubiquitin smear or synthetic polyubiquitin 
chain changed to mono-ubiquitin and some di-ubiquitin (Ub2) after incubation with 
DUB enzyme.  
Following elution of proteins from the ZNF216 matrices, the elute was subjected to 
in-solution digestion followed by Liquid chromatography–mass spectrometry 
(LC/MS-MS) in Biomedical Sciences, University of Nottingham. However, the 
protein identification using this method of analysis was limited. Candidate proteins 
were identified with low mascot scores and number of peptides. It is possible that 
the amount of protein captured by the affinity matrices was too low for this method 
of identification and further experiments were carried out to optimize the results. 
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Figure 3.8  
 
 
 
 
 
 
Figure 3.8 Schematic representation of deubiquitination using USP2. Target 
proteins captured via the A20 ubiquitin binding domain are released into the soluble phase 
by incubation with ubiquitin specific protease 2 (USP2). The elute was collected for target 
protein identification by mass spectrometry. Proteins identified in the ZNF216-Wt, but not 
in the ZNF216-Mutant will be considered as ubiquitinated proteins. Proteins also identified 
in the ZNF216-Mutant will be non-specific, e.g. protein 2. 
 
 
 
 
 
CNBr beads
ZNF216-Wt
Ub Ub
Ub Ub Ub
Elution
Ub
Ub
Ub
Ub
Ub
CNBr beads
+
Target 
protein
Target 
protein
2
1
1
2
ZNF216-Wt
 78 
 
Figure 3.9 
 
 
 
 
Figure 3.9 Ubiquitin Western blot showing deubiquitination of captured 
polyubiquitinated proteins using USP2 DUB enzyme. (A) ZNF216-Wt affinity matrices 
bound to proteins from cortical mouse brain homogenate (bound). (B) ZNF216-Wt affinity 
matrices bound to synthetic Lysine -48 polyubiquitin chains (bound). DUB enzyme action 
results in the loss of the high molecular weight ubiquitin smear associated with the matrices 
and the appearance of mono-ubiquitin in addition to some di-ubiquitin in the flow-through 
(flow). Ub1, mono ubiquitin; Ub2, di-ubiquitin. 
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3.2.7 Two dimensional profile of proteins bound to ZNF216 affinity matrices 
To optimize the identification of target proteins captured using ZNF216 affinity 
matrices, we used 2-dimensional gel (2-DG) electrophoresis in addition to the in-
solution digestion for mass spectrometry described in section 3.2.6. Two 
modifications were made to this experiment: (1) a 4-fold increase (10 mg) of 
Psmc1
fl/fl;CaMKIIα-Cre cortical homogenate was used; and (2) following protein 
elution from ZNF216 affinity matrices, the elute was filtered through a 5 kDa filter 
to concentrate the protein before mass spectrometry. The concentrated protein 
samples were subjected to 2DG electrophoresis as described in the section 2.3.4, and 
stained with silver nitrite compatible with mass spectrometry.  
Figure 3.10 shows the 2DG profile of proteins eluted from ZNF216-Wt and ZNF-
Mutant affinity matrices. The arrows show a small number of spots were detected in 
the ZNF216-Wt sample (Figure 3.10A). These spots were visible in the stained gel 
above a light box and 8 spots were excised from the gel and prepared for mass 
spectrometry. These spots were submitted for identification by MALDI-TOF-MS. 
These spots were not detected in the ZNF216-Mutant 2DG (Figure 3.10B). 
This approach only identified one protein (Figure 3.10A; ubiquitin). This was most 
likely due to the low protein abundance in the spots for identification by the mass 
spectrometry approach. The identified spot at approximately 10 kDa was identified 
as ubiquitin (Figure 3.10A). This had a mascot score of 132 (a significant score for 
mascot is > 55) and 52% peptide coverage of the candidate protein.  
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Figure 3.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10  Two dimensional gel electrophoresis protein profiles following elution 
of ubiquitinated proteins from ZNF216-Wt (A) and ZNF216-Mutant (B) affinity 
matrices. Proteins were captured using ZNF216 affinity matrices from 6 weeks of age 
Psmc1
fl/fl;CaMKIIα-Cre cortical tissue and eluted with DUB enzyme. The eluted proteins 
were subjected to 2DG electrophoresis and silver staining. Arrows indicate spots that were 
excised and processed for MADLI-TOF mass spectrometry protein identification.  
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3.2.8 One dimensional profile of proteins bound to ZNF216 affinity matrices  
The 2DG electrophoresis approach was unsuccessful (see section 3.2.7); therefore 
we used one dimensional gel (1DG) separation following concentration of the eluted 
target proteins as described in section 3.2.7. This approach minimizes any loss of 
sample as a consequence of the IEF. Figure 3.11 shows several discreet protein 
bands in the ZNF216-Wt sample that are not evident in the ZNF216-Mutant. Twenty 
one bands were excised from the ZNF216-Wt lane and prepared for MALDI -TOF-
MS identification. Table 3.1 shows the proteins that were identified. Although two 
proteins had a mascot score below 55, they were included as potential ubiquitin-
bound proteins because multiple peptides were identified. 
The proteins bands denoted by asterisks in Figure 3.11 were present in both 
ZNF216-Wt as well as ZNF216-Mutant eluted fractions. However, they were more 
abundant in the ZNF216-Wt sample. Band 3* was identified as Tryptophanyl-tRNA 
synthetase -1, cytoplasmic. Bands 1* and 2* were ubiquitin. This suggests that the 
ZNF216-Mutant may associate with low levels of ubiquitin or there is some non-
specific binding when using relatively high cortical protein concentrations. 
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Figure 3.11 
 
 
  
 
Figure 3.11 One dimensional gel electrophoresis protein profiles following elution 
of ubiquitinated proteins from ZNF216-Wt and ZNF216-Mutant affinity matrices. 
Proteins were captured using ZNF216 affinity matrices from 6 weeks of age of 
Psmc1
fl/fl;CaMKIIα-Cre cortical tissue and eluted with DUB enzyme. The eluted proteins 
were subjected to 1DG electrophoresis and silver staining. The labeled bands correspond to 
Table 3.1.  
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Table 3.1 Proteins identified by MALDI-TOF mass spectrometry. The table corresponds to Figure 3.11.  
 
* represents ubiquitin peptides.  
¡¡
 Mascot score is a statistical score for how well the experimental data (peptide masses) match the database sequence. A score value of 55 or more represents 
significant values (p < 0.05).  
+
Lower values can be considered if matched protein appears at the top of the hit list of the resultant identified proteins.                  
γ
 Matched peptides are the number of peptides identified as matching the database sequence of candidate protein.                                                                              
φ
 Sequence coverage is the percentage of the database protein sequence covered by matching peptides from the experimental data. The larger the sequence 
coverage the more certain is the identification. 
 
 
 
 
Band 
number 
NCBI- 
Gene ID 
Uni Prot 
Accession code  
STRING  
Accession code 
Protein ID Mascot  
Score 
¡¡
  
Matched 
peptides 
γ
 
Sequence 
coverage 
(%) 
φ
 
1* 22186 RL40_MOUSE Uba52/ Ubc/ Ubb Ubiquitin-60S ribosomal protein L40 (Ub peptides) 122 10 52 
2* 22186 RL40_MOUSE Uba52/ Ubc/ Ubb Ubiquitin-60S ribosomal protein L40 (Ub peptides) 77 6 35 
3* 7453 SYWC_MOUSE Wars Tryptophanyl-tRNA synthetase 64 9 22 
4 
 
 68972 
22186 
TATD3_MOUSE 
RL40_MOUSE 
Tatdn3 Putative deoxyribonuclease 
Ubiquitin-60S ribosomal protein L40 (Ub peptides) 
61 
58 
6 
8 
16 
54 
5 14569 GDIB_MOUSE Gdi2 Rab GDP dissociation inhibitor beta 56 10 32 
6 53379 ROA2_MOUSE Hnrnpa2b1 Heterogeneous nuclear ribonucleoproteins A2/B1 149 15 24 
7 227682 TRUB2_MOUSE Trub2 Probable tRNA pseudouridine 83 13 42 
8 871 SERPH_MOUSE Serpinh1 Serpin H1 51
+
 7 29 
9 60 ACTB_MOUSE Actb Actin- cytoplasmic 1 79 10 43 
10 7257 TSNAX_MOUSE Tsnax Translin-associated protein X 52
+
 11 37 
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3.3 Discussion 
3.3.1 Age-related accumulation of polyubiquitinated proteins and unanchored 
polyubiquitin chains 
Ubiquitinated proteins are a consistent feature of the major human neurodegenerative 
diseases (Lowe et al., 1993). Therefore, it is of considerable interest to identify 
proteins that are targeted for ubiquitination in neurones to understand physiological as 
well as pathological cellular pathways associated with the UPS. Our mouse with 
neuronal 26S proteasomal depletion (Psmc1
fl/fl;CaMKIIα-Cre) provides a novel 
model in which ubiquitinated proteins can be investigated in vivo.  
This study showed an age-related increase in polyubiquitinated proteins between two 
and six weeks of age in Psmc1
fl/fl;CaMKIIα-Cre compared to control mice cortex. 
Previously, we reported that 26S proteasomal depletion in cortical neurones caused 
neurodegeneration and the formation of ubiquitin-positive intraneuronal inclusions 
resembling human pale bodies at 6 weeks of age (Bedford et al., 2008). Components 
of the UPS have recently been linked to the quality control system for aberrant 
proteins (Pegoraro et al., 2012; Chhangani et al., 2013). 
Interestingly we note the possibility of increased unanchored polyubiquitin chains 
following 26S proteasomal depletion in the Psmc1
fl/fl;CaMKIIα-Cre cortex. Figure 3.1 
D shows ubiquitin bands on Western blot at 6 weeks of age corresponding to the 
synthetic unanchored lysine-48 polyubiquitin. Classically, the 26S proteasome has 
been associated with the degradation of polyubiquitinated proteins (Liu and Jacobson, 
2012). However, our observation suggests that the proteasome may also be involved 
in the degradation of free polyubiquitin chains and further investigations in this model 
will be valuable. For example, it will be interesting to study whether free unanchored 
polyubiquitin accumulated within the ubiquitinated inclusion bodies following 26S 
proteasomal depletion in mouse neurones. 
Lysine-48 and lysine-11 linked unanchored polyubiquitin have been identified in rat 
skeletal muscle (Strachan et al., 2012). Interestingly, evidence suggests that 
unanchored polyubiquitin chains can be metabolised by specific enzymes, supporting 
an important physiological role in the cell. USP5 enzyme has been shown to 
specifically trim unanchored lysine-48 chains in mammalian cells (Dayal et al., 2009). 
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In addition, uunanchored Lysine-63 polyubiquitin chains have been investigated as a 
signal to activate innate immunity against viruses (Zeng et al., 2010). 
In our study, the increase in unanchored polyubiquitin chains may represent the 
cellular activation of enzymes that release polyubiquitin chains from conjugated 
proteins or the expression of ubiquitin may be increased to compensate for 26S 
proteasome failure. The latter possibility is not supported because the levels of mono-
ubiquitin in Psmc1
fl/fl;CaMKIIα-Cre cortex were not significantly different from 
controls (Figure 3.1). A previous study has shown the release of unanchored 
polyubiquitin chains from the ubiquitinated proteins by the action of DUB enzymes 
such as ataxin 3 following chemical inhibition of the 20S proteasome by MG132 
(Ouyang et al., 2011).  
 
3.3.2 Capture of ubiquitinated proteins from the Psmc1
fl/fl;CaMKIIα-Cre cortex  
Previous studies have shown that ubiquitin binding domains (UBD) can be used for 
the capture of ubiquitinated proteins from protein homogenate (Ventadour et al., 
2007). The A20 UBD of ZNF216 has been shown to behave as a shuttle protein for 
the proteasome (Hishiya et al., 2006). The A20 ZnF domain binds to a polar patch on 
ubiquitin molecules at Aspartate-58 (Hurley et al., 2006). In our study we have used 
the ZNF216 protein to produce affinity matrices for the capture of ubiquitinated 
proteins from mouse brain. The ZNF216-Wt affinity matrices captured ubiquitinated 
proteins, but not mono-ubiquitin. A previous study showed that diverse polyubiquitin 
chains accumulated following 26S proteasomal depletion in the mouse brain (Bedford 
et al., 2011) that may be captured in this study. A ZNF216-mutant in the A20 domain 
was used as a control that did not capture ubiquitinated proteins. 
The aim was to use the ZNF216 affinity matrices to capture ubiquitinated proteins for 
subsequent identification by mass spectrometry. The major disadvantage of our 
approaches was the low abundance of proteins for identification. It is possible that 
these were below the detection limits of the mass spectrometry available for this 
study. 
Using 2DG electrophoresis, only ubiquitin was identified and would be the most 
abundant protein in the sample of captured polyubiquitinated proteins. The 1DG 
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electrophoresis approach proved to be more informative leading to the identification 
of 8 potential target proteins in Psmc1
fl/fl;CaMKIIα-Cre cortex. Further explanations 
for the low target identification in this study are described. It is possible that the target 
proteins are ubiquitinated with extensive polyubiquitin chains, including branched 
chains, which would skew the identification of the lower abundance target protein. 
Alternatively, a large proportion of the sample may be unanchored polyubiquitin 
chains and therefore not attached to target proteins. This would lead to the 
identification of ubiquitin.  
Overall, we identified a relatively low number of target proteins. Increasing the 
amount of cortical protein homogenate may improve these results together with the 
use of a more sensitive mass spectrometry such as the Orbi-trap.  
The candidate proteins identified in this study were investigated to identify cellular 
pathways that might be affected in the brain of Psmc1
fl/fl;CaMKIIα-Cre mouse cortex 
following proteasomal dysfunction using software such as STRING (http://string-
db.org) and UniProt (http://www.uniprot.org). An example of the results from 
STRING is shown in Figure 3.12. Experimental studies have shown an interaction 
between ubiquitin and the Translin-associated protein X. Also, there is literature to 
suggest an interaction between ubiquitin and actin. 
The proteins identified in this study function in gene expression and regulation. The 
heterogeneous nuclear ribonucleoproteins A2/B1 are RNA binding proteins involved 
in the processing of primary mRNA transcripts to yield functional mRNA and 
transport to the cytoplasm (Dreyfuss et al., 1993). Translin-associated protein X is 
post-translationally modified by sumoylation by small ubiquitin-like modifier protein 
(SUMO) which is not for proteasomal degradation. It is thought to act with the RNA 
and DNA binding protein Translin in DNA damage response, RNA transport and 
translational control (Jaendling and McFarlane, 2010). The tryptophanyl-tRNA 
synthetase protein catalyzes tryptophanyl-tRNAtrp formation. This protein is 
abundant in brain tissue and post-translationally modified by phosphorylation. The 
protein activates signal transduction such as extracellular signal-regulated kinases 
pathways. tRNA pseudouridine functions in RNA processing such as splicing and 
production of mature RNA. Putative deoxyribonuclease has a role in DNA hydrolysis 
and the guanosine diphosphate (GDP) dissociation inhibitor beta regulates the 
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GDP/GTP exchange. Serpin H1 (47 kDa heat shock protein or serine (or cysteine) 
peptidase inhibitor) may behave as a chaperone in the collagen biosynthetic pathway. 
Serpins are a superfamily that share the same well-conserved structure, but differ in 
their function (Silverman et al., 2001). Inclusions containing neuro-serpin (one of the 
serpin family) aggregates have been described in brain sections from familial 
dementia patients. This was confirmed by a Western blotting study and indicated to be 
due to amino acid substitutions leading to protein conformational changes and 
aggregation (Davis et al., 2002). Actin is a cytoskeletal protein that has been shown to 
be post-translationally modified by ubiquitin, supporting our findings. The proteins 
identified in this study, except for actin, have not previously been reported as targets 
for ubiquitination. These results may suggest a feedback between systems controlling 
protein synthesis and degradation. 
Although potential ubiquitinated proteins were identified in this study, the use of a 
more sensitive mass spectrometer may significantly improve the results. 
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Figure 3.12 
 
 
 
 
Figure 3.12 The results of STRING software analysis of proteins identified in Table 3.1. 
 STRING is a database of known protein interactions or association (functional) sourced from genomic 
context, high-throughput experiments and previous knowledge from Pubmed. Different line colours 
represent the interaction type and association. 
  Experiments line; indicates interaction detected by experimental work (high score of interaction); 
 Textminig line represents the association of two protein in publications (low score) 
Uba52 and Ubc, Ubiquitin; Wars, tryptophanyl-tRNA synthase; Tatdn3, Putative deoxyribonuclease; 
Gdi2, Rab GDP dissociation inhibitor beta; Hnrnpa2b1, Heterogeneous nuclear ribonucleoproteins 
A2/B1; Trub2, Probable tRNA pseudouridine; Serpinh1, Serpin H1; Actb, Actin-cytoplasmic 1; Tsnax, 
Translin-associated protein X. 
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CHAPTER 4 
 
Proteomic investigation of the Psmc1fl/fl;CaMKIIα-Cre 
mouse cortex reveals differential expression of 
cytoskeletal, antioxidant and mitochondrial proteins
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4.1 Introduction 
Proteomic studies have been used to investigate protein networks involved in several 
disease states, including neurodegeneration. These studies include the analysis of 
protein expression levels, protein-protein interactions and post-translational 
modifications. Differential protein expression between normal and diseased samples 
may lead to the discovery of early potential biomarkers for specific disease states, 
decipher mechanisms involved in disease progression and identify pharmacological 
targets.  
Proteome investigations are based on the understanding that proteins mediate an 
important part of the biological actions in the cell. Although mRNA is the molecule 
for protein synthesis, numerous factors can prevent the linear association between 
mRNA and protein expression level, including post-transcriptional changes in mRNA 
and post-translational protein modifications which might affect protein function 
(Anderson and Seilhamer, 1997; Gygi SP, 1999).  
Global profiling of protein expression based on 2-dimensional fluorescence difference 
in-gel electrophoresis (2-D DIGE) was introduced by Unlu et al in 1997 (Unlü M, 
1997). This is a sensitive technique to resolve and visualize thousands of proteins 
spots following two-dimensional protein analysis gel electrophoresis (2-D PAGE). 
The 2-D DIGE has now been extensively used in research, including investigations of 
animal models and clinical research. The 2-D DIGE method depends on minimal 
labeling of the protein sample by fluorescent dyes called cyanine dyes (CyDyes: Cy2, 
Cy3, and Cy5). These dyes carrying N-hydroxysuccinimidyl ester group can 
covalently bind to the ε-amino groups of lysine residues of proteins. They have a 
matched charge and mass and therefore do not cause differences in protein migration. 
Normally, Cy3 and Cy5 are used for sample labeling (control and diseased) and Cy2 
for labeling a pooled mixture from all samples to be analyzed (internal standard). 
Because of the distinct excitation and emission spectra of each CyDye, the labeled 
samples and internal standard are mixed and run together on a single 2-D PAGE gel. 
This technique minimizes gel-to-gel variability, allowing easily protein spot matching 
for analysis. In general, the separation of proteins by 2-D electrophoresis, according 
to their pI and molecular weight, is crucial for investigating protein isoforms and post-
translational modifications. 2-D electrophoresis is usually coupled to mass 
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spectrometry for identification of proteins spots of interest. Previous studies have 
shown 2-D DIGE to be a sensitive and reproducible technique for differential protein 
expression analysis (Gharbi et al., 2002; Kurz et al., 2012). 
2-D DIGE of the striatum from a Parkinson’s disease mouse model over-expressing 
α-synuclein (A53T-SNCA) coupled to mass spectrometry identified differentially 
expressed proteins associated with pre-synaptic dysfunction, bioenergetics failure and 
dysregulation of cytoskeletal proteins (Kurz et al., 2012). A similar study in the cortex 
and striatum of a Parkin knockout mouse showing behavioural and biochemical 
changes related to PD revealed dysregulation of proteins involved in energy 
metabolism, stress, protein folding and degradation by the UPS (Periquet et al., 2005). 
2-D DIGE has also been used in the clinical research field to search for disease 
biomarkers. Investigations of the proteome of CSF from normal, PD and PDD showed 
changes in the levels of specific proteins that may be promising biomarkers for PD 
and dementia developed in PD (Jesse et al., 2012; Wang E-S, 2010). These studies 
involving animal models as well as clinical research support the use of 2-D DIGE 
coupled to mass spectrometry for a comprehensive proteomic study into 
neurodegeneration presented here. 
The conditional deletion of Psmc1
fl/fl;CaMKIIα-Cre expressing neurones of mouse 
brain was associated with neuropathological changes resembling human dementia 
with Lewy bodies (DLB), i.e. neurodegeneration and the formation of Lewy-like 
inclusions in surviving neurones of the cortex. Immunohistochemical staining also 
showed significant gliosis as indicated by glial fibrillary acidic protein (GFAP) as 
well as expression of p53 and cleaved caspase 9 (Bedford et al., 2008). An in vitro 
model of Psmc1-KO in mouse embryonic fibroblasts further revealed changes in genes 
linked to apoptosis such as Bcl2 (Bedford et al., 2008). The Psmc1
fl/fl;CaMKIIα-Cre 
mouse is a unique in vivo model to investigate global protein profile changes that 
accompany neurodegeneration and Lewy-like inclusions formation in mouse cortical 
neurones following 26S proteasomal dysfunction. This investigation is important for 
understanding the mechanisms leading to neurodegeneration and may be relevant to 
human disease. 
In this chapter we aimed to identify differentially expressed proteins in 6 week old 
Psmc1
fl/fl;CaMKIIα-Cre mouse cortex. This age was chosen because there were 
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extensive neuropathological changes following Psmc1 inactivation (Bedford et al., 
2008). We used 2-D DIGE coupled to MALDI-TOF mass spectrometry for protein 
identifications. We identified 17 proteins that were differentially regulated in the 
cortex of Psmc1
fl/fl;CaMKIIα-Cre mouse. The analysis revealed up-regulation of 
cytoskeletal astrocytic proteins, the glial acid fibrillary protein and vimentin, as well 
as another astrocyte-specific protein related to the oxidative homeostasis, 
peroxiredxoin-6. Several proteins were identified that were down-regulated; 
mitochondrial fumarate hydratase and stathmin-1, related to the tricarboxylic acid 
cycle and cytoskeletal microtubule dynamics respectively. Overall, the data presented 
here will increase our knowledge of pathways associated with neuronal loss following 
26S proteasomal depletion and be important in understanding mechanisms involved in 
neurodegeneration diseases such as DLB.  
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4.2. Results 
Differential protein expression in the Psmc1
fl/fl;CaMKIIα-Cre mouse brain cortex 
following depletion of 26S proteasome was investigated using 2-D DIGE coupled to 
mass spectrometry (MADLI-TOF). Identified proteins were validated by Western 
blotting. 
 
4.2.1. Differential expression of proteins in the Psmc1
fl/fl ;CaMKIIα-Cre cortex 
Four cortical samples from control and Psmc1
fl/fl;CaMKIIα-Cre mice were used in 
this analysis. A dye swap was also incorporated where control and 
Psmc1
fl/fl;CaMKIIα-Cre samples are labeled with both Cy3 and Cy5 to limit any dye 
bias. Cy2 was used for the pooled internal standard. The labeled samples were 
resolved on four 2-D DIGE gels as described in methods section 2.4. Each gel was 
scanned at the three wavelengths corresponding to the Cy dyes (Cy2 images were 
scanned at 473 nm, Cy3 at 532 nm and for Cy5, 635 nm). This produced 12 images 
for analysis as shown in Figure 4.1. The images show scattered protein spots between 
relative molecular mass of 10 – 150 kDa, and approximately pI 4-8. After fluorescent 
imaging, a randomly selected gel was further silver stained to reveal the spot pattern 
and is shown in Figure 4.2A. 
2-D DIGE images were analyzed for differences in protein expression using 
SameSpots image analysis software (Progenesis). This software generates a list of 
statistically significant differentially expressed spots (Appendix II). 24 spots showed 
differential abundance in the Psmc1
fl/fl;CaMKIIα-Cre cortex; identified by an ID 
number, fold-change (Psmc1
fl/fl;CaMKIIα-Cre versus control) and average 
normalized volume of each spot. Spots were selected as significant for protein 
identification with a p value < 0.05 and fold change of ≥ 1.2. The master image 
generated by SameSpot software shows the location of each spot to be identified (Fig. 
4.3). A preparative gel stained with colloidal Coomassie stain is used to match and 
excise the protein spots of interest for identification by mass spectrometry (Fig. 4.2B).  
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Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 False-colored images of the gels following 2-D DIGE analysis (n = 4). 
Samples were from control, Psmc1
fl/fl;CaMKIIα-Cre or a pooled (control plus 
Psmc1
fl/fl;CaMKIIα-Cre) mixture. (A) Images for Cy3-labeled control and Cy5-labeled 
Psmc1
fl/fl;CaMKIIα-Cre. (B) Images for dye swap labeling; Cy5-labeled control and Cy3-
labeled Psmc1
fl/fl;CaMKIIα-Cre. Pooled samples were labeled with Cy2 and used as an 
internal reference of protein loading for normalization. 
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Figure 4.2 
 
      
 
 
 
 
 
 
Figure 4.2 (A)  A representative silver staining following 2-D DIGE of a pooled Cy2-
labeled sample. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 (B)  Preparative 2DG electrophoresis visualized with colloidal Coomassie 
stain. Differentially expressed spots from the master gel shown in Figure 4.3 were matched 
with this gel, excised and identified by MALDI-TOF-MS. 
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230 kDa pI 3 10 
10  kDa 
230 kDa p I 3 10 
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Figure 4.3  
 
 
 
 
 
Figure 4.3  Master image of the 2-D DIGE analysis produced by the Samespots 
software. Differentially expressed spots in the Psmc1
fl/fl;CaMKIIα-Cre cortex are indicated 
by ID numbers. These spots were > 1.2 fold change in protein abundance between control and 
Psmc1
fl/fl;CaMKIIα-Cre, and p < 0.05 (ANOVA). The spots labeled in yellow were identified 
by MALDI-TOF-MS and are listed in table 4.1. The spots labeled in red were not identified 
due to low expression levels.  
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4.2.2. Proteins spots identified by MALDI-TOF-MS 
To identify the differentially expressed protein spots from the 2-D DIGE, a pooled 
protein sample from Psmc1
fl/fl;CaMKIIα-Cre and control mouse brain cortices was 
focused and resolved on a preparative 2-D gel and stained with colloidal Coomassie 
stain (Figure 4.2B). The location of the spots from the Samespots Master image was 
visually matched to spots on the preparative gel. 18 of the 24 spots were recognized 
(Figure 4.3, yellow labels), but it was not possible to confidently locate the remaining 
6 spots (Figure 4.3, red labels). 
The located spots were excised from the preparative gel and prepared for MALDI-
TOF-MS as described in the methods section 2.4.4, mass spectrometer analysis was 
carried out at Nottingham Trent University, Nottingham UK. MS analysis was 
accompanied by a Mascot database search for protein identification (ID). According 
to the Mascot algorithm criterion; peptides matching the internal sequence of a 
theoretical candidate protein with a score greater than 55, were considered significant 
(p < 0.05).  
All of the identified proteins are listed in Table 4.1. The table summarizes the protein 
accession code (UniProt Accession code), gene ID, protein name, fold change, 
percentage of identified sequence coverage, molecular mass, pI value and mascot 
score. It is noted that several spots (474, 668, 708, 770, 988, and 1130) were found to 
contain more than one protein. This leads to difficulty in identifying the protein 
displaying change. This could result from similar migration patterns of these proteins 
on the IPG strip, protein post-translational modifications, and protein cleavage or the 
presence of protein isoforms. Appendix II illustrates the results of the peptide data and 
Mascot search relating to protein identification.  
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Table 4.1  Differentially expressed proteins in Psmc1
fl/fl;CaMKIIα-Cre mice brain cortex 
2DIGE image analysis Protein identified by MALDI-TOF-MS and MASCOT 
Spot 
No. 
Fold 
change 
p-value 
 
NCBI- 
Gene ID 
Uniprot Accession 
code 
Protein ID MW pI 
Mascot 
Score 
¡¡
 
Matched 
peptides 
γ
 
Sequence 
Coverage % 
φ
 
474 1.4 0.003 
22352 
227613 
VIME_MOUSE 
TBB2C_MOUSE 
Vimentin 
Tubulin beta-2C chain 
53 
50 
5.06 
4.79 
165 
187 
32 
37 
69 
68 
506 -1.3 0.023 11947 ATPB_MOUSE ATP synthase subunit beta, mitochondrial. 56 5.19 115 18 41 
527 -1.3 0.022 14194 FUMH_MOUSE 
Fumarate hydratase, 
Mitochondrial 
54 9.12 83 13 26 
529 3.2 1.02E-04 14580 GFAP_MOUSE Glial fibrillary acidic protein 50 5.27 407 65 82 
531 -1.4 0.043 235072 SEPT7_MOUSE Septin-7 50 8.73 107 15 46 
668 1.6 1.76E-04 
22151 
22142 
15481 
TBB2A_MOUSE 
TBA1A_MOUSE 
HSP7C_MOUSE 
Tubulin beta-2A chain 
Tubulin alpha-1A chain 
Heat shock cognate 71 
50 
50 
71 
4.78 
4.49 
5.37 
108 
53
+
 
48
+
 
18 
9 
11 
43 
32 
23 
708 1.2 9.77E-004 26876 
14447 
AK1A1_MOUSE 
G3P_MOUSE 
Alcohol dehydrogenase [NADP+] 
Glyceraldehyde-3-phosphate 
dehydrogenase 
36 
36 
6.9 
8.44 
369 
158 
31 
20 
71 
61 
767 -1.2 0.025 17957 SNAB_MOUSE Beta-soluble NSF attachment protein 33 5.52 74 8 32 
770 1.7 0.005 14580 
11816 
GFAP_MOUSE 
APOE_MOUSE 
Glial fibrillary acidic protein 
Apolipoprotein E 
50 
36 
5.27 
5.56 
141 
66 
28 
18 
47 
48 
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Table 4.1 continued. 
2DIGE image analysis Protein identified by MALDI-TOF-MS and MASCOT 
Spot 
No. 
Fold  
change 
p-value 
 
NCBI- 
Gene ID 
Uniprot Accession 
code 
Protein ID MW  pI Mascot 
Score 
¡¡
 
Matched 
peptides
 γ
 
Sequence 
Coverage %
 φ
 
908 1.4 0.006 11758 PRDX6_MOUSE Peroxiredoxin-6 26 5.71 177 25 84 
 
988 -1.2 0.019 
16396 
227613 
ITCH_MOUSE 
TBB2C_MOUSE 
E3 ubiquitin-protein ligase Itchy 
Tubulin beta-2C chain 
9.96 
50.2 
5.93 
4.79 
60 
54
+
 
15 
13 
24 
21 
1039 1.3 4.17E-004 22195 
 
UB2L3_MOUSE 
 
Ubiquitin-conjugating enzyme E2 L3  
 
18 8.68 157 16 79 
1089 -1.2 0.003 12859 
 
COX5B_MOUSE Cytochrome c oxidase subunit 5B, 
mitochondrial 
14 8.68 80 8 56 
1130 1.2 0.008 12858 
 
 
COX5A_MOUSE 
 
PHP14_MOUSE 
Cytochrome c oxidase subunit 5A, 
mitochondrial 
14 kDa phosphohistidine phosphatase 
16.3 
 
14.1 
6.08 
 
5.26 
143 
 
79 
9 
 
8 
65 
 
70 
1231 1.3 0.046 78330 NDUV3_MOUSE 
 
NADH dehydrogenase [ubiquinone] 
flavoprotein 3, mitochondrial  
11.8 9.34 58 4 40 
1249 
1250 
-1.4 
-1.4 
0.008 
0.002 
64011 NEUG_MOUSE 
 
Neurogranin 7.7 6.57 144 
131 
5 
5 
57 
58 
1253 -1.2 0.023 16765 STMN1_MOUSE Stathmin-1 
 
17.2 5.76 111 12 77 
 
¡¡
 Mascot score is a statistical score for how well the experimental data (peptide masses) match the database sequence. A score value of 55 or more represents 
significant values (p < 0.05).  
+
Lower values can be considered if matched protein appears at the top of the hit list of the resultant identified proteins. 
γ
 Matched peptides are the number of peptides identified as matching the database sequence of candidate protein. 
φ
 Sequence coverage is the percentage of the database protein sequence covered by matching peptides from the experimental data. The larger the sequence 
coverage the more certain is the identification. 
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4.2.3 Protein validation by Western blot 
In order to validate the proteins identified by 2-D DIGE and MALDI-TOF-MS, 1-
Dimensional (1-D) Western blotting was performed. 50-100 µg protein were extracted 
from control and Psmc1
fl/fl;CaMKIIα-Cre cortices (n = 4) using the same urea lysis 
buffer used for 2-D DIGE. Proteins were resolved using 12% SDS-PAGE and 
transferred onto nitrocellulose membrane. The membrane was probed with an 
antibody for the protein of interest and then re-probed with an actin antibody for 
normalization. The protein levels were quantified using densitometry analysis 
(ScnImage software) of the bands developed on the autograph following western 
blotting. Data was statistically analyzed using Graph Pad prism 5. Western validation 
was performed at least twice for each protein and representative images are shown. 
4.2.3.1 Glial fibrillary acidic protein (GFAP) is increased and post translationally 
modified in Psmc1
fl/fl;CaMKIIα-Cre mouse cortex  
GFAP is a classical astrocytic protein marker. GFAP is a 50 kDa (432 amino acid 
residues) type III intermediate filament protein. Its coiled-coil domains provide 
mechanical strength for the formation of firm bundles fibers. In this study GFAP was 
identified in two protein spots; 529 and 770 (Figure 4.3 and Table 4.1). These spots 
showed 3.2- and 1.7-fold increase respectively in Psmc1
fl/fl;CaMKIIα-Cre versus 
control cortex. The ApoE protein was identified in addition to GFAP in spot 770.  
1-D Western blot analysis of GFAP showed a 4-fold increase (P < 0.01) in GFAP 
expression in Psmc1
fl/fl;CaMKIIα-Cre cortex compared to control (Figure 4.5A). 
Figure 4.5A also shows a high molecular weight smear above 50 kDa in the 
Psmc1
fl/fl
;CaMKIIα-Cre cortical samples.  
Upregulation of GFAP in this study confirms the extensive astrocytic gliosis revealed 
by cortical immunohistochemistry, accompanying neurodegeneration (Bedford et al., 
2008) and is supported by other neurodegenerative disease models showing increased 
GFAP expression. 2D-DIGE global proteome analysis of striatal tissue from the A53T 
α-synuclein PD mouse model showed a 3-fold increase in GFAP versus controls 
(Kurz et al., 2012). Moreover, a 220 % increase in GFAP expression was reported in 
the striatum of an MPTP ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxin 
model of PD (Muroyama et al.).  
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Upregulation of GFAP expression is not confined to animal models of 
neurodegeneration. Increased expression of GFAP has also been detected in the 
entorhinal cortex of postmortem brain samples from patients affected by 
neurodegeneration such as AD (Porchet et al., 2003). Although neurodegeneration has 
been associated with astrocytic gliosis in animal models and human studies, there is 
limited data specifically connecting astrocytic activation with cortical Lewy body 
disease (DLB). 
GFAP was identified in two differentially-expressed protein spots. To further 
investigate GFAP expression we performed 2-D PAGE followed by Western blotting 
for GFAP (Figure 4.4). Interestingly, comparison of control versus 
Psmc1
fl/fl;CaMKIIα-Cre cortical samples showed a different protein expression 
pattern with additional GFAP protein spots in the Psmc1
fl/fl;CaMKIIα-Cre sample that 
were absent from the control sample (spot number 1,2, 5 and 6). Two spots were 
approximately 30 kDa and may match spot ID 770 identified in 2-D DIGE containing 
both GFAP and ApoE (Table 4.1). Therefore, we suggest that the 1.7-fold change is at 
least partly related to GFAP in this spot. However, this does not exclude changes in 
ApoE which have not been investigated. Interestingly, ApoE is also expressed in 
astrocytes (Bachoo et al., 2004).  
The major form of GFAP is 50 kDa. Therefore, the low molecular weight protein spot 
ID 770 may represent accumulation of GFAP isoform or fragments as a consequence 
of degradation in Psmc1
fl/fl;CaMKIIα-Cre mouse cortex. The mascot search results for 
peptide matched for GFAP from spot 529 (regular from-at 50 kDa) showed 70 % of 
peptide identified from total protein, while GFAP identified from spot 770 (at lower 
kDa) showed 47 % of peptide matches. 
In addition to the lower molecular weight spots, two additional GFAP spots are shown 
in Figure 4.4 (spot number 1 and 2) with a similar molecular weight to the normal 
GFAP (~ 50 kDa), but a shift toward acidic pI. These spots were not identified by the 
2-D DIGE analysis. This may be due to sensitivity of Western blotting in addition to 
increased protein loading of these gels compared to 2-D DIGE. Protein 
phosphorylation can reduce a protein’s pI value (Yamagata et al., 2002). GFAP may 
undergo posttranslational modification by phosphorylation (Inagaki et al., 1994) 
causing the shift toward acidic pI in Psmc1
fl/fl;CaMKIIα-Cre cortex. 
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Figure 4.4 
 
 
 
 
 
 
 
 
Figure 4.4  2-D Western blotting for GFAP of control and Psmc1
fl/fl;CaMKIIα-Cre 
mice cortices samples. 300 µg of protein was focusing on 3-10 NL IPG strips followed by 
second dimensional electrophoresis using 12% SDS-PAGE. The major GFAP spots are 
numbered 3 and 4, which are clearly increased in the Psmc1
fl/fl;CaMKIIα-Cre cortex. 
Additional spots at ~ 45-50 kDa with lower pI (spot numbered 1 and 2) as well as lower 
molecular weight spots 5 and 6 (~20 -30 kDa) are also evident in the Psmc1
fl/fl;CaMKIIα-Cre 
cortex.  
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4.2.3.2 Vimentin (VIME) is up-regulated in Psmc1
fl/fl;CaMKIIα-Cre mouse cortex  
Vimentin was identified in protein spot 474. Vimentin is a 53 kDa (466 amino acid 
residues) type III intermediate filament protein of the cellular cytoskeleton. There was 
a 1.4-fold increase in this spot in the Psmc1
fl/fl;CaMKIIα-Cre cortex sample compared 
to control (Table 4.1, p = 0.003). 1-D Western blotting showed vimentin was not 
expressed in control samples, but significantly up-regulated in the 
Psmc1
fl/fl;CaMKIIα-Cre cortex (Figure 4.5B, p < 0.01). The absence of vimentin 
expression in control mouse brain cortex is supported by studies showing low 
vimentin levels in normal human subjects (Pekny and Nilsson, 2005). Increased 
vimentin is considered to be a marker of astrogliosis (Yamada et al., 1992; Porchet et 
al., 2003). Therefore, vimentin expression in the Psmc1
fl/fl;CaMKIIα-Cre cortex is 
consistent with the increased GFAP expression and extensive astrocytic gliosis 
described in section 4.2.3.1. However, tubulin beta-2C, another cytoskeleton protein, 
was also identified in this spot. Tubulin beta-2C was not further investigated and we 
cannot exclude the possibility that this protein also increases in the 
Psmc1
fl/fl;CaMKIIα-Cre cortex. 
 
4.2.3.3 Up-regulation of peroxiredoxin-6 (PRDX-6) in Psmc1
fl/fl;CaMKIIα-Cre 
mouse cortex  
Peroxiredoxin-6 is a bifunctional enzyme with glutathione peroxidase and 
phospholipase A2 activities (Chen et al., 2000). The protein had been called non-
selenium GSH peroxidase (contains no selenium atom) to differentiate it from other 
subtypes of the peroxiredoxin class. PRDX-6 has a molecular weight of 26 kDa and 
the mouse protein has a predicted length of 224 residues. PRDX-6 has two active 
sites; cysteine-47 for the peroxidase activity and cysteine-32 associated with 
phospholipase activity. Its pI is ~ 5.1, which may vary depending on the oxidation 
and/or phosphorylation of the protein (Power and Nicholas, 1999; Wu et al., 2009). 
PRDX-6 was identified in spot 908, showing a 1.4-fold increase in expression in the 
Psmc1
fl/fl;CaMKIIα-Cre cortex (Table 4.1, p = 0.006). Increased PRDX-6 expression 
was validated by 1-D Western blotting and densitometric analysis showed a 2-fold 
increase in expression in Psmc1
fl/fl;CaMKIIα-Cre versus control mouse cortex (Figure 
4.5C, p < 0.001). 
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Previous proteomic investigations in mouse models of neurodegenerative disease 
support our findings. Models of familial amyotrophic lateral sclerosis and 
Alzheimer’s disease have shown up-regulation of PRDX-6 (Strey et al., 2004; Yata K, 
2011). PRDX-6 up-regulation was also detected in postmortem AD, PD and PDD 
brain (Power et al., 2002; Power JH, 2008). Interestingly, these results suggest that the 
up-regulation of PRDX-6 is protective against oxidative stress.  
4.2.3.4 Stathmin-1 (STMN-1) is down-regulated in the Psmc1
fl/fl
;CaMKIIα-Cre 
mouse cortex  
Stathmin-1 has a molecular weight of 18 kDa, corresponding to 149 amino acid 
residues. STMN-1 was identified in spot 1253, showing a 1.2-fold decrease in 
Psmc1
fl/fl;CaMKIIα-Cre cortex compared to controls (Table 4.1, p = 0.02). The 
significant decrease in STMN-1 expression was validated by 1-DG Western blotting 
followed by densitometry analysis (Figure 4.6 A, p < 0.001). This decrease in the 
expression of STMN-1 is more significant than suggested by the 2-D DIGE because 
STMN-1 expression is absent in Psmc1
fl/fl;CaMKIIα-Cre mice cortex as showed by 
Western blotting. Previous data has indicated STMN-1 down-regulation in frontal and 
temporal cortices of AD associated with neurodegeneration (Cheon et al., 2001). In 
addition, the STMN-1-KO mouse develops age-related axon pathology (Liedtke et al., 
2002). The Psmc1
fl/fl;CaMKIIα-Cre mouse model is the first model of 
neurodegeneration to describe differential regulation of STMN-1 in cortical tissue 
associated with neurodegeneration and Lewy body pathology. 
4.2.3.5 Mitochondrial fumarate hydratase (mFUMH) is down-regulated in 
Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex 
Mitochondrial FUMH (mFUMH) is a nuclear encoded mitochondrial enzyme 
responsible for the reversible conversion of fumarate to malate in the citric acid cycle. 
mFUMH is a 54 kDa protein of 507 amino acid residues. This protein was identified 
in spot 527, showing a 1.3-fold decrease in expression (Table 4.1, p = 0.02). 
Decreased mFUMH expression was validated by 1-DG Western blotting and 
densitometric analysis, revealing 2-fold lower expression in Psmc1
fl/fl;CaMKIIα-Cre 
cortex compared to control (Figure 4.6B, p = 0.03). Data linking specifically mFUMH 
to neurodegeneration is limited; however, mitochondrial dysfunction is well 
documented in neurodegenerative diseases such as PD and PDD. 
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4.2.3.6 Neurogranin (NEUG) is down-regulated in Psmc1
fl/fl;CaMKIIα-Cre mouse 
cortex 
Neurogranin was identified in two spots in the 2-D DIGE analysis; 1249 and 1250, 
both showing a 1.4-fold fold decrease (Table 4.1, p = 0.008 and 0.002 respectively). It 
is ~ 8 kDa and 78 amino acid residues. This protein was not validated by 1-DG 
Western blotting as no suitable antibody was available. However, the identification of 
NEUG in two spots, demonstrating a high mascot score and high fold change in spot 
intensity (see tabel 4.1 and appendix II); can confirm its down-regulation in 
Psmc1
fl/fl;CaMKIIα-Cre mouse cortex. NEUG is a tissue specific protein; it is found 
in the cell body of layer II-VI cerebral cortex neurones, and also in the apical and 
basal dendrites of pyramidal neurones. NEUG has been indicated to be lost in the 
neurodegeneration diseases (Reddy et al., 2005). 
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Figure 4.5 
 
A        
  
 
 
B 
 
 
C 
 
 
Figure 4.5  GFAP, VIME and PRDX-6 are up-regulated in Psmc1
fl/fl;CaMKIIα-Cre 
cortex. Representative 1-DG Western blotting (left-hand-side) and densitometric analyses 
(right-hand-side) of cortical homogenates from control and Psmc1
fl/fl;CaMKIIα-Cre mice for 
GFAP (A), VIME (B) and PRDX-6 (C). Each blot was probed with the antibody of interest 
and then stripped and re-probed with β-actin (ACTN). Graphs depict mean protein levels 
(optical density values) normalized to β-actin. Error bars indicate SEM, n = 4. **p < 0.01; 
***p < 0.001, Student’s t-test. 
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Figure 4.6 
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Figure 4.6  STMN-1 and mFUMH are decreased in Psmc1
fl/fl;CaMKIIα-Cre cortex.  
Representative 1-DG Western blotting (left-hand-side) and densitometric analyses (right-
hand-side) of cortical homogenates from control and Psmc1
fl/fl;CaMKIIα-Cre mice for 
STMN-1 (A) and mFUMH (B). Each blot was probed with the antibody of interest and then 
stripped and re-probed with β-actin (ACTN). Graphs depict mean protein levels (optical 
density values) normalized to β-actin. Error bars indicate SEM, n = 4. **p < 0.01; ***p < 
0.001, Student’s t-test. 
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4.2.3.7 Differentially expressed Proteins identified by 2D-DIGE -MS, but not 
validated by Western blotting 
Several proteins identified by 2-D DIGE were not validated by 1-DG Western 
blotting. Figure 4.7 shows 1-DG Western blotting for Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH or G3P, spot 708); Cytochrome c oxidase subunit 5A, 
mitochondrial (COX5A, spot1130); Heat shock cognate 71 kDa protein (HSP7C spot 
668), Beta-soluble NSF attachment protein (SNAB, spot 767); and Septin-7 (SEPT-7 
spot 531). This may be due to differences in the sensitivity of the techniques used 
and/or protein expression levels in the total pool. A further explanation may be the 
identification of more than one protein in a spot, e.g. GAPDH, COX5A and HSP7C 
were identified in spots containing other proteins (Table 4.1). In these cases not all 
proteins identified were investigated and further work may reveal the differentially 
expressed protein in these spots.  
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Figure 4.7 
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Figure 4.7 continued. 
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Figure 4.7 GAPDH, COX5A, HSP7C, SNAB and SEPT-7 do not show differential 
expression in Psmc1
fl/fl;CaMKIIα-Cre mouse cortex. Representative 1-DG Western blotting 
(left-hand-side) and densitometric analyses (right-hand-side) of cortical homogenates from 
control and Psmc1
fl/fl;CaMKIIα-Cre mice for GAPDH (A), COX5A (B), HSP7C (C), SNAB 
(D) and SEPT-7 (E).       Each blot was probed with the antibody of interest and then stripped 
and re-probed with β-actin (ACTN).      Graphs depict mean protein levels (optical density 
values) normalized to β-actin. Error bars indicate SEM. No significant difference, Student’s t-
test (n = 4). 
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4.2.4 Immunohistochemical investigations of differentially-expressed proteins 
4.2.4.1 GFAP and VIME are expressed in astrocytes. 
Immunohistochemistry of cortical brain sections from control and 
Psmc1
fl/fl;CaMKIIα-Cre mice was performed for GFAP and VIME proteins. GFAP is 
a well characterized marker of astrocytes (Jacque et al., 1978). Figure 4.8 shows 
increased GFAP and VIME-positive cells in the Psmc1
fl/fl;CaMKIIα-Cre cortical 
mouse brain sections. Double-immunofluorescent staining of sections with GFAP and 
VIME was unsuccessful. However, although GFAP staining is more extensive and 
showed branched astrocytes in the Psmc1
fl/fl;CaMKIIα-Cre cortex, the VIME-positive 
cells have some characteristic features of the GFAP-stained astrocytes. VIME is 
mostly in the astrocytic cell body rather than the end feet like GFAP. We suggest that 
VIME is most likely expressed in astrocytes. This is also supported by previous 
studies showing VIME co-localized with GFAP in astrocytes (Escartin et al., 2006; 
Seehusen et al., 2007). 
 
4.2.4.2  Preoxiredoxin-6 is expressed in astrocytes. 
We investigated the cellular localization of PRDX-6 in cortical mouse brain sections 
using double immunofluorescent staining. GFAP and microtubule-associated proteins 
(MAP2) were used as markers of astrocytes and neurones respectively. Previous 
studies have shown extensive astrocytic gliosis in this mouse model (Bedford et al., 
2008). Figures 4.9 and 4.10 show PRDX-6 is expressed in astrocytes and not neurones 
respectively. PRDX-6 is evident in control brain and we suggest that these are not 
reactive astrocytes and hence do not express GFAP, explaining the absence of co-
localization. Figure 4.9 also shows the subcellular distribution of PRDX-6 is more 
focused around the cell body, whereas GFAP staining is in astrocytic processes. The 
absence of GFAP staining in control cortex differs from the Western blot analysis, 
showing GFAP expression. The reason behind this may be differences in the 
sensitivity between techniques. For example, the tissue lysis buffer used for Western 
blotting could make the GFAP protein more accessible for antibody binding. We 
suggest that the increase in PRDX-6 expression in Psmc1
fl/fl;CaMKIIα-Cre cortex is 
associated with reactive astrocytes and is consistent with previously reported studies 
(Jin et al., 2005). 
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Figure 4.8 
 
 
 
 
 
 
Figure 4.8 Astrocytic expression of GFAP and VIME. Immunohistochemical staining 
chromogenic brown for GFAP and VIME in control and Psmc1
fl/fl;CaMKIIα-Cre mouse 
cortical sections (scale bar 50 µm). Figure kindly provided by Dr L Bedford. 
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Figure 4.9 
 
  
Figure 4.9 PRDX-6 is expressed in astrocytes. Double immmunofluorescent staining 
for GFAP (astrocytes/green) and PRDX-6 (red) in control and Psmc1
fl/fl;CaMKIIα-Cre 
mice cortical sections. The merged image shows co-localization of PRDX-6 in GFAP-
positive astrocytes. Scale bar 50 µm.  Figure kindly provided by Dr L Bedford. 
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Figure 4.10 
 
 
Figure 4.10 PRDX-6 is not expressed in the neurones. Double immmunofluorescent 
staining for MAP2 (Neurones/green) and PRDX-6 (red) in control and Psmc1
fl/fl;CaMKIIα-
Cre mice cortical sections. The merged image shows no co-localization of PRDX-6 in 
MAP2-positive neurones. Scale bar 50 µm.  Figure kindly provided by Dr L Bedford. 
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4.3 Discussion 
We have carried out a comparative proteomic study of mouse cortex following 26S 
proteasome deletion in CaMKIIa-expressing neurones. Using 2-D DIGE we found 24 
protein spots showing differential expression in the Psmc1
fl/fl;CaMKIIα-Cre cortex 
compared to controls. We were able to identify 18 of these spots by MS and went on 
to validate several proteins based on antibody availability by 1DG Western blotting. 
We have found significantly up-regulation of astrocytic proteins GFAP, VIME and 
PRDX-6. We also validated the down-regulation of mFUMH and STMN-1.  
To our knowledge this is a unique proteomic study in vivo using in a mouse model of 
neurodegeneration caused by 26S proteasomal deletion. This offers the possibility to 
identify proteins that are involved in the neuropathological mechanisms of inclusion 
body formation and neurodegeneration and may be relevant to human disease. 
4.3.1 Upregulation of GFAP in Psmc1
fl/fl;CaMKIIα-Cre mouse cortex indicates 
reactive astrogliosis 
Upregulation of intermediate filament proteins GFAP and VIME is a characteristic 
feature of astrogliosis following brain injury and neurodegeneration (Yamada et al., 
1992; Porchet et al., 2003). We previously reported astrogliosis accompanying 
neurodegeneration in Psmc1
fl/fl;CaMKIIα-Cre mice by GFAP immunohistochemical 
staining of cortical mouse brain sections (Bedford et al., 2008). Here we validate 
significantly increased expression of GFAP protein using proteomics approaches. 
The control cortex showed limited GFAP expression. This does not indicate absence 
of astrocytes in the healthy brain, but that non-activated normal astrocytes express 
undetectable or very low levels of GFAP, which has been documented in previous 
studies (Sofroniew and Vinters, 2010; Marques et al., 2012). 
GFAP knockout mice show a healthy brain and normal abundance of astrocytes 
indicated by S100β staining, suggesting GFAP is not essential for the formation of 
astrocytes in healthy brain. However, the GFAP knockout mouse is susceptible to 
reactive gliosis following brain injury (Pekny et al., 1995). However, more recent 
studies have shown GFAP expression is associated with astrogliosis an important 
feature of the inflammatory response involving reactive astrocytes (Jardanhazi-Kurutz 
et al., 2011; Diaz et al., 2012).  
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The role of GFAP expression and astrogliosis during brain injury such as 
neurodegeneration is still unclear. In addition, whether astrocytes are protective or 
harmful is the subject of extensive debate. The expression of GFAP and reactive 
gliosis has been shown to be triggered by several molecules in the brain, including 
cytokines, growth factors, glutamate, nitric oxide and reactive oxygen species 
(Sofroniew, 2009). Interestingly, these molecules could be released from different 
neural cell types. Therefore, it is possible that reactive astrogliosis and increased 
GFAP expression in the Psmc1
fl/fl;CaMKIIα-Cre cortex is a consequences of pro-
inflammatory mediators released from neurones. This is supported by the fact that 
26S proteasomal deletion is conditionally targeted to neurones in the mouse model. 
Therefore, astrogliosis is a consequence of neuronal changes. 
Although we have clearly shown a significant increase in GFAP protein expression by 
proteomics and immunohistochemistry, using 2-DG Western blotting we have 
identified variant forms of GFAP in the Psmc1
fl/fl;CaMKIIα-Cre cortex that are not 
evident in the control brain. These could reflect post-translational modification, splice 
variants and/or degradation products. 
Lower molecular weight GFAP spots were detected, approximately at 30 kDa. A 
GFAP protein of similar size has been described in the entorhinal cortex of normal 
elderly and associated with neurodegeneration. The authors suggested this was a 
degradative form (Porchet et al., 2003). Interestingly, it has also been suggested that 
the more acidic form of GFAP is more vulnerable to degradation (Porchet et al., 
2003), which is increased in the Psmc1
fl/fl;CaMKIIα-Cre cortex and discussed below. 
Therefore, it is possible that the lower molecular weight forms of GFAP we see are 
degradation products. However, GFAP splice variants have also been described that 
show differential expression patterns in the human brain. The low molecular weight 
GFAP identified on our 2DG Western blot is similar in size to the reported GfapΔEx6 
isoform (Kamphuis, 2012). To our knowledge this isoform has not been described in 
the mouse brain (Kamphuis, 2012). 
In 2-DG Western blotting, we also show an acidic shift in the GFAP protein in 
Psmc1
fl/fl;CaMKIIα-Cre cortex that is not found in the control. GFAP phosphorylation 
is known to make the protein more acidic, changing its focus on 2-DG toward acidic 
pI, but at the same molecular weight (Bigbee and Eng, 1982; Inagaki et al., 1994).     
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It was suggested that this was involved in astrocytes frameworks remodeling during 
mitosis (Inagaki et al., 1994). Therefore, in the Psmc1
fl/fl;CaMKIIα-Cre cortex it is 
possible that GFAP is phosphorylated to mediates extensive astrocytes proliferation. 
However, the effect of GFAP phosphorylation was unclear.  
 
4.3.2  VIME upregulation supports reactive astrogliosis 
Vimentin is the major astrocyte-specific intermediate filament protein in the neonatal 
brain, it expressed in immature astrocytes and it is the natural partner of GFAP for 
maintaining cell integrity. We have shown significantly increased expression of 
VIME in Psmc1
fl/fl;CaMKIIα-Cre cortex following 26S proteasomal deletion as well 
as VIME-positive astrocyte staining focused in the cell body. Upregulation of VIME 
has been associated with several neurodegeneration diseases, such as 
Alzheimer's disease, Pick's disease, amyotrophic lateral sclerosis and PD (Yamada et 
al., 1992). VIME is essential for formation of intermediate filaments (IF) normal 
structure, in VIME deficient astrocytes it was indicated to be necessary for GFAP 
stabilization and consequently the IF network creation (Galou et al., 1996). Glial cells 
can impair nerve regeneration due to its scar formation, where those devoid of GFAP 
and VIME showed less scar formation. It has been suggested that therapeutic 
suppression of IF upregulation in reactive glial cells may assist neuroregeneration (Lu 
et al., 2011). Therefore, increased expression of VIME can supports reactive gliosis in 
the Psmc1
fl/fl
;CaMKIIα-Cre mouse brain, and this might have role in the 
neurodegeneration. 
 
4.3.3 Upregulation PRDX-6 indicates oxidative stress 
In addition to the increased expression of GFAP and VIME, we identified 
peroxiredoxin-6 as a significantly increased protein in the Psmc1
fl/fl;CaMKIIα-Cre 
cortex. Interestingly we and others show this is an astrocyte-specific protein. PRDX-6 
is a bifunctional enzyme with peroxidase and phospholipase A2 (PLA2) activities, 
acting as an antioxidant and in phospholipid hydrolysis respectively (Fisher et al., 
1999). PRDX-6 is expressed in the control cortex in cells with astrocytic morphology. 
We consider these to be non-reactive astrocytes in the normal brain because they do 
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not express GFAP. Our results demonstrate that PRDX-6 is expressed in both non-
reactive as well as reactive astrocytes and it’s up-regulation is most likely associated 
with the astrogliosis as a consequence of neurodegeneration in the 
Psmc1
fl/fl;CaMKIIα-Cre mouse brain. 
The astrocytic-specific expression of PRDX-6 is supported by previous studies. Jin et 
al. found that astrocytes, but not neurones, in normal mouse brain express PRDX-6 
(Jin et al., 2005). In human AD frontal cortex tissue, astrocytes were significantly 
increased and overexpressed PRDX-6 (Power et al., 2002). A low level of neuronal 
expression was also detected in this study. A study performed on PD and DLB brain 
tissue showed that although the number of astrocytes in diseased cortical tissue varied 
and was not significantly increased, they expressed more PRDX-6 compared to 
controls (Power et al., 2002). Taken together, these studies support our finding that 
PRDX-6 is increased in astrocytes in a mouse model of neurodegeneration and 
inclusion body formation causing dementia. Interestingly, in consistent with our 
study, Power et al. (2002) also showed that α-synuclein positive LB in neurones 
stained with PRDX-6. Direct binding of PRDX-6 and α-synuclein was confirmed by 
immunoprecipitation and the authors proposed PRDX-6 may be involved in 
protecting neurones from oxidative stress caused by aggregated α-synuclein (Power et 
al., 2002). In our studies we did not detect co-localisation of PRDX-6 and neuronal 
marker MAP2 and did not detect PRDX-6 association with inclusion bodies in 26S 
proteasome-deleted neurones. It is still possible that astrocyte-specific PRDX-6 has a 
role in neuronal protection mechanisms in the Psmc1
fl/fl;CaMKIIα-Cre mouse cortex. 
Upregulation of PRDX-6 may be a general response to neuronal injury and 
neurodegeneration because this has been detected in different diseases as well as 
neural cell types. 
Despite the general idea that PRDX-6 plays a protective role during 
neurodegeneration, studies involving PRDX-6 in different tissue and biological 
systems have been inconsistent. In vivo, PRDX-6 failed to protect ethanol-induced 
chronic liver intoxication mediated by oxidative stress in mice and exacerbated 
hepatic lipid accumulation, suggested an unknown function of PRDX-6 in lipid 
metabolism (Roede et al., 2009). Another study using the PRDX-6 knockout mouse 
challenged the lung with Lipopolysaccharides (LPS). This acute lung injury was 
exaggerated in PRDX-6 knockout mice compared to controls (Yang et al., 2011). 
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Investigations of neurodegeneration in the absence of PRDX-6 have not been 
reported, but would be interesting to investigate the antioxidant functions of PRDX-6 
in neurodegeneration. 
Regulation of the expression of PRDX-6 has been investigated in several biological 
systems and will be important in understanding its function. In an in vitro study 
performed in murine bone marrow derived macrophages the expression of PRDX-6 
was induced by prostaglandins such as PGE2 and PGD2 through adenylate cyclase 
with the involvement of transcription factor Nrf2 (Erttmann et al., 2011). Nrf2 
(Nuclear factor erythroid 2-related factor 2) is a redox-sensitive transcription factor 
which controls the expression of antioxidant proteins (Zhang, 2006). In human 
bronchial epithelial cells, PRDX-6 was protective against H2O2-induced apoptosis; 
through its cysteine-47 residue and mutation at this site reversed this protective effect 
(Kim et al., 2011). The PLA2 activity of PRDX-6 can hydrolyze phospholipids (Fisher 
et al., 1999) and therefore can increase the release of arachidonic acid (AA) form 
phospholipid membranes and consequently increases the production of pro-
inflammatory cytokine Interleukins, IL-1β (Kim et al., 2011). Astrocytes can secrete 
IL-1β in vitro (Akama and Van Eldik, 2000). These studies indicate PRDX-6 may 
play a role in inflammatory signalling through its PLA2 activity, as well as an 
antioxidant action through peroxidase activity. We do not know at this time whether 
PRDX-6 is providing antioxidant and/or inflammatory function in the 
Psmc1
fl/fl;CaMKIIα-Cre. 
 
4.3.4 Downregulation of STMN-1 suggests dysregulation of the cytoskeleton 
We found that Stathmin-1 was significantly decreased to undetectable levels in the 
Psmc1
fl/fl;CaMKIIα-Cre brain cortex. In human brain tissue, double 
immunofluorescent staining has shown that STMN-1 co-localizes with neuronal 
marker MAP2, but not with GFAP, a marker of astrocytes, suggesting this protein is 
neuronal (Zhao et al., 2012). Therefore, we suggest that the STMN-1 decrease 
observed in Psmc1
fl/fl;CaMKIIα-Cre cortex is in neurones which are affected by 26S 
proteasomal deletion. This finding can place the question of whether STMN-1 
expression is regulated by UPS; and dysfunction of this system can cause its 
downregulation, or this was consequences of ubiquitin pathology and 
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neurodegeneration which normally change protein homeostasis. To place a possible 
applicable answer for this question, it is necessary to come cross STMN-1 function 
and role in the normal and in the neurodegenerative system in relation to cytoskeleton 
regulation.  
STMN-1 is an important regulatory protein involved in microtubule (MT) dynamics 
and therefore the cell’s cytoskeleton. MTs are highly dynamic structures that 
continuously assemble and dissemble. MT dynamics must be controlled to maintain 
normal cell function and remodeling in response to the cell’s needs (Feinstein and 
Wilson, 2005). STMN-1 interacts with tubulin dimers and its function described as a 
microtubule (MT) dynamic regulator (Belmont and Mitchison, 1996) 
We would expect that the loss of STMN-1 in Psmc1
fl/fl;CaMKIIα-Cre cortex will 
disrupt MT dynamics. In neurones, the synaptic structure is reliant on regulated MT 
dynamics. Improper dynamics can reduce neuronal plasticity leading to cognitive 
impairment. Excessive plasticity can also cause neurological disorders such as 
seizures (Scharfman, 2002). Several studies implicate STMN-1 in neuronal plasticity. 
The STMN-1 null mouse shows age-dependent axonopathy and deficits in long term 
potentiation, suggested STMN-1 involvement in synaptic plasticity for learning and 
memory (Liedtke et al., 2002; Shumyatsky GP et al., 2005). Therefore, decreased 
STMN-1 in the Psmc1
fl/fl;CaMKIIα-Cre cortex may be involved in the learning and 
memory deficits previously reported in these mice (Bedford et al., 2008). However, a 
histological study in the temporal cortex of epileptic patient showed STMN-1 positive 
neurones associated with increased expression (Zhao et al., 2012)  
Regulation of the expression of STMN-1 has been studied. It has been shown that 
STMN-1 mRNA levels were downregulated following p53 induction by apoptotic 
insults such as UV irradiation, temperature shift and doxorubicin treatment (Ahn et 
al., 1999). In addition, p53 negatively regulated STMN-1 expression at the level of 
both transcription and translation in a human cancer cell line. This study indicated 
transcriptional repression of STMN-1 by P53 (Johnsen et al., 2000). We previously 
reported that 26S proteasome deletion in the mouse brain causes upregulation of p53 
(Bedford et al., 2008). Therefore, it is possible that STMN-1 downregulation is 
connected to increased expression of p53 and that this is part of a p53-regulated 
apoptotic signalling process controlled by p53 leading to neuronal loss. 
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4.3.5 Downregulation of mFUMH suggests mitochondrial dysfunction in 
Psmc1
fl/fl;CaMKIIα-Cre mouse cortex 
Mitochondrial Fumarate hydratase (mFUMH) is an enzyme that catalyses the 
reversible conversion of fumarate to malate in the Krebs cycle. A mutant form has 
been identified that causes fumarase deficiency leading to encephalopathy (Zinn et al., 
1986; Gellera et al., 1990). In Psmc1
fl/fl;CaMKIIα-Cre mouse cortex, mFUMH 
expression was decreased ~ 25 % compared to controls, indicating decreased 
mitochondria and/or mitochondrial dysfunction.  
The mitochondrion is an essential energy-generating organelle; it produces ATP via 
the respiratory chain reaction and Krebs cycle. ATP is critical for high energy-
requiring organs such as the brain. Mitochondrial dysfunction has been extensively 
implicated in neurodegenerative disease, particularly PD. It has been shown that 
inhibition of complex I of the respiratory chain by MPTP in the substantia nigra 
causes degeneration of dopaminergic neurones and acute models of Parkinsonism 
(Langston et al., 1983). Other PD-related proteins have been linked to mitochondrial 
function, including PINK1(mitochondrial serine/threonine-protein kinase), Parkin (E3 
ubiquitin ligase), DJ-1(redox-sensitive chaperone ) and LRRK2 (Leucine-rich repeat 
kinase 2, function in protein folding) (Onyango, 2008).  To our knowledge there is no 
study investigating specifically mFUMH in PD, DLB, AD or related animal models. 
Therefore, we report a novel connection between neurodegeneration following 26S 
proteasomal deletion and decreased mFUMH expression that may be a consequence 
of mitochondrial dysfunction and energy metabolism impairment in 
Psmc1
fl/fl;CaMKIIα-Cre mouse cortex.  
The major consequence of mFUMH deficiency is increased fumarate levels. This was 
detected in the CSF of patients with mFUMH deficiency (Deschauer et al., 2006) and 
in the cardiomyocytes of FUMH-M null mice (Ashrafian et al., 2012). In the latter 
study, fumarate increase was shown to be protective against ischemic-reperfusion 
injury; an injury causes oxidative stress, inducing the nuclear factor erythroid 2-
related factor 2 (Nrf2) transcription factor associated with antioxidant pathways 
(Ashrafian et al., 2012). Nrf2 has been shown to be ubiquitinated for proteasomal 
degradation  (Sekhar et al., 2002 ; Eggler et al., 2009 ) indicating that the UPS may be 
involved in the regulation of Nrf2 and the antioxidant response. In general we can 
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conclude that Psmc1
fl/fl;CaMKIIα-Cre mice suffering from energy metabolism 
impairment in their cortices which probably affects other neuronal vital function. 
4.3.6 Downregulation of neurogranin (NEUG) may cause postsynaptic 
impairment 
Neurogranin is highly expressed in selective neurones of the mammalian cerebral 
cortex, hippocampus, and amygdala; areas known for their learning and memory tasks 
(Watson et al., 1990). NEUG is involved in the regulation of postsynaptic signalling. 
The absence of NEUG has been associated with altered Ca
2+
 dynamics in cortical 
neurones (Gerendasy and Sutcliffe, 1997; Vanden Hoek et al., 1997). We found that 
NEUG was ~ 30 % less in the mouse cortex following 26S proteasome deletion. We 
previously reported deficits in spatial learning and memory in these mice, which are 
consistent with the learning and memory deficits reported in NEUG knockout mice 
(Pak et al., 2000; Bedford et al., 2008). Therefore, it is possible that the learning and 
memory defects in Psmc1
fl/fl;CaMKIIα-Cre may be associated with downregulation of  
NEUG.  
NEUG is a specific substrate for Protein Kinase C (PKC) (Baudier, 1991 ) and binds 
to calmodulin (CaM) (Huang et al., 2004b). Phosphorylation of NEUG by PKC can 
reduce its binding to the CaM protein, thereby increasing free Ca
2+
. In addition, at the 
postsynaptic membrane, phosphorylated NEUG can stimulate G-protein coupled 
receptors of the phosphoinositide pathway leading to release of intercellular Ca
2+
  
(Cohen et al., 1993). Therefore, NEUG phosphorylation by PKC can stimulate Ca
2+
 
and Ca
2+
/CaM-dependent enzymes involved in synaptic plasticity, learning and 
memory (Huang et al., 2004b). Since CaMKIIα expressing neurones are targeted by 
26S proteasomal depletion in the mouse model, this supports the decreased expression 
of NEUG. Studies have shown decreased post-synaptic NEUG in the frontal cortex of 
neurodegenerative disease patients, including AD (Reddy et al., 2005). Elevated 
NEUG was also shown in the CSF of patients with AD, suggested this was due to 
synaptic degeneration (Thorsell et al., 2010). Postsynaptic loss is also a feature of PD 
and DLB (Revuelta et al., 2008; Nikolaus et al., 2009). 
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Summary 
26S proteasomal deletion in CaMKIIα-expressing neurones of the mouse brain 
associated with neurodegeneration and inclusion body formation is accompanied by 
changes in several pathways, including inflammation, energy metabolism, synaptic 
plasticity and axonal integrity. 26S proteasomal deletion is conditionally targeted to 
neurones and therefore the astrogliosis must be a consequence of cross-talk between 
neural cells in the mouse brain as a consequence of neuronal changes leading to 
neurodegeneration. Increased expression of PRDX-6 is an indication of changes in 
cortical oxidative homeostasis and/or phospholipase activity and now merits further 
investigation (see chapter 5).  
This is the first proteomics study of a mouse model of cortical inclusion body 
formation and neurodegeneration as a consequence of 26S proteasomal deletion. The 
proteins identified will need to be investigated in human samples from PD, DLB and 
PDD. However, the data so far has provided known and novel mechanisms for further 
investigation. 
 
4.3.7 Limitations of Proteomics in Psmc1
fl/fl;CaMKIIα-Cre brain cortex mice 
Although our 2-D DIGE study successfully identified differentially expressed 
proteins, a much higher number than 24 spots was expected to be identified. The fact 
that 26S proteasomal deletion is conditionally targeted to CaMKIIa neurones means 
that this study is conducted in a mixed cell population containing targeted and non-
targeted neural cells. This is further complicated by the increased number of 
astrocytes in the Psmc1
fl/fl;CaMKIIα-Cre cortex. Proteins with low abundance, even if 
they are differentially expressed, may not be detected using this approach. There may 
also be some inconsistency between 2-DG and 1-DG Western blotting as a result of 
different isoforms that cannot be resolved on 1-DG. In addition, basic proteins (pI > 
10) as well as hydrophobic proteins with difficult solubility may not be best suited to 
this approach. In general, these are some inherent limitations of this technique.  
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CHAPTER 5  
 
Changes in redox homeostasis and PLA2 activity in 
Psmc1fl/fl;CaMKIIα-Cre mouse cortex
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5.1 Introduction 
The 2-D DIGE proteomic investigation described in Chapter 4 showed reactive 
astrogliosis in Psmc1
fl/fl
;CaMKIIα-Cre cortex by upregulation of GFAP and VIME. 
Interestingly, the increased expression of antioxidant enzyme PRDX-6 was also 
associated with astrocytes. PRDX-6 has been reported to be associated with oxidative 
stress and neurodegeneration (Power et al., 2002; Boukhtouche et al., 2006; Yoon et 
al., 2009). Several studies have also shown oxidative stress as a result of changes in 
protein homeostasis in brain in PD and DLB (Castellani et al., 1996; Giasson et al., 
2000; Yan et al., 2012). Since proteasomal dysfunction and oxidative stress are 
implicated in the pathogenesis of neurodegenerative disease, this chapter aimed to 
further investigate oxidative stress and PRDX-6 in vivo in the brain following 26S 
proteasomal depletion in cortical neurones. This was investigated at various ages 
following Psmc1 deletion to provide a general picture of the changes occurring in the 
mouse brain associated with neurodegeneration, astrogliosis and PRDX-6. 
PRDX-6 can reduce H2O2 as well as phospholipid hydroperoxides (Fisher et al., 
1999). PRDX-6 upregulation in cortical tissue of Psmc1
fl/fl
;CaMKIIα-Cre mice lead 
us to investigate whether 26S proteasomal depletion causes the production of reactive 
oxygen species (ROS) and a cascade of oxidative stress targeting lipids, protein as 
well as DNA.  
Although the peroxidase activity of PRDX-6 is associated with antioxidant properties, 
PRDX-6 also has phospholipase A2 (PLA2) activity that may be associated with other 
beneficial and/or detrimental functions. Therefore, we further investigate this activity 
of PRDX-6 in this chapter. 
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5.2 Results 
5.2.1 Malondialdehyde levels are increased in Psmc1
fl/fl
;CaMKIIα-Cre cortices 
The high polyunsaturated fatty acid content of the brain lipids makes it susceptible to 
oxidation. An increased concentration of malondialdehyde (MDA) is used as an index 
of lipid peroxidation in vivo and in vitro (Lazzarino et al., 1995). We measured the 
total amount of MDA in control and Psmc1
fl/fl
;CaMKIIα-Cre mouse cortices at 4, 5 
and 6 weeks of age. In this experiment, homogenization buffers contained the 
antioxidant butylated hydroxytoluene (BHT) that has been shown to prevent auto-
oxidation of samples (Pikul and Leszczynski, 1986) was used . Importantly, in this 
experiment we measured total MDA. Since MDA can react and bind to proteins or 
DNA forming cross-linked products (Marnett, 1999; Rittie et al., 2002).  
Figure 5.1 shows significantly increased MDA concentrations in Psmc1
fl/fl
;CaMKIIα-
Cre cortex at 5 and 6 weeks of age. At 6 weeks, the MDA concentration was 8.62 ± 
0.42 nM /µg in Psmc1
fl/fl
;CaMKIIα-Cre cortex compared to 6.513 ± 0.55 nM /µg in 
the control (p < 0.01). At 5 weeks of age, the MDA concentration was 18.25 ± 1.01 
nM /µg and 12.63 ± 0.56 nM /µg in Psmc1
fl/fl
;CaMKIIα-Cre and control cortices 
respectively (p < 0.001). The MDA levels were not significantly different between 
Psmc1
fl/fl
;CaMKIIα-Cre and controls at 4 weeks of age. The increased MDA levels in 
Psmc1
fl/fl
;CaMKIIα-Cre cortex following 26S proteasomal dysfunction are suggestive 
of increased lipid peroxidation (or abnormal lipid metabolism). In both 
Psmc1
fl/fl
;CaMKIIα-Cre and control cortices, the level of MDA at 6 weeks was lower 
than at earlier ages. This may be explained by interassay variation. The assays at 6 
weeks were measured on a different day to the other age groups.  
MDA can be measured by different methods. Increased MDA-Lysine-modified α-
synuclein was detected in the frontal cortex of PD and DLB patients by Western 
blotting with anti-MDA-Lysine antibody, indicating the ability of MDA to covalently 
modify to disease-associated proteins (Dalfo and Ferrer, 2008). Another study used 
the thiobarbituric acid assay to show increased MDA levels in the substantia nigra of 
a mouse model of PD induced by chemical toxin MPTP (Sun et al., 2010). These 
previous studies support our findings that increased MDA is associated with 
neurodegeneration. 
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In our study, the increased concentration of MDA was associated with reactive 
gliosis, since MDA was significantly elevated in Psmc1
fl/fl
;CaMKIIα-Cre mice 
cortices at age of 5 weeks and reactive astrocytes was evident at 4 weeks in the 
Psmc1
fl/fl
;CaMKIIα-Cre cortical mice tissue (Bedford et al., 2008).  
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Figure 5.1 
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Figure 5.1 Cortical MDA concentrations in Psmc1
fl/fl
;CaMKIIα-Cre and control 
mice at 4, 5 and 6 weeks of age. Data were statistically analyzed by unpaired Student’s t-test 
and presented as mean ± SEM. n = 8. ** p < 0.01, *** p < 0.001. 
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5.2.2 Measurement of protein carbonyl group in Psmc1
fl/fl
;CaMKIIα-Cre cortex 
showed no change compared to control. 
The protein carbonyl group is a hallmark of protein oxidation (Shacter, 2000). Several 
amino acid side chains can be oxidized, e.g. Lys, Arg, Pro, Thr,  into carbonyl 
derivatives (Shacter, 2000). Figure 5.3 shows that protein carbonyl groups were not 
significantly different between Psmc1
fl/fl
;CaMKIIα-Cre and control cortices at 6 
weeks of age. Therefore, this investigation was not carried out with 4 and 5 week-old 
samples. This result suggests that neurodegeneration following 26S proteasomal 
depletion in mouse cortical neurones is not associated with protein oxidation. 
 
 
Figure 5.2 
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Figure 5.2 The level of protein carbonyl groups in Psmc1
fl/fl
;CaMKIIα-Cre and 
control mice cortices at 6 weeks age. Data were statistically analyzed by Student’s t-test and 
presented as mean ± SEM. n = 10. 
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5.2.3 Increased nitro-tyrsoinated proteins in Psmc1
fl/fl
;CaMKIIα-Cre cortex 
Although protein carbonyl groups were not changed in Psmc1
fl/fl
;CaMKIIα-Cre 
cortex, we investigated nitrated proteins in Psmc1
fl/fl
;CaMKIIα-Cre and control 
cortices. Reactive nitrogen species (RNS), such as peroxynitrite, are produced by the 
reaction of nitric oxide and superoxide radicals. Tyrosine residues in proteins can 
undergo nitration by peroxynitriate (Shacter, 2000). 
In this experiment, we used Western blotting of 6 week-old Psmc1
fl/fl
;CaMKIIα-Cre 
and control cortical protein samples homogenized in RIPA buffer with a nitro-
tyrosine mouse monoclonal antibody. Figure 5.3 shows a representative Western blot 
image. A positive control for nitrated proteins was prepared with 1 mM peroxynitrite 
solution as described in the materials and methods (see section 2.6.3) 
Four nitrated protein bands were detected in control and Psmc1
fl/fl
;CaMKIIα-Cre 
cortices as indicated in Figure 5.3. These bands were subject to densitometry and 
statistical analysis as shown in Figure 5.4. Nitrosylated protein bands 2-4 were 
significantly increased in the Psmc1
fl/fl
;CaMKIIα-Cre cortex compared to control (p < 
0.01). This suggests the presence of nitrative stress following 26S proteasomal 
depletion in the mouse cortex. 
Previous studies have shown that nitrative stress is a feature of neurodegeneration. 
Nitro-tyrosinylated proteins were observed in surviving neurones of the substantia 
nigra in PD and the Lewy body core immunolabeled with nitro-tyrosine antibody, 
which may correspond to nitrated neurofilament proteins (Good et al., 1998). In 
another postmortem study in a patient with acute multiple sclerosis, hypertrophic 
astrocytes stained positive with nitro-tyrosine antibody (Oleszak et al., 1998). 
Psmc1
fl/fl
;CaMKIIα-Cre showed extensive astrogliosis and it would be interesting to 
investigate whether astrocytes are positive for nitro-tyrosine.  
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Figure 5.3 
 
 
 
 
 
Figure 5.3 Representative Western blot analysis of nitrated proteins. The blot was 
re-probed with anti-GAPDH antibody as a protein loading control for normalization. Four 
nitrated protein bands were identified. A positive control (+ control) was included in the 
Western blot produced as described in section 2.6.3. The results of densitometry analysis are 
presented in Figure 5.4 
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Figure 5.4 
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Figure 5.4 Densitometry analyses of nitrated proteins from Figure 5.3. Densitometry 
of the four bands was normalized to the corresponding GAPDH and analyzed using unpaired 
Student’s t-test. The data are presented as mean ± SEM. n = 4. ** p < 0.01. 
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5.2.4 Reactive oxygen species decline with increasing age in the cortex of 
Psmc1
fl/fl
;CaMKIIα-Cre mouse 
To further investigate changes in redox homeostasis, we measured reactive oxygen 
species (ROS) in Psmc1
fl/fl
;CaMKIIα-Cre and control cortices. Since ROS trigger 
oxidative changes, we investigated time-points from Psmc1 deletion at 2 weeks of age 
to allow correlation with our previous data on oxidative stress. We measured ROS in 
control and Psmc1
fl/fl
;CaMKIIα-Cre cortical tissue at 17 days, 3, 4, and 6 weeks of 
age. Figure 5.5 shows the results of ROS analysis. In 17 day-old mice, there was a 
tendency for ROS to be increased, but this was not significant (Figure 5.5). No 
significant difference in ROS was found at 3 weeks of age, but interestingly, at 4 and 
6 weeks of age ROS significantly decreased. Correlation analysis showed a 
statistically significant linear relationship between Psmc1
fl/fl
;CaMKIIα-Cre mice age 
and change in ROS level (p < 0.05) (Figure 5.6). As expected, for control mice the 
data was not significant (Figure 5.6).  
In general, ROS are diverse species, including superoxide, hydroxyl radicals and non-
radical H2O2. The DCFDA kit; 2, 7-dichlorofluorescein diacetate (see section 2.7.3) 
used in our study detects hydroxyl and peroxyl species. Other studies have shown 
DCFDA is not sensitive to the superoxide radical, but oxidized by the hydroxyl 
radical or H2O2 (Rothe and Valet, 1990; Vanden Hoek et al., 1997). In addition, we 
found tert-butyl hydrogen peroxide induced oxidative stress similarly in both 
Psmc1
fl/fl
;CaMKIIα-Cre and control cortex homogenates. Since the hydroxyl radical 
has a very short half-life, particularly in a cell-free system, we suggest that we are 
measuring mostly measured H2O2 in cortical homogenates using DCFDA. 
The decreased ROS in 4 and 6 week-old Psmc1
fl/fl
;CaMKIIα-Cre mouse cortices is 
not consistent with the evidence of oxidative stress as indicated by increased lipid 
peroxidation and nitrated proteins as shown in sections 5.2.1 and 5.2.3 respectively. 
However, ROS may have triggered oxidative stress at an early time point. There was a 
tendency for increased ROS at 17 days old in 26S proteasome-depleted cortex that 
may have caused oxidative stress. Interestingly, lipid peroxidation is self-catalytic 
once initiated. Therefore, lipid oxidation may increase through these mechanisms 
despite evidence that hydroxyl and hydrogen peroxide species are decreased. This 
increases the complexity of observations made in the Psmc1
fl/fl
;CamKIIα-Cre cortex 
associated with neurodegeneration. 
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Figure 5.5 
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Figure 5.5 Fluorescent intensities produced by ROS in control and 
Psmc1
fl/fl
;CaMKIIα-Cre mice cortices. Measurements were performed at different ages as 
indicated. The data are presented as mean ± SEM. n = 5 for two weeks; n = 8 three weeks;   n 
= 9 four weeks and n = 11 for six weeks. *** p < 0.01, * p < 0.05, Student’s t-test. 
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 Figure 5.6 
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Figure 5.6 Correlation and regression analysis of ROS levels with age. The linear 
regression analysis was significant for Psmc1
fl/fl
;CaMKIIα-Cre cortex (p < 0.0001) and R2 = 
0.69, but not control (p = 0.36) and R
2 
= 0.03. There is significant inverse correlation between 
ROS and mice age in Psmc1
fl/fl
;CaMKIIα-Cre, R = 0.9; but not for control. The data are 
represented as mean ± SEM.  
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5.2.5 PRDX-6 expression increases with age in Psmc1
fl/fl
;CaMKIIα-Cre  cortex 
To further investigate PRDX-6, identified in the 2-D DIGE proteomic study as 
significantly increased at 6 weeks of age, we investigated the expression of PRDX-6 
from 2 weeks of age when Psmc1 is deleted in cortical neurones initiating 
neurodegeneration. The results of Western blotting analysis are shown in Figure 5.7. 
Densitometry was used to quantitate PRDX-6 expression between control and 
Psmc1
fl/fl
;CaMKIIα-Cre cortices, normalized to β-actin and is shown in Figure 5.8. 
The results were then analyzed by unpaired Student’s t-test. PRDX-6 expression 
showed an increase at 5 weeks of age (p = 0.07), but was not statistically significant 
until 6 weeks of age (p < 0.01). Further statistical analysis showed a significant 
correlation between increased PRDX-6 expression and age (p < 0.05) (Figure 5.9). 
This data indicates that an antioxidant system is activated in the brain following 26S 
proteasomal depletion in cortical neurones accompanying neurodegenerative changes. 
Analysis of the relationship between PRDX-6 and ROS in Psmc1
fl/fl
;CaMKIIα-Cre 
mice showed an inverse correlation in Figure 5.10. 
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Figure 5.7 
 
 
 
 
Figure 5.7  Western blots of cortical homogenates from control and 
Psmc1
fl/fl
;CaMKIIα-Cre mice for PRDX-6 at 2, 3, 4, 5 and 6 weeks of age. β-actin (ACTN) 
was used as a protein loading control. The band intensities from these images were measured 
by densitometry and the data statistically analyzed as shown in Figure 5.8. 
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Figure 5.8 
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Figure 5.8 Relative PRDX-6 expression levels in Psmc1
fl/fl
;CaMKIIα-Cre mice 
compared to controls at different ages. The data are presented as mean ± SEM. n = 3.        
** p < 0.01 versus control by using a post hoc Dunnett's Multiple Comparison Test. 
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Figure 5.9 
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Figure 5.9  Correlation analysis of PRDX-6 expression and age in 
Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex. There is a positive correlation with p < 0.05 and R = 
0.84. The data are represented as mean ± SEM. Dotted lines show the 95 % confidence 
interval. 
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Figure 5.10 
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Figure 5.10 Inverse relationships between % increase of PRDX-6 expression and % 
decrease of ROS in Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex from the control (p < 0.05);          
R = 0.9, and R = 0.84 respectively. Values are presented as mean ± S.E.M.  
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5.2.6 Modification of PRDX-6 in the Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex 
We further investigated PRDX-6 expression profile at 6 weeks of age using 2DG 
electrophoresis followed by PRDX-6 Western blotting. We noted increased 
expression of the major PRDX-6 spot (Figure 5.11; spot 1) in Psmc1
fl/fl
;CaMKIIα-Cre 
cortex compared to control. In addition, there was a more acidic minor PRDX-6 spot 
(Figure 5.11; spot 2) that was also increased in the Psmc1
fl/fl
;CaMKIIα-Cre cortex. 
A previous study reported oxidation of Cysteine-47 residue of PRDX-6 in the 
presence of H2O2 in vitro in melanoma cell line that would cause a similar acidic shift 
in 2DG analysis (Jeong et al., 2012). Therefore, PRDX-6 is known to undergo post-
translational modifications, including oxidation. 
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Figure 5.11 
 
 
 
 
 
 
 
Figure 5.11 2DG PRDX-6 Western blotting of control and Psmc1
fl/fl
;CaMKIIα-Cre 
cortices. Two PRDX-6 spots were identified as indicated. Spot 1 is the major spot identified 
by 2-D DIGE analysis. Spot 2 represents an acidic shift (arrow) that may be a post-
translational modification such as oxidation. 
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5.2.7 Phospholipase A2 enzyme activity is increased the Psmc1
fl/fl
;CaMKIIα-Cre 
cortex 
PRDX-6 is a bifunctional enzyme with peroxidase and phospholipase A2 (PLA2) 
activities (Fisher et al., 1999). Therefore, we decided to investigate PLA2 activity in 
control and Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex.  
PLA2 activity was measured in control and Psmc1
fl/fl
;CaMKIIα-Cre cortices at 4, 5 
and 6 weeks of age (Figure 5.12). The results show that PLA2 activity was 
significantly increased in Psmc1
fl/fl
;CaMKIIα-Cre (1.472 ± 0.1247 U/ml/mg protein) 
compared to control (0.8145 ± 0.1274 U/ml/mg protein) mice at 6 weeks of age (p < 
0.01). The increase at 5 weeks of age was also reaching significance (p = 0.07).  
These results show PLA2 activity is increased in Psmc1
fl/fl
;CaMKIIα-Cre cortices. 
Since, the phospholipase enzymes are a superfamily, we then investigated whether 
this increased activity was due to PRDX-6. 1-Hexadecyl-3-trifluoroethylglycero-sn-2-
phosphomethanol (MJ33) is a fluorinated phospholipid analogue that can inhibit the 
PLA2 activity of PRDX-6 (Chatterjee et al., 2011). Therefore, MJ33 was incubated 
with the cortical homogenate prior to PLA2 activity measurement. Figure 5.13 shows 
significant inhibition of PLA2 activity in Psmc1
fl/fl
;CaMKIIα-Cre mouse cortices. 
Inhibition of enzyme activity was also evident in the control cortex, but the levels of 
PLA2 activity in general were low and therefore inhibition was not significant. 
Therefore, we suggest that at least some of the increased PLA2 activity is due to 
increased expression of PRDX-6 in the Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex. 
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Figure 5.12 
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Figure 5.12 PLA2 enzyme activities in control and Psmc1
fl/fl
;CaMKIIα-Cre mice cortices 
at 4, 5 and 6 weeks of age. The data was analyzed by unpaired Student’s t-test (n = 4). 
Values are presented as mean ± S.E.M. ** p < 0.01. 
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Figure 5.13 
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Figure 5.13 PLA2 enzyme activities in control and Psmc1
fl/fl
;CaMKIIα-Cre mice 
cortices at 6 weeks of age in the presence and absence of MJ33 inhibitor. The data was 
analyzed by unpaired Student’s t-test (n = 4). Values are presented as mean ± S.E.M.          
*** p < 0.001. 
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5.3 Discussion  
Oxidative stress has been implicated in the pathogenesis of neurodegenerative disease 
(Dalfo et al., 2005; Gironi et al., 2011). We have shown here changes in oxidative 
homeostasis in the cortex following 26S proteasomal depletion in cortical neurones. 
Markers of lipid peroxidation and nitrated proteins were increased in 
Psmc1
fl/fl
;CaMKIIα-Cre brain compared to controls. Interestingly, these changes were 
associated with decreased levels of ROS at similar ages. Furthermore, the PLA2 
activity of PRDX-6 was increased that may be associated with a change in oxidative 
homeostasis and/or phospholipid metabolism. This complex scenario in the 
Psmc1
fl/fl
;CaMKIIα-Cre brain provides interesting data related neurodegenerative 
changes as a consequence of 26S proteasome depletion. 
One of the significant biochemical changes observed in the Psmc1
fl/fl
;CaMKIIα-Cre 
cortex was increased PLA2 activity associated with increased PRDX-6. We found 
PRDX-6 expression in astrocytes as part of the extensive astrogliosis accompanying 
neurodegeneration in this mouse model. In general, the phospholipase enzymes 
facilitate membrane phospholipid remodeling and synthesis of some eicosanoids 
(Figure 5.14). 
Previous studies have suggested that increased phospholipase activity may be 
harmful.  In PC12 cells, increased PLA2 activity was shown to have a significant role 
in hypoxic nuclear shrinkage; a feature of pyknosis (Shahnawaz et al., 2007). 
Hyperoxidation of PRDX-6 by H2O2 was associated with increased PLA2 activity and 
cell cycle arrest in HeLa cells (Kim et al., 2008). In vivo, inhibition of PLA2 activity 
decreased MPTP-induced dopamine loss in the PD mouse model of 
neurodegeneration (Tariq et al., 2001). Therefore, the increased PLA2 activity in 
astrocytes in the Psmc1
fl/fl
;CaMKIIα-Cre cortex may be involved in harmful rather 
than protective mechanisms during neurodegeneration. For example, this may be 
involved in inflammatory signalling by astrocytes, possibly through activation of 
eicosanoid pathway. However, upregulation of PRDX-6 was also correlated with 
significantly decreased ROS levels in Psmc1
fl/fl
;CaMKIIα-Cre cortex, suggesting 
protective actions for PRDX-6, possibly associated with its peroxidase activity, in 
addition to mechanisms involving PLA2 activity. 
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Figure 5.14 
 
 
 
  
 
Figure 5.14 Eicosanoid biosynthesis pathway.                                                 
Abbreviations: HPETE, hydroperoxyeicosatetraenoic acid; Tx, Thromboxane;                     
PG, Prostaglandines.  
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Changes in the expression of antioxidant enzymes are considered an indirect 
biomarker of oxidative stress (Kamsler et al., 2001; Harish et al., 2013 ). In addition 
to increased expression of the antioxidant enzyme PRDX-6, we found evidence of 
increased lipid peroxidation and nitrated proteins, indicative of oxidative stress. 
However, the levels of ROS decreased in the Psmc1
fl/fl
;CaMKIIα-Cre cortex. There 
was an inverse correlation between PRDX-6 expression and ROS levels suggesting 
PRDX-6 may detoxify ROS in the Psmc1
fl/fl
;CaMKIIα-Cre cortex in an antioxidant 
protective mechanism. PRDX-6 has recently been shown to have peroxidase activity 
against H2O2 (Kim et al., 2008; Kim et al., 2011). Increased ROS could have occurred 
at an earlier time point before significant upregulation of PRDX-6 was detected. The 
results suggest that this may be between 2 and 3 weeks of age around the time when 
Psmc1 is deleted in cortical neurones. Alternatively, it is possible that we did not 
detect all ROS with the kit used in this study. In addition, lipid peroxidation is self-
catalytic and PRDX-6 is unique in its ability to reduce phospholipid hydroperoxides 
further supporting a role of increased PRDX-6 in protection against lipid 
peroxidation. Interestingly, we showed an acidic shift in PRDX-6 by 2DG Western 
blotting suggestive of its oxidative modification (Jeong et al., 2012). This oxidation 
might support the conversion of H2O2 to water and hence detoxification. PRDX-6 has 
a conserved cysteine residue (Cys
47
) that oxidizes to sulfonic acid upon reduction with 
peroxide substrates (Wood et al., 2003).  
A possible source of ROS is mitochondria. The mitochondrial electron transport chain 
has several redox complexes. Dysfunction of these complexes has the potential to leak 
electrons to oxygen forming superoxide radicals. Complex I (NADH dehydrogenase) 
has been shown to be the primary source of ROS in PD (Kushnareva, 2002 ; 
Trojanowski, 2003 ). Mitochondrial function is under investigation in the 
Psmc1
fl/fl
;CaMKIIα-Cre. However, we know that the Lewy-like inclusions in 
surviving neurones following 26S proteasomal depletion contain morphologically 
abnormal mitochondria with disrupted cristea (Paine et al., 2013). Moreover, in this 
work mitochondrial fumarate hydratase was significantly decreased in the 
Psmc1
fl/fl
;CaMKIIα-Cre cortex. 
In several neurodegeneration diseases, proteins have been shown to undergo oxidation 
and nitration causing their aggregation (Martinez et al., 2010). The detection of 
increased nitrated protein in the Psmc1
fl/fl
;CaMKIIα-Cre cortex is suggestive of 
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nitrative stress in the brain following neuronal 26S proteasomal depletion. Abnormal 
protein nitration can cause protein dysfunction. Nitration of α-synuclein causes the 
formation of a fibrillar form that resembles α-synuclein isolated from PD brains and 
the formation of stable intracellular α-synuclein inclusions requires tyrosine residues 
(Norris et al., 2003). Nitric oxide (NO) is a small, highly diffusible and reactive 
molecule; it can be generated by the action of nitric oxide synthase (NOS) on amino 
acid L-arginine (Alderton et al., 2001). There are three type of NOS; neuronal, 
endothelial and inducible (nNOS, eNOS and iNOS). In general, NOS can generate 
NO and superoxide radicals. If these radicals are not scavenged by antioxidants, they 
can react together to form the peroxynitrite radical; a powerful oxidant (Beckman and 
Koppenol, 1996; Pou et al., 1999). The peroxynitrite radical is very diffusible within 
cellular layers and can oxidize cellular constituents causing lipid peroxidation and 
protein nitrated (Pacher et al., 2007). A study performed on postmortem brain tissue 
from PD showed iNOS expressed in astrocytes can produce high level of NO (Hunot 
et al., 1996). Further histopathological studies have shown nitro-tyrosine-positive 
hypertophic astrocytes and nitrated α-synuclein in classical and cortical Lewy bodies 
in patients with dementia (Oleszak et al., 1998, Giasson et al., 2000, Gomez-Tortosa 
et al., 2002). Nitric oxide was also identified in the CSF and plasma of a patient 
suffering from DLB and it was suggested that excessive NO production may be 
related to the pathogenesis of this disorder (Molina et al., 2002). These previous 
studies support our data that nitrative stress may be involved in the mechanisms of 
neurodegeneration. Interestingly, studies have indicated an involvement of NOS and 
the UPS; nNOS and iNOS are targets of ubiquitination and degradation by the 26S 
proteasome (Bender et al., 2000; Dunbar et al., 2004). Further investigations in the 
Psmc1
fl/fl
;CaMKIIα-Cre cortex should include these enzyme activities.  
In general, MDA is considered to be an index of lipid peroxidation resulting from the 
attack of ROS on membrane phospholipids (Lazzarino et al., 1995). However, MDA 
can be generated through the metabolism of arachidonic acid (Hecker and Ullrich, 
1989). MDA is a reactive molecule that has been shown to cause lipid, protein and 
DNA damage. Lipid peroxidation may inhibit membrane function, destroying its 
barrier properties and ultimately lead to cell death (Stadelmann-Ingrand et al., 2004). 
Interestingly pyknotic nuclei are evident in the Psmc1
fl/fl
;CaMKIIα-Cre cortex at 6 
weeks of age (Bedford et al., 2008). Given that MDA levels are increased following 
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the extensive astrogliosis and neuropathological changes, it is unlikely that MDA 
toxicity itself initiates these processes, but more likely MDA is a product of lipid 
peroxidation or phospholipid metabolism. Additionally, we suggest there is a 
relationship between gliosis and increased MDA concentration, where astrocytic 
activation preceded increasing MDA raises another question that MDA may be a 
result of inflammatory processes associated with reactive astrocytes. 
The idea that increased MDA may be a consequence of increased phospholipid 
metabolism cannot be excluded in this study. MDA can be generated through the 
action of PLA2 on membrane phospholipids through the eicosanoid pathway. In this 
pathway, for example, thromboxane synthase can convert prostaglandin H2 to 
thromboxane A2 and fragmentation into MDA, and also prostaglandin G2 can be 
transformed to MDA (Hecker et al., 1987; Hecker and Ullrich, 1989). To support this 
data, anti-inflammatory drugs such as acetylsalicylic acid and indomethacin can 
inhibit the formation of MDA from arachidonic acid in rat platelets rich plasma 
through inhibition of the cyclo-oxygenase enzyme (de Gaetano et al., 1980). Others 
have confirmed that PRDX-6 has PLA2 activity (Kim et al., 2008; Wu et al., 2009; 
Chatterjee et al., 2011) and can release arachidonic acid from lipid membranes (Ho et 
al., 2010; Kim et al., 2011). It is possible that increased phospholipase activity of 
PRDX-6 increases the concentration of MDA through changes in eicosanoid 
synthesis, indicating an inflammatory response following 26S proteasome depletion in 
the mouse cortex. 26S proteasome depletion has been described previously to cause 
inflammation in vitro (Rockwell et al., 2000). 
Protein carbonylation is another form of protein oxidation caused by oxidative stress. 
This did not increase in the Psmc1
fl/fl
;CaMKIIα-Cre cortex. It is possible that the 
method used to detect protein carbonyls may not be of sufficient sensitivity to detect 
protein carbonylation in the mixed cell population of the brain. The concept of protein 
decarbonylation has been accepted via activation of the thioredoxin pathway (Wong 
et al., 2008). This is a pathway regulating cellular redox balance and alleviated 
damage caused by ROS. 
The precise role of PRDX-6 upregulation in the Psmc1
fl/fl
;CaMKIIα-Cre cortex is 
unclear. Whether this is associated with antioxidant protection and/or lipid 
metabolism associated with deleterious activities required further investigation. 
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Increased PRDX-6 may be involved in decreasing ROS or increasing the MDA 
concentration through its bifunctional enzymatic activities. Deleterious effects of the 
astrocytic expression of PRDX-6 will affect neurones that are not targeted by 26S 
proteasomal depletion. We show novel evidence that 26S proteasomal depletion in 
cortical neurones leads to evidence of oxidative stress by increased lipid peroxidation 
and nitrated proteins. The observations of ROS levels are interesting and it may be 
necessary to investigate alternative methods for the measurement of these species to 
clarify the results.   
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CHAPTER 6 
 
General discussion and conclusion 
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The depletion of 26S proteasomal in neurones leads to the significant accumulation of 
ubiquitinated proteins, but our investigations into the ubiquitome were challenging. 
Ubiquitinated proteins were captured by bioaffinity chromatography using UBDs, 
which was optimized for the brain in this study and identified several potential 
ubiquitinated proteins. These were mostly associated with gene regulation and 
expression. The identification of ubiquitinated proteins requires their intracellular 
enrichment and careful sample preservation. It is possible that the mixed cell 
population and extensive gliosis in the brain following 26S proteasomal dysfunction 
limits the identification of ubiquitinated proteins accumulating in targeted neurones. 
The accumulation of ubiquitinated proteins in neurones may play a role in 
degeneration since recent evidence suggests intracellular protein accumulation is 
involved in pathological events leading to neuronal death (Huang and Figueiredo-
Pereira, 2010). 
The 2D-DIGE investigation of the 26S proteasome-depleted mouse cortex identified 
several differentially expressed proteins associated with neurodegeneration and 
inclusion formation. Several of these proteins were validated by 1D Western blotting. 
Decreased expression of mitochondrial fumarate hydratase, which is essential for the 
Kreb’s cycle, suggests defects in energy metabolism following 26S proteasomal 
depletion. In humans, a deficiency in this enzyme is characterized by progressive 
neurological abnormalities (Pagon et al., 2006). Downregulation of the postsynaptic 
protein neurogranin and stathmin 1 suggest impairment of neuronal plasticity and may 
be associated with the previously reported spatial and learning deficits in these mice 
(Bedford et al., 2008). Neurogranin is a postsynaptic protein indicative of 
postsynaptic function impairment added evidence of dysfunction in the neuronal 
plasticity. This indicated a complex proteomic feature linked 26S depletion with 
toxicity of accumulated proteins possible impairment in mitochondria, and axonal 
disease leading to neuron die. 
Neurodegeneration in this model was associated with activation of astrocytes. 
Upregulation of GFAP and VIME was identified in the 2D-DIGE proteomics study, 
indicative reactive astrogliosis. The activation of astrocytes may be trigged by many 
intracellular signalling  molecules such as IL-6, TNF-α and NO (Sofroniew and 
Vinters, 2010). Increased expression of the astrocytic antioxidant enzyme PRDX-6 
was indicative of oxidative stress involvement following 26S proteasomal depletion. 
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This is the first evidence in vivo in the mammalian brain that 26S proteasomal 
dysfunction directly causes oxidative stress. 
Further biochemical studies of oxidative and nitrative stress were carried out in the 
Psmc1
fl/fl
;CaMKIIα-Cre cortex. The lipid peroxidation marker MDA and protein 
nitration were increased. However, protein carbonyl groups were not significantly 
different between control and 26S proteasome depleted cortical tissue. Interestingly, 
ROS levels were dramatically decreased. Taken together, we have identified changes 
in oxidative homeostasis caused by 26S proteasomal depletion in neurones. PRDX-6 
may be involved in neuroprotection against ROS, indicated by the inverse relationship 
between levels of PRDX-6 and ROS. 
It is possible that MDA may originate from the inflammatory processes. Increased 
phospholipase A2 activity was present in the 26S proteasome-depleted cortex, 
correlating with increased expression of PRDX-6. Whether the PLA2 activity is 
beneficial or detrimental in the progression of neuronal death is unknown. PLA2 
activity has been implicated in the neurodegeneration disease (Allyson and 
Massicotte, 2011; Lee et al., 2011), but studies also suggest this may be a house 
keeping enzyme under basal conditions (Ong et al., 2010). Therefore, further 
investigations of this activity are necessary to further elucidate its role in the brain. 
Conclusion 
Our study has provided new information about the role of astrocytes in 
neurodegeneration. PRDX-6 may be an important antioxidant mechanism in the brain 
to limit oxidative stress. Dysfunction of proteasomal degradation and oxidative stress 
are both important hypotheses involved in neurodegenerative disease and this study 
has provided a potential novel insight into the interaction of these processes. 
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Future work 
The 2D-DIGE experiment identified several differentially expressed proteins in 
Psmc1
fl/fl
;CaMKIIα-Cre mouse cortical tissue. We focused the studies in this thesis on 
the most abundant identified proteins; GFAP, VIME and PRDX-6 which is the first in 
vivo evidence of oxidative stress as a direct consequence of 26S proteasome 
dysfunction. It may be possible to further these investigations and identify other 
protein changes by sub-cellular fractionation of the cortical tissue before 2D-DIGE 
analysis. Bernocco et al, (2008) used a detergent tissue pre-fractionation method to 
isolate sub-cellular fractions from primary culture neurones (Bernocco et al., 2008). 
We could perform a sequential protein solubilization of mouse cortical tissue using 
various detergents such as digitonin, Triton X-100 and Tween 40 using deoxycholate 
and urea buffers, producing sub-cellular tissue fractions according to protein 
solubility. This would reduce the complexity of proteins and may identify lower 
abundant protein changes. This future work would provide a more detailed map of the 
proteome changes in Psmc1
fl/fl
;CaMKIIα-Cre mouse cortex and allow exploration of 
additional targets and biomarkers in neurodegenerative mechanisms. 
Investigations into the consequences of increased PLA2 activity in the mouse brain 
may be possible with the administration of MJ33 a PRDX6 inhibitor to mice as done 
in a recent study examining this activity in the mouse lung (Lee et al., 2013). This 
would involve intravenous administration of MJ33 using mixed unilamellar liposomes 
to ensure drug up-take into the brain tissue of Psmc1
fl/fl
;CaMKIIα-Cre mice. The 
PLA2 activity would then be determined at several time points (hours) after MJ33 
administration. Measurements of ROS and MDA levels as well as 
immunohistochemical investigations of astrocytes would be carried out. These studies 
may indicate the relationship between these parameters, PLA2 activity, astrocyte 
activation and neurodegeneration. 
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Appendix I 
A. Sequence of primers used for mice genotyping 
Primer Forward Primer (5’-3’) Reverse Primer (5’- 3’) 
Cre GGTAGCACCGCAGGTGTAG CTAATCGCCATCTTCCAGCAG 
Psmc1- LB3 TACGAACCTCCTGTCCCAAC - 
Psmc1- 
D1360 
CAGAAATACAGCCAGTGACC - 
Psmc1- X316 - CTGGAACTCAGTGGATTGAG 
 
 
 
B. DNA Sequencing p GEX-fwd for ZNF216 wild (Query) and C30/33A ZNF216 
mutant (Sbjct)- (http://blast.ncbi.nlm.nih.gov/Blast.) 
                                                                                                                              
wild    1     ATGGCTCAGGAGACTAACCAGACCCCAGGGCCCATGCTGTGTAGTACTGGATGTGGCTTT  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
mutant  1     ATGGCTCAGGAGACTAACCAGACCCCAGGGCCCATGCTGTGTAGTACTGGATGTGGCTTT  60 
 
wild    61    TATGGGAATCCTAGGACAAATGGAATGTGTTCTGTTTGCTACAAAGAACATCTTCAGAGA  120 
              |||||||||||||||||||||||||||  |||||||  |||||||||||||||||||||| 
mutant  61    TATGGGAATCCTAGGACAAATGGAATGGCTTCTGTTGCCTACAAAGAACATCTTCAGAGA  120 
 
wild   121    CAGCAGAATAGTGGCAGAATGAGCCCAATGGGGACAGCTAGTGGTTCCAACAGTCCTACC  180 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Mutant 121    CAGCAGAATAGTGGCAGAATGAGCCCAATGGGGACAGCTAGTGGTTCCAACAGTCCTACC  180 
 
wild   181    TCAGACTCTGCGTCTGTACAAAGAGCAGATGCTACTTTAAACAACTGTGAAGGTGCTGCT  240 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Mutant 181    TCAGACTCTGCGTCTGTACAAAGAGCAGATGCTACTTTAAACAACTGTGAAGGTGCTGCT  240 
 
wild   241    GGCAGCACATCTGAAAAATCAAGAAATGTGCCTGTGGCTGCCTTGCCTGTAACTCAACAA  300 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Mutant 241    GGCAGCACATCTGAAAAATCAAGAAATGTGCCTGTGGCTGCCTTGCCTGTAACTCAACAA  300 
 
wild   301    ATGACAGAAATGAGCATTTCAAGAGAGGACAAAATAACCTCCCCGAAAACAGAGGTGTCA  360 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
mutant 301    ATGACAGAAATGAGCATTTCAAGAGAGGACAAAATAACCTCCCCGAAAACAGAGGTGTCA  360 
 
wild   361    GAGCCAGTTGTCACTCAGCCCAGTCCATCAGTTTCTCAGCCCAGTTCTTCTCAAAGTGAA  420 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
mutant 361    GAGCCAGTTGTCACTCAGCCCAGTCCATCAGTTTCTCAGCCCAGTTCTTCTCAAAGTGAA  420 
 
wild   421    GAAAAAGCTCCTGAGTTGCCCAAACCAAAGAAGAACAGATGTTTTATGTGTAGAAAGAAA  480 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
mutant 421    GAAAAAGCTCCTGAGTTGCCCAAACCAAAGAAGAACAGATGTTTTATGTGTAGAAAGAAA  480 
 
wild   481    GTTGGCCTTACAGGGTTTGACTGCCGATGTGGAAATTTGTTTTGTGGACTTCACCGTTAC  540 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
mutant 481    GTTGGCCTTACAGGGTTTGACTGCCGATGTGGAAATTTGTTTTGTGGACTTCACCGTTAC  540 
 
wild   541    TCTGACAAGCACAACTGTCCTTATGATTACAAAGCAGAAGCTGCAGCAAAAATCAGAAAA  600 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
mutant 541    TCTGACAAGCACAACTGTCCTTATGATTACAAAGCAGAAGCTGCAGCAAAAATCAGAAAA  600 
 
wild   601    GAAAATCCAGTTGTTGTGGCTGAAAAAATCCAGAGAATATAA  642 
              |||||||||||||||||||||||||||||||||||||||||| 
mutant 601    GAAAATCCAGTTGTTGTGGCTGAAAAAATCCAGAGAATATAA  642 
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C. Comparing the amino sequences of ZNF216 wild and C30/33A ZNF216 
mutant. 
 
 
wild   M A Q E T N Q T P G P M L C S T G C G F-20 
mutant M A Q E T N Q T P G P M L C S T G C G F 
                                        
wild   Y G N P R T N G M C S V C Y K E H L Q R-40 
mutant Y G N P R T N G M A S V A Y K E H L Q R 
 
wild   Q Q N S G R M S P M G T A S G S N S P T-60 
mutant Q Q N S G R M S P M G T A S G S N S P T 
 
wild   S D S A S V Q R A D A T L N N C E G A A-80 
mutant S D S A S V Q R A D A T L N N C E G A A 
 
wild   G S T S E K S R N V P V A A L P V T Q Q-100 
mutant G S T S E K S R N V P V A A L P V T Q Q 
 
wild   M T E M S I S R E D K I T S P K T E V S-120 
mutant M T E M S I S R E D K I T S P K T E V S 
 
wild   E P V V T Q P S P S V S Q P S S S Q S E-140 
mutant E P V V T Q P S P S V S Q P S S S Q S E 
 
wild   E K A P E L P K P K K N R C F M C R K K-160 
mutant E K A P E L P K P K K N R C F M C R K K 
 
wild   V G L T G F D C R C G N L F C G L H R Y-180 
mutant V G L T G F D C R C G N L F C G L H R Y 
 
wild   S D K H N C P Y D Y K A E A A A K I R K-200 
mutant S D K H N C P Y D Y K A E A A A K I R K 
 
wild   E N P V V V A E K I Q R I Stop  
mutant E N P V V V A E K I Q R I Stop  
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Table I, Antibodies used throughout all protein analysis 
 
Antibody for 
indicated 
proteins 
Animal source Concentration. 
Used mostly 
Buffer 
used for 
western blot 
Manufacturing 
company 
Ubiquitin rabbit 1:1000 TBST House made 
PRDX-6 rabbit 1:1000 TBST GenTex 
115262 
ACTN Rabbit / mouse 1:1000/1: 5000 TBST Sigma-A2066 
GFAP mouse 1:1000 TBST Sigma-G 3893 
Nitrotyrosine 
HM 11 
mouse 1:250 PBST Santa Cruz-sc-
32733 
SEPT7 rabbit 1:500 PBST Gene Tex 
GTX101533 
COX5A rabbit 1:1000 TBST Gene Tex 
GTX101487 
β- SNAP rabbit 1:250 PBST Gene Tex 
GTX116728 
HSC 71/ 
HSP70 
mouse 1:5000 TBST ------------- 
FUMH rabbit 1:500 PBST Gene Tex 
GTX109877 
STMN-1 rabbit 1:250 PBST Gene Tex 
GTX113341 
VIME rabbit 1:1000 TBST Gene Tex 
GTX100619 
GAPDH rabbit 1:1000  TBST Sigma, G9545 
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Appendix II 
CaMKII-alpha-cortex April 2011Report created: 03/05/2011 13:26:37  
 Experiment Design:     
         
Condition control Psmclfl/fl;CaMKIIα-Cre 
Replicates 4 4 
 
 
Results of SameSpot analyses:     
Tags 
 
Edited 
 
Anova p-value ≤ 0.05 
 
All condition p≤ 0.05 Fold >1.1 
 
control >  Psmclfl/fl;CaMKIIα-Cre 
 
pick "up" expressed in control 
mice 
 
pick up expressed in  
Psmclfl/fl;CaMKIIα-Cre mice 
 
Psmclfl/fl;CaMKIIα-Cre > control 
Spot 
No.  
Anova (p)  Fold  Tags  Notes  pI  MW  Average Normalised 
Volumes  
control mutant 
529 1.016e-004 3.2 
 
   0.293 0.947 
668 1.757e-004 1.6 
 
   0.667 1.091 
1039 4.173e-004 1.3 
 
   1.038 1.400 
708 9.766e-004 1.2 
 
   1.027 1.245 
1250 0.002 1.4 
 
   1.428 1.048 
1089 0.003 1.2 
 
   1.130 1.376 
1072 0.003 1.5 
 
   1.767 1.194 
474 0.003 1.4 
 
   0.640 0.915 
770 0.005 1.7 
 
   0.671 1.117 
908 0.006 1.4 
 
   0.817 1.184 
1130 0.008 1.2 
 
   0.908 1.087 
705 0.008 1.4 
 
   1.011 0.716 
1249 0.008 1.4 
 
   1.495 1.077 
1174 0.012 1.2 
 
   1.370 1.096 
832 0.014 1.2 
 
   1.190 1.012 
988 0.019 1.2 
 
   0.923 0.776 
527 0.022 1.3 
 
   1.003 0.759 
1253 0.023 1.2 
 
   1.520 1.303 
506 0.025 1.3 
 
   0.923 0.686 
767 0.025 1.2 
 
   0.932 0.762 
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Identified proteins by MALDI -TOF mass spectrometer: 
Spot No. 529.  Mascot search peptides matches for GFAP 
Protein sequence coverage: 82% 
The identified peptide highlighted red 
        1 MERRRITSAR RSYASETVVR GLGPSRQLGT MPRFSLSRMT PPLPARVDFS  
    51 LAGALNAGFK ETRASERAEM MELNDRFASY IEKVRFLEQQ NKALAAELNQ  
   101 LRAKEPTKLA DVYQAELREL RLRLDQLTAN SARLEVERDN FAQDLGTLRQ  
   151 KLQDETNLRL EAENNLAAYR QEADEATLAR VDLERKVESL EEEIQFLRKI  
   201 YEEEVRELRE QLAQQQVHVE MDVAKPDLTA ALREIRTQYE AVATSNMQET  
   251 EEWYRSKFAD LTDAASRNAE LLRQAKHEAN DYRRQLQALT CDLESLRGTN  
   301 ESLERQMREQ EERHARESAS YQEALARLEE EGQSLKEEMA RHLQEYQDLL  
   351 NVKLALDIEI ATYRKLLEGE ENRITIPVQT FSNLQIRETS LDTKSVSEGH  
   401 LKRNIVVKTV EMRDGEVIKD SKQEHKDVVM  
  
 
Spot No. 770.  Mascot search peptides matches for GFAP 
Protein sequence coverage: 47% 
The identified peptide highlighted red 
     1 MERRRITSAR RSYASETVVR GLGPSRQLGT MPRFSLSRMT PPLPARVDFS  
    51 LAGALNAGFK ETRASERAEM MELNDRFASY IEKVRFLEQQ NKALAAELNQ  
   101 LRAKEPTKLA DVYQAELREL RLRLDQLTAN SARLEVERDN FAQDLGTLRQ  
   151 KLQDETNLRL EAENNLAAYR QEADEATLAR VDLERKVESL EEEIQFLRKI  
   201 YEEEVRELRE QLAQQQVHVE MDVAKPDLTA ALREIRTQYE AVATSNMQET  
   251 EEWYRSKFAD LTDAASRNAE LLRQAKHEAN DYRRQLQALT CDLESLRGTN  
   301 ESLERQMREQ EERHARESAS YQEALARLEE EGQSLKEEMA RHLQEYQDLL  
   351 NVKLALDIEI ATYRKLLEGE ENRITIPVQT FSNLQIRETS LDTKSVSEGH  
   401 LKRNIVVKTV EMRDGEVIKD SKQEHKDVVM  
 
 
  
903 0.035 1.4 
 
   0.957 1.336 
1140 0.038 1.3 
 
   0.923 1.180 
531 0.043 1.4 
 
   1.042 0.765 
1231 0.046 1.3 
 
   1.370 1.835 
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Spot No. 1250, Mascot search peptides matches for Neurogranin 
Protein sequence coverage: 58% 
The identified peptide highlighted red 
1 MDCCTESACS KPDDDILDIP LDDPGANAAA AKIQASFRGH MARKKIKSGE 
51 CGRKGPGPGG PGGAGGARGG AGGGPSGD 
  
 
 
 
Spot No. 1249, Mascot search peptides matches for Neurogranin 
Protein sequence coverage: 57% 
The identified peptide highlighted red 
1 MDCCTESACS KPDDDILDIP LDDPGANAAA AKIQASFRGH MARKKIKSGE 
51 CGRKGPGPGG PGGAGGARGG AGGGPSGD 
  
 
 
 
Spot No. 908, Mascot search peptides matches for Peroxiredoxin-6 
Protein sequence coverage: 84% 
The identified peptide highlighted red 
1 MPGGLLLGDE APNFEANTTI GRIRFHDFLG DSWGILFSHP RDFTPVCTTE 
51 LGRAAKLAPE FAKRNVKLIA LSIDSVEDHL AWSKDINAYN GETPTEKLPF 
101 PIIDDKGRDL AILLGMLDPV EKDDNNMPVT ARVVFIFGPD KKLKLSILYP 
151 ATTGRNFDEI LRVVDSLQLT GTKPVATPVD WKKGESVMVV PTLSEEEAKQ 
201 CFPKGVFTKE LPSGKKYLRY TPQP 
  
 
 
 
Spot No. 474, Mascot search peptides matches for Vimentin 
Protein sequence coverage: 69% 
The identified peptide highlighted red 
1 MSTRSVSSSS YRRMFGGSGT SSRPSSNRSY VTTSTRTYSL GSALRPSTSR 
51 SLYSSSPGGA YVTRSSAVRL RSSVPGVRLL QDSVDFSLAD AINTEFKNTR 
101 TNEKVELQEL NDRFANYIDK VRFLEQQNKI LLAELEQLKG QGKSRLGDLY 
151 EEEMRELRRQ VDQLTNDKAR VEVERDNLAE DIMRLREKLQ EEMLQREEAE 
201 STLQSFRQDV DNASLARLDL ERKVESLQEE IAFLKKLHDE EIQELQAQIQ 
251 EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEEW YKSKFADLSE 
301 AANRNNDALR QAKQESNEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN 
351 FALEAANYQD TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY 
401 RKLLEGEESR ISLPLPTFSS LNLRETNLES LPLVDTHSKR TLLIKTVETR 
451 DGQVINETSQ HHDDLE 
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Spot No. 527, Mascot search peptides matches for Fumarate hydratase, 
mitochondrial  
Protein sequence coverage: 26% 
The identified peptide highlighted red 
1 MYRALRLLAR SRRLLRVPSA GAAVSGEATT LPRCAPNVAR MASQNSFRVE 
51 FDTFGELKVP TDKYYGAQTV RSTMNFKIGG ATERMPIPVI QAFGILKRAA 
101 AEVNQEYGLD PKIASAIMKA ADEVAEGKLN DHFPLVVWQT GSGTQTNMNV 
151 NEVISNRAIE MLGGELGSKK PVHPNDHVNK SQSSNDTFPT AMHIAAAVEV 
201 HKVLLPGLQK LHDALSAKSK EFAQVIKIGR THTQDAVPLT LGQEFSGYVQ 
251 QVQYAMVRIK AAMPRIYELA AGGTAVGTGL NTRIGFAEKV AAKVAALTGL 
301 PFVTAPNKFE ALAAHDALVE LSGAMNTAAC SLMKIANDIR FLGSGPRSGL 
351 GELILPENEP GSSIMPGKVN PTQCEAMTMV AAQVMGNHVA VTVGGSNGHF 
401 ELNVFKPMMI KNVLHSARLL GDASVSFTDN CVVGIQANTE RINKLMNESL 
451 MLVTALNPHI GYDKAAKIAK TAHKNGSTLK ETAIELGYLT AEQFDEWVKP 
501 KDMLGPK 
    
 
 
Spot No. 1253, Mascot search peptides matches for Stathmin-1  
Protein sequence coverage: 111% 
The identified peptide highlighted red 
1 MASSDIQVKE LEKRASGQAF ELILSPRSKE SVPDFPLSPP KKKDLSLEEI 
51 QKKLEAAEER RKSHEAEVLK QLAEKREHEK EVLQKAIEEN NNFSKMAEEK 
101 LTHKMEANKE NREAQMAAKL ERLREKDKHV EEVRKNKESK DPADETEAD 
 
 
